reason report
bottom line host eighth annual svb leerink global
healthcar confer februari march
analyst compos list question tailor
manag team meet manag listen
present next day think find
answer question help gain invest edg
current market
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
februari edt rx trend deriv im health
siffert ceo christin silverstein cfo scott santiamo director
statu manufactur infrastructur invest necessari suppli late-stag clinic trial earli
epidermolysi bullosa eb opportun us vs europ japan regulatori manufactur nuanc
differenti market us
see clinic practic eb evolv success develop commerci
benefit iv administr vs direct central nervou system administr mp program
gene therapi program improv clinic progress batten patient current standard-of-car
clinic trial start batten diseas
regulatori review phase vital
phase vital studi start
short interest float
analyst daniel antalffi medic suppli devic
impella rp expect impact rp sale -- albeit total revenu -- doctor get less aggress treat sick
patient dear doc letter fda dear letter note patient enrol pa would met enrol criteria
pre-market clinic studi mean nearli impella rp patient fall outsid inclusion/exclus criteria pma trial
stemi expect provid updat stemi think trial design size endpoint trial need
show order secur approv drive adopt patient popul sign read feasibl studi determin
potenti success
think potenti expans
adopt barrier adopt today knock barrier adopt ramp
impella alreadi site expect even site potenti use impella initi target
close final detail stemi pivot trial fda
expect start second half
first-in-man ecp expand cardiac power expect
ecp deliv design clinic durat hour
fr pump expand fr
first-in-man impella expect impella next
gener pump smaller profil design implant
axillari arteri wean algorithm
short interest float
updat growth trajectori nuplazid recent commerci
expect upcom phase data
educ effort new dtc campaign program
schizophrenia inadequ respons implic
updat fda feedback clinic design
on-going schizophrenia neg symptom studi
phase adjunct mdd studi nuplazid
could give us updat trofinetid program
think nuplazid compar late clinic stage
think trofinetid diseas modifi therapi
antidepress js esketamin allergan rapastinel
path explor order
diversifi portfolio
nuplazid pimavanserin start phase adjunct studi major depress
nuplazid pimavanserin phase data schizophrenia inadequ
nuplazid pimavanserin interim phase data dementia-rel psychosi
trofinetid phase studi initi rett syndrom
short interest float
see uncertainti outlook luspatercept
latest think chronic anemia
collabor due pend bmy-celg merger
file take long prepar
commerci launch payer discuss go
thought price luspatercept
beta thalassemia indic myelodysplast syndrom
md time
indic luspatercept could prove use beyond
view potenti impact hif inhibitor
luspatercept variou anemia condit
function data look phase ii studi
fshd cmt expect
luspatercept nda/maa file md beta thalassemia
phase ii data part facioscapulo-humer muscular
sotatercept phase ii pulsar result pulmonari arteri hypertens
short interest float
prioriti timelin on-going strateg review
latest plan bloodstream infect bsi
indic zemdri
initi launch metric indic zemdri
develop plan market opportun c-
request inform rfi request project
bioshield entail think opportun
eu day question plazomicin
fda feedback formal disput resolut request plazomicin bsi
barda rfi respons zemdri project bioshield
result phase clinic pharmacolog studi
launch progress zemdri us
short interest float
distinguish on-going studi
recent pnh data show specif
balanc speed qualiti studi
briefli remind us natur histori studi what
latest expect data
expect end phase meet
regul data would expect meet
preliminari thought phase trial design phase trial
suffic registr
phase partial respond eculizumab data paroxysm nocturn
hemoglobinuria/pnh
phase data
phase open label data
ind submiss
thought patient reach uln ldh
strateg posit cfd inhibitor compound
anticip ultomiri
led pursu dual path pnh
treatmen-nav patient sv eculizumab-experienc
indic contempl beyond pnh
short interest float
inbrija fit treatment paradigm parkinson
provid color pipelin progress next
diseas patient potenti market opportun
program move clinic studi
updat inbrija launch progress physician patient
think revenu outlook ampyra/fmpyra
commerci plan inbrija ex-u
inbrija commerci launch us
short interest float
gocovri launch go youv invest
kind data would clinic meaning phase
studi ms
bar success clinic regulatori
partail onset seizur studi
short interest float
progress gain insur coverag gocovri
strategi ensur long-term growth gocovri
fit multipl sclerosi ms market
initi phase studi partial onset seizur
announc new indic
initi phase studi inroad multipl sclerosi walk
adap t-cell receptor tcr platform posit
talk hurdl clinic execut
talk screen safeti test take place
minim off-target bind cross reactiv
step adap taken ensur time clinic progress
help set expect updat mage
tcr data youv guid provid financi
talk reason confid tcr abl
result may
address solid tumor see key hurdl
clinic updat basket studi financi
result may
durabl data program target dose
target cell
short interest float
adro recent public suggest sting agon
way believ sting agon differenti
bell-shap dose curv moder dose result long-term adatp
oncolyt virus sting investor interpret
immun high dose tumor t-cell abl give short-
overal abscop result studi tvec pembrolizumab
term tumor shrinkag translat find dose
melanoma
patient clinic
soon combin trial approv anti-
spartalizumab ipilimumab
think synergist sting agon
nv impact develop choic
differenti sting agonist
excit anti-april multipl
myeloma could efficaci follow bcma-target therapi
tell us adro recent chang research
partnership refocus announc januari
initi iga nephropathi igan studi healthi volunt
dose escal result spartalizumab advanc
metastat solid tumor lymphoma poc trial clinic activ
initi dose expans spartalizumab
initi approv earlier-lin squamou cell
carcinoma head neck scchn
dose escal result multipl myeloma mm initi
dose expans mm
short interest float
expect timelin next data updat wet age-rel macular degener program
administ intravitr profil compar subretin competitor role
think construct design vector select promot optim tool improv efficaci intravitr adminsitr
express data look guidanc expect
expect see data rare diseas portfolio
think indic select vector design outsid ophthalmolog
cash balanc burn rate
top-line result phase optic studi
optic phase wet enrol updat
ind file phase trial begin hereditari
updat preclin rare diseas program
move new facil
short interest float
head ir vatnak vat-ho vice-president busi develop
provid background rational behind engag nk
take next develop give us
cell bispecif follow afmd collabor
genentech expect industri focu modal
direct bispecif competitor think
relev competit approach compar nk
engag mab nk antagonist
updat partnership discuss hodgkin lymphoma hl
expect clinic hold bispecif
lift respond critic suggest hold evid
format greater off-target toxic
plan focu resourc across pipelin asset
recent announc acceler registr strategi
nk engag
peripher t-cell lymphoma possibl add
data cohort mycosi fungoid mf
speak rational path well efficaci bar believ
would support regulatori file across popul
mani potenti afm combin strategi excit
expect see clinic
thought tri-specif engag
potenti lift clinic hold
start registration-direct trial mf
ind file egfrwt overexpress solid tumor
updat trial hl cutan lymphoma
potenti partnership hl
short interest float
analyst puneet souda life scienc tool diagnost
end-market mr mcmahon spent month
character overal opportun room grow china given
agil fresh perspect view
exposur would food situat turn around
sustain end-market overal across pharma patholog
view expect tariff impact china busi
chemic
capit alloc view capit alloc
chemic gc launch lead posit
prioriti go forward tradit first seem
product refresh round entir portflio
see acceler share repurchas
feel long-term growth market expect
view capit alloc strategi go forward
price gross margin improv new launch
overal top-lin growth strong oil ga market
nasd build-up updat us colorado oligo facil
expect capital-expenditure overal long-term expect
china china rev key market food weak
quarter though face comp
uptak intuvo product chemic end-market
sinc launch
growth colorado nucleic acid facil
short interest float
comment uptak tibsovo acut mteloid leukemia
advanc vorasidenib glioma trial
aml see market evolv given broad act new
plan late year give us overview
agent like venclexta shown robust activ
thought opportun potenti trial design
trial go studi tibsovo idhifa
aml combin standard induct chemo singl
character vorasidenib profil better fit opportun
tibsovo
agent mainten therapi describ opportun
dose escal data mtap delet tumor
mainten agent aml paradigm current
expect give us overview target
expectng initi data present
approach pivot data tibsovo
cholangiocarcinoma describ opportun
updat data tibsovo vidaza newli diagnos aml
potenti approv tibsovo aml patient elig
therapi june pdufa
top-line data claridhi trial tibsovo
cholangiocarcinoma
dose escal data trial mtap delet tumor
submit snda tibsovo cholangiocarcinoma base
claridhi trial
short interest float
could tell us on-going launch tegsedi uptak vs europ
could talk real-world physician patient recept monitor requir tegsedi
mani patient commer product util akcea connect
takeaway launch onpattro put work tegsedi strategi commerci execut
discuss regul europ on-going regard approv waylivra famili chylomicronemia syndrom track
eu regulatori feedback waylivra
nv opt-in akcea-apo -lrx program
short interest float
commerci offic john orloff head susan altschul vice-president ir
current myasthenia gravi mg run rate
proport soliris/ultomiri total compani revenu
point exceed paroxysm nocturn hemoglobinuria
risk biosimilar competit
pnh atyp hemolyt urem syndrom ahu revenu
basi us
percentag pnh patient us switch
ultomiri gaug patient physician payer
interest switch
ultomiri pnh approv europ
phase ii data warm autoimmun hemolyt
bla file ultomiri ahu
fda approv soliri neuromyel optica nmo
phase trial initi ultomiri mg nmo amyotroph later
brand gener competit greater threat
short interest float
outlook base busi term manufactur
povid color on-going intern drug
royalti expect growth
develop discoveri program
strategi go forward ensur long-term growth
elabor plan updat
vivitrol aristada
on-going studi
provid updat commerci plan alks-
thought around bd
posit product schizophrenia market
aristada phase data head-to-head studi vs invega sustenna
nda file schizophrenia
phase data studi vs tecfidera multipl sclerosi
short interest float
strategi outlook long-term growth botox therapeut
much addit sale expect would increas
given ramp inject cgrp recent
sale forc accommod new indic
discuss effort doubl medic aesthet
given payer dynam weve seen inject cgrp
busi go run hurdl
exclud select cgrp other anticip
meaning progress expans medic aesthet
oral cgrp ubrogep
strategi ensur broad coverag patient access
import bipolar depress major depress
disord mdd indic vraylar
ubrogep
may vraylar pdufa date bipolar depress
rapastinel data phase acut mdd studi
abicipar data mapl studi phase age-rel macular
abicipar initi phase studi diabet macular edema dme
short interest float
start onpattro form trend eu commerci launch go vs expect
ttr diagnosi rate chang past month sens diagnosis/treat rate chang next year
driver
enrol timelin helios-a/b takeaway attr-act inform expect
outsid us market import launch ultim market opportun givosiran
statu manufactur facil norton
build capac norton chang manufactur strategi vi -- vi use cmo product
expect regard competit posit tafamidi mix phenotyp ttr patient plan counter-detail os
benefit expect tafamidi
expens growth outstrip street expect handili opportun rein cost fat cut program
sg infrastructur
top-line data readout envis ph studi givosiran ahp
full registr file givosiran
top-line result lumasiran ph illuminate-a trial
nda file inclisiran
short interest float
addit gener like impact makena franchis
avail proof concept data
ferahem growth potenti expand label
impact intrarosa direct-to-consum dtc
campaign gross-to-net like evolv
preeclampsia read-through data provid
ciraparantag differenti revers agent
develop anticip clinical/regulatori path
vyleesi addit consider fda
shape
june pdufa date vyleesi hypoact sexual desir disord
potenti launch vyleesi
end phase meet initi phase trial ciraparantag
complet enrol phase trial
potenti approv addit intramuscular im gener makena
short interest float
physician respond reduce-it data
like time potenti gener competit
month data readout
potenti consider fda label expans
intern expans plan vascepa
base reduce-it data
expand commerci strategi consist
submiss snda cardiovascular cv event prevent vascepa
sale progress vascepa
late potenti snda approv cv event prevent vascepa
short interest float
galafold launch dynam eu japan us
next updat gene therapi studi
elabor galafold peak opportun
seen preclin gene therapi
what latest data at-gaa fvc
rational cohort on-going phase studi
remind us phase propel studi design
inclusion/exclus criteria studi
hope show natur histori studi
expect translat plan clinic trial
think competit dynamic/cannib
given fabri pomp gene therapi pipelin
comment gene therapi manufactur capac
at-gaa natur histori data pomp diseas
at-gaa phase cohort data pomp disea
gene therapi phase data
at-gaa phase propel enrol complet pomp diseas
short interest float
path forward look like diabet peripher
hypothesi work ptsd
neuropathi dpn confid efficaci could
seem like challeng indic drug
dial
commerci strategi go alon partner right time
learn full fibromyalgia dataset
program
interim biomark analysi alter convict
discuss regulatori hurdl novel moa pain indic
phase result rapastinel major depress disord mdd
phase ii top-line data fibromyalgia
phase top-line data parkinson cogs impair
phase ii top-line data ptsd
present phase ii dpn data medic meet
short interest float
lead program kinas inhibitor c-myc
file ind earlier week seen
oncogen myc notori difficult inhibit
pre-clin toxicolog studi expect see
specif differ approach
first clinic data program
recent re-initi dose phase trial
think opportun aml b-
r/r aml md patient enrol go
cell malign envis abl develop
expect see first clinic data program
would potenti look partner
non-coval pan-btk inhibitor
describ multi-clust kinas inhibitor approach
initi clinic data
initi clnical data
short interest float
market opportun ornithin transcarbamylas over-the-counter timelin next data updat program
see rna therapi fit exist treatment landscap
point materi differenti deliveri platform vs competitor
indic select strategi choos partner vs keep in-hous
statu cash balanc current burn rate
ind file treatment urea cycl disord ucd
data updat tide summit
short interest float
data expect june on-going phase
what plan compet nsclc market merck
what compani expect respons
becom domin
readout non-smal cell lung cancer nsclc cohort
could describ design underli rational
push back ye instead june
hold back trial
new plan studi kra mutant pancreat
short interest float
phase i/ib dose escal data combin multipl
final dose escal data
phase data healthi volunt
phase i/ib escal data combin nsclc
phase escal data
first tenapanor phase provid read-through
potenti hyperkalemia
second phase result expect
compani partnership plan ibs-c statu
may potenti tailwind headwind around
exist ou partnership
commerci launch tenapanor hyperphosphatemia
recent interact fda progress ahead
septemb pdufa date tenapanor constip predomin
septemb pdufa date tenapanor ibs-c
phase phreedom data tenapanor hyperphosphatemia patient
end-stag renal diseas esrd dialysi
phase amplifi data tenapanor combin phosphat binder
potenti nda file tenapanor hyperphosphatemia
short interest float
see phase oasi studi etrasimod
briefli discuss preclin data present
data compar uc agent includ jak
inhibitor ozanimod
estim address market
thought phase trial design uc
briefli recap ralinepag deal
 day discuss new program etrasimod
indic pursu rational
see phase olorinab studi
plan olorinab give confid sinc
phase open-label studi
etrasimod phase studi initi ulcer colitis/uc
etrasimod phase studi initi crohn disease/cd
etrasimod phase studi initi atop dermatitis/ad
etrasimod phase induct studi data uc
etrasimod phase induct studi interim data cd
short interest float
repres paolo pucci ceo marc schegerin svp head
talk view overal burton tyrosin kinas
investor think expect next
btk landscap oncolog arq fit
arq updat much data vs
view revers btk inhibitor landscap oncolog
opportun miransertib proteu
arq differenti other develop
size cll market opportun
arq phase data updat cell malign like eha
initi registr studi proteu
arq phase ib solid tumor updat end
next develop step
short interest float
key factor drive braftovi/mektovi uptak braf
need show anchor colorect cancer
melanoma larg initi braf/mek switch patient
trial drive braftovi/mektovi usag treatment nave braf
opportun sens current patient mix
switch target tx nave
sever partnership explor use binimetinib
combin i/o describ rational strategi
interim analysi phase beacon trial
combin
evalu object respons rate orr durat respons
orr durat respons would view clinic
meaning braftovi/mektovi erbitux warrant acceler
think next oncology-focus ind target
mechan consid interest
top-line interim data phase beacon trial
braftovi/mektovi launch updat braf melanoma may
top-line data partner program tucatinib pivot trial
metastat breast cancer
initi clinic data partner program kra tumor
short interest float
data expect april on-going phase iia trial
hepat viru hbv
compani expect respons
understand regulatori path forward abi-
base recent fda guidanc industri hbv
look phase ia data next-
proport patient believ need cure core
gener core inhibitor would indic
attract profil compar
inhibitor gener commerci demand creat viabl
april interim phase iia data hbv
april interim phase ia data
full phase iia data hbv
ye announc plan announc pivot program
short interest float
analyst daniel antalffi medic suppli devic
guidanc key put take sale guidanc growth driver revenu growth
beyond could potenti drive sale upsid downsid guidanc
long-term growth trajectori sustain growth profil busi open ablat mi atriclip tavr
move risk curv sustain market growth outlook surgic ablat driver
converg updat timelin converg manag expect data present
like forum given converg superior trial bogey recurr rate clinician order drive adopt
deep saw studi statu chang activ recruit clinicaltri gov websit latest updat deep-af trial
fulli enrol converg complet enrol might role deep procedur mi
cryoic product just-launch cryospher probe block pain temporarili ablat peripher nerv could help us
understand pain manag portfolio fit overal strategi
data expect converg hybrid surgic ablat
abdomen coupl cathet ablat treat persist
frost trial data expect evalu effect
cryoanalgesia pain manag cardiac procedur involv thoracotomi
enrol deep-af trial expect continu updat
like on-going deep-af meant establish safeti effect dual
epicardi endocardi ablat procedur patient persist
long-standing persist af util atrc bipolar system atriclip
endoscop open ablat procedur
short interest float
statu updat phase aspiro studi latest
happen pomp diseas
feedback regul
adjust went
remind us your test vg/kg dose given
consider went
robust function improv cohort vg/kg
latest updat evolut
data investor expect asgct
preval incid estim
latest updat valen studi
remind us manufactur capac
improv patient identif
tackl pomp diseas gene therapi
phase valen data updat crigler-najjar syndrome/cn
phase aspiro data updat x-link myotubular myopathy/xlmtm
candid program updat
ind file pomp diseas
short interest float
ln phase data show includ aura-lv
phase studi de show recent
remind us led imbal patient death
compare/contrast phase aurora trial phase aura-lv
design drop discomfort primari endpoint
hindsight better object endpoint de
prelminari thought next studi design path approv
remind us power assumpt aurora
walk us rational explor fsg
next updat fsg plan
voclosporin phase data focal segment glomerulosclerosis/fsg
voclosporin phase aurora data lupu nephritis/ln late
vo statu updat dri eye syndrome/d
short interest float
suspect may caus disconcord
see tivozanib fit rcc treatment pardigm
os tivozanib
think chang follow introduct i/o
base discuss fda next step
plan compani early-stag compound
analyz data trial potenti submit
includ ficlatuzumab
potenti readthrough result
tivozanib approv europ
interim overal surviv os analysi phase trial aug
updat data phase tinivo trial tivozanib opdivo
short interest float
analyst richard newitt medic suppli devic
exist new market
senior sale commerci leadership chang
key assumpt incid rate elig
consecut chang two commercial/sal
underli compani trauma extrem procedur
compani strategi breast reconstruct
initi integration/transit progress
neurot brn mani new center
sale strategi chang init
compani plan target beyond initi center updat
roll sale forc incent growth
compani clinic initi time premilinari data
factor give management confid achiev revenue
compani plan full scale launch surgic
growth guidanc much cushion alloc leadership
manag pain key product assumpt
transit sale organ
underli initi market opportun
interim analysi recon data expect completed/review
recon trial complet time-frame
surgic manag pain launch
sensation-now data readout breast reconstruct neurot time tbd
three clinic studi enrol repos rct-resect neuroma
short interest float
gavin corcoran evp tricia truehart head ir
vector design axo-lenti-pd compar compet parkinson gene therapi differenti program
rang axo-lenti-pd dose evalu sunrise-pd trial therapeut level dopamin product expect reach
initi dose test
screen high-preval popul chang incid rate tay-sach sandhoff diseas time
think rate patient recruit clinic trial patient easili identifi
four clinical-stag gene therapi program expect ong plan prioritz among asset
expect see addit pipelin near futur see focu clinic develop
initi clinic data gangliosidosi
initi data readout axo-lenti-pd parkinson diseas
first patient dose gangliosidosi
clinic data readout
short interest float
analyst daniel antalffi medic suppli devic
capit deploy updat thought capit deploy prioriti much will lever quickli
aggress deploy capit rel last year balanc among share buyback dividend
share repurchas guidanc outstand share meaning decreas exit remind us
much author left share repurchas program quarterli cadenc perspect plan share buy-back
much prioriti within overal context capit deploy
 strategi gap product portfolio compani eager fill and/or press excit
new market doesnt current play could leverag compani expertis know-how perhap mayb even
sale growth trajectori give manag confid long-rang plan sale compound-annual-growth-rate time-frame remain intact
hiccup tailwind acceler growth beyond
hdx therapi enabl theranova expect launch hdx
therapi extend rang molecul filter blood
dialysi result filtrat profil close mimic natur kidney
point-of-car solut periton dialysi pd expect launch
new system design produc steril pd solut use small
water filtrat devic would place patient home integr
baxter uniqu amia autom periton dialysi system
expect new product pipelin acceler growth
contribut busi
short interest float
becton dickinson compani
analyst richard newitt medic suppli devic
bd bcr integr timelin anyth
factor give management confid revenue growth acceler
surpris bd /- biggest oppti vs risk
full-year cc growth much accl
cadenc rev/cost synergi look like
order time vs execution-rel headwinds/tailwind qtr
synergi expect complet year-end
busi present greatest oppti drive upsid
anticip synergi fit context cc
reason think mgmt assumpt around normal vs
revenue growth cc ep growth materi faster-
sever flu season bake cushion much
than-expect could push bd revenue guidanc
visibl management current intra-qtr flu trend
trend bd see capital-expenditure environ much
lutonix btk still track commerci
growth bd specif vs market dispens market
think revenue contribut
bd sale strategi patch
competit landscap look like us/eu
commerci
swatch patch pump approval/launch expect end
venovo venou stent covera stent graft fistula indic launch expect
end year
short interest float
see chines pharmaceut market develop
discuss acquisit celg chang global
statu regulatori reform
investor think upcom pivot data
zanubrutinib waldenstrom view success
tislelizumab program potenti opportun
anticip chang market approv celg
product china
trial succeed without superior primari endpoint
opportun pamiparib differenti market
view global btk market gener
zanubrutinib place
pivot bladder cancer data nda file china hepatocellular
carcinoma data global trial tislelizumab
potenti chines approv tislelizumab r/r hodgkin lymphoma hl
data trial zanubrutinib vs imbruvica r/r waldenstrom
macroglobulinemia wm
data trial zanubrutinib vs br tn chronic lymphocyt leukemia cll
patient inelig fcr
data mainten trial pamiparib platinum sensit gastric cancer
short interest float
latest thought commerci strategi
pipelin program rank highest prioriti mind
rimegep regard go alon strategi commerci
respect resourc alloc
believ underappreci asset
view oral cgrp market opportun
portfolio think investor miss
rimegep studi acut
prevent treatment migrian
physician indic concern satur
cgrp receptor use inject cgrp plu oral cgrp
view
plan futur bd diversifi portfolio
troriluzol start phase trial gener anxieti disord gad
start phase trial acut migrain
rimegep nda file acut migrain
verdiperstat start phase trial multipl atrophi
troriluzol phase data alzheim diseas
short interest float
repres geoff nichol svp head global clinic
remind us gene therapi manufactur capac
walk us dna circular hypothesi
envis pku treatment landscap evolv
hope show next updat
kuvan palynziq potentilali mix
main consider valrox acceler file
palynziq launch us focus effort
valrox data look adjust chromogen
recap phase vosoritid trial design hope show
what latest guidanc revenu profit
preliminari thought valrox price
palynziq eu chmp opinion phenylketonuria/pku
palynziq eu approv pku
valrox phase data updat hemophilia
valrox strategi updat acceler file
vosoritid phase top-line data achondroplasia
short interest float
analyst puneet souda life scienc tool diagnost
exosom dx epi updat time exosom dx epi medicar
protein platform sustain growth protein
coverag overal outlook test
platform divis recent remark growth product
exosom dx platform technolog long-term pipelin
opportun see exosom degre invest
ella we give us view long-term
expect protein platform
will commit bring product market
opportun view new
acd advanc cell diagnost detail us major
chang occur acd acd posit
drive growth go forward confid recoveri y/i
growth acd
recoveri growth acd
opportun exosom technolog acquisit
specif area growth clinic area interest
short interest float
submit first nda avapritinib platelet-deriv
import first approv new agent ret driven
growth factor receptor alpha pdgfr mutant kit
cancer expect egfr-lik paradigm
gastrointestin stromal tumor gist discuss
multipl line therapi anticip class base
see gist market evolv
plan begin phiii trial avapritinib
talk chanlleng bring avapritinib
gist discuss reason pursu
advanc sm indol patient driver
biomark strategi potenti challeng clinic practic
adopt patient manag toler
potenti competitor pursu all-com strategi
discuss overal develop strategi
file breakthrough therapi design btd blu-
updat data ret driven malign includ ret fusion non
small cell lung cancer nsclc retm medullari thyroid cancer mtc
submit avapritnib nda pdgfr kit gist
pivot data dcph phiii invictu trial gist mid
submit nda ret fusion nsclc retm mtc
submit snda avapritinib advanc system mastocytosi asm
short interest float
analyst daniel antalffi medic suppli devic
tam analyst day manag note rhythm manag market grow new market adjac could
potenti grow address market
product portfolio view bsx current rhythm manag portfolio within exist portfolio much bundl occur
sale synergi key products/pipelin drive sustain growth next year
market dynam market seem cyclic depend upon new product cycl drive above-market growth
replac cycl view long-term trend market price/volum perspect
ep could help us understand market dynam afib ablat busi ramp presenc
player map sustain ep market growth key driver sustain market growth
margin expans rhythm manag busi margin expans initi increment margin expans
come cost-cut mix shift/pipelin
product launch apama rf cryterion pvi balloon eu
product launch lux dx icm monitor
product launch sens cathet eu
product launch empow leadless pacing/modular
product launch pg
product launch apama rf cryterion pvi balloon
product launch sens cathet
short interest float
analyst puneet souda life scienc tool diagnost
uhf could provid updat instal two
lc-m updat us broader opportun see timstof
ghz magnet see roll revenu
emerg well establish proteom marketplac
uhf could remind us ultra high frequenc backlog
current
acceler provid view success project acceler
far prioriti given progress seen
mass spec microbiolog area
margin expans updat us view oper margin
expans contribut see gross margin
new product includ uhf mass spec launch
addit uhf ghz nmr instal sale
addit larg instrument sale timstof fluoresc microscopi
short interest float
emerg immuno-oncolog io space highli competit
view evolv renal cell carcinoma rcc
talk immun tumor cell metabol
landscap see potenti posit
attract space
given experi inci ido program talk
youv guid clinic data help set
reason confid metabol space broadli
investor expect ahead data
data medic meet
top-lin data phase ii entrata trial evalu plu everolimu
patient rcc
talk rational arginas inhibit cystic
fibrosi develop plan
short interest float
analyst daniel antalffi medic suppli devic
achiev long-term guidanc csii goal achiev revenu repres sale compound-annual-growth-rate
reflect sale geograph expans new product launch give manag confid
execut particularli given increment risk depend upon success bring new product market
product portfolio broad deep pipelin build around revascular chang core busi prompt
transit pipelin stori manag strategi strengthen posit competit complet toolkit revascular
busi long-term growth driver manag believ long-term sale growth trajectori csii busi
peripher coronari driver
paclitaxel meta-analysi data paclitaxel paper publish jaha meta-analysi data fda dear doctor letter impact
peripher intervent volum
price price trend last month long-term contract obl office-bas lab impact price
product launch next gener pump larg vessel
data releas eclips trial expect
product launch ii small vessel score balloon
product launch a/v fistula
product launch laser atherectomi
product launch cpci hemodynam support mix plaqu
short interest float
winlevi differenti avail acn product
forthcom de-risk mileston breezula
cassiopea commerci strategi winlevi
addit pipelin opportun pursu
breezula opportun androgen alopecia
result phase dose rang studi breezula alopecia
nda file winlevi acn
initi phase studi breezula
result phase dose rang studi acn
result phase dose rang studi human
short interest float
repres toni liu ceo derrick li head strategi investor
collabor nv fit
given crowd bcma car-t landscap believ
busi strategi
cbmg product differenti
current qualiti cost structur turnaround time car-
 product plan launch global vs china
manufactur compar compani cmo scale
common us investor misconcept chines
plan turn manufactur capabl busi disrupt
biopharma cell therapi market
china global
januari ind allojoin approv cda trial
one catalyst initi readout bcma car-t
multipl myeloma year end expect term number
ind someth see fda mean
program commerci strategi rejoin allojoin
patient treat extent durabl data patient composit
start ist car-t patient relaps car-t
start ist car-t nhl patient relaps car-t
start ist cell therapi aml
start afp-tcr
start til nsclc
data on-going bcma car-t mm
short interest float
cyad product uniqu target domain
current plan move forward metastat colorect cancer
compar scfv mab target
relapsed/refractor aml/md think trial evalu patient
cyad autolog allogen platform plan
achiev cr/crh/cri without chemo precondit
balanc focu resourc platform
cyad product enabl approach
cyad allogen platform two tcr knock-down approach tim
 look think dose level cohort
schedul optim deplethink result
guid registr plan aml/md
 treatment path therapi best place
inhbit tcr signal shrna rather gene edit knock
potenti advantag approach
next pipelin
dose data think without precondit r/r aml/md
data think cohort evalu frequent dose without
precondit r/r aml/md
dose-escal data deplethink trial follow
precondit r/r aml/md
data think shrink trial follow cyflu concurr
folfox respect metastat colorect cancer mcrc
data alloshrink trial allogen folfox mcrc
initi r/r aml
short interest float
avacopan target differ
pros/con target receptor vs ligand
see phase classic studi
current known receptor
current standard care aav limit
inhibit shunt caus build-up
goal avacopan
see evalu dn patient
chang implement phase advoc trial
given dn result chang focu fsg
evid led pursu hidraden suppurativa
perceiv approv pathway fsg
avacopan phase advoc top-line data anca-associ vasculitis/aav
glomerulosclerosis/fsg
avacopan phase top-line data
avacopan phase aurora top-line data hidraden suppurativa/h
phase nephrot syndrom data fsg
pursu nephrot sub-nephrot studi phase
short interest float
comment market parp inhibitor ovarian
walk us develop plan bladder
cancer plan europ commerci
prostat cancer opportun parp inhibitor
see rubraca differenti competit agent
set
eye prescrib attribut key
describ plan lucitanib see
see oper commerci risk rubraca ovarian
cancer time athena confid
trial enrol gsk prima trial report posit data
primarili combin stori stand-alone valu
initi data atla trial rubraca bladder cancer orr
data prima trial zejula ovarian cancer mainten late
potenti snda file rubraca brca metastat castrat resist prostat
cancer mcrpc base
data trial rubraca opdivo mcrpc
data athena studi rubraca/opdivo ovarian cancer
mainten
short interest float
comput program system inc
would describ competit environ posit market
trubridg continu growth driver see recent momentum book continu
declin leverag think invest pipelin
see meditech athenahealth market meditech good ambulatori product athenaealth acqusit
final impact busi competit environ
differenti offer market view largest competitor chang past year
trubridg ntrust growth
increas proport recur revenu
short interest float
management indic allow revenue upsid drop
what drive us ortho acceler take
ep bigger way compar prior yr
continu momentum
upsid materi short-term philosophi someth
expect broadli beyond rule thumb
state current regulatori legisl mandat smoke
evacu product implent management think
could op margin could go long-term
right time establish plan given
multipl year turnaround
legisl state-by-st type tailwind begin inflect
bf deal competit process best
bf acquisit impact outlook
home asset
smaller tuck-in d-type acquisit focu would act
right transform deal
buffalo filter integr deal close
qtrli oper leverag top-line out-performance materi
new orthoped product showcas american academi orthopaed
industri confer aao orthoped societi
american gastrointestin endoscop surgeon sage apr
short interest float
develop bet inhibitor myelofibrosi
take us design prostar trial
describ develop program rational
advanc next gen inhibitor phase
trial solid tumor describ differ
manifest trial studi monotherapi
two agent priorit develop
combin jakafi discuss see
agent differenti potenti complementar
inhibitor develop prostat
cancer role diseas
updat data phase portion prostar trial
prostat cancer
interim updat phase manifest trial myelofibrosi
initiatephas trial gen inhibitor solid tumor mid-
interim phase data zytiga xtandi prostar trial
prostat cancer
updat data phase manifest trial myelofibrosi
short interest float
differenti therapi develop
upon novarti octreotide/ipsen lanreotid efficaci acromegali
could agonist hyperinsulinemia offer
data support ideal target acromegali vs
improv benefit efficaci current standard care
octreotid lanreotid also target lesser
neuroendocrin tumors/net subpopul aim
treat bias agonist good
two phase evolv edg trial design
target patient net
demonstr efficaci among patient respond complet
partial somatostatin monotherapi respect
oral agonist
differ food effect
phase initi hyperinsulinemia
phase initi neuroendocrin tumors/net
phase result hyperinsulinemia
phase evolv complet enrol full respond acromegali
phase edg complet enrol partial respond acromegali
phase result neuroendocrin tumors/net late
short interest float
analyst puneet souda life scienc tool diagnost
market give us view overal regen medicin market
gross margin view long-term gross margin
confid feel long-term opportun cyroport
target near investor
approv product market clinic
view long-term gross margin target
trial pipelin
competet differenti one question come
clinic trial would character posit clinic
frequent compeit advantag would answer
trial especi phase vs last year expect overal
today particip nearli clinic trial give us sens
funnel new project trial could util product
barrier entri busi
custom could give us sens major
fda us view fda complianc longer term
custom view vs let say year ago
step take posit regul
mix commerci drug revenu vs clinic think
mix trend near mid-term
achiev fda complianc
anounc allianc regen medicin cell gene therapi
short interest float
gate factor initi next phase trial
given potenti competit myelofibrosi ruxolitinib
pacritinib myelofibrosi mf
popul intend address forthcom phase
fedratinib current develop timelin see
pacritinib fit treatment paradigm mf
follow phase trial read juli path
top-line data phase trial anticip
hope learn trial
anticip incorpor learn phase
forward pixuvri europ
top-lin data phase trial
scientif guidanc ema regard pacritinib develop plan
initi phase trial pacritinib myelofibrosi
short interest float
offer flexibl tax reform regard rebat
talk headwind tailwind underpin revenu
drug price reform rebat elimin
ep guidanc
revenu earn outlook
see impact time propos hh rule
rebat elimin payor mix
omnicar break open gener brand inflat headwind
transient outlook pbm sell season
retail health hub strategi econom
offer color strategi glide path econom earli
synergi aet enterpris save off-set headwind
feedback houston
talk capit deploy outlook
talk go-to-market strategi aet across
short interest float
unmet need primari biliari cholang pbc small diseas
drug avail
seladelpar attract gave best class properti
see durabl market opportun given could price
eros treatment coincid approv non-alcohol
steatohepat nash price strategi assum
seladelpar get approv pbc nash
test liver fat reduct fibrosi reduct phase
studi nash see one achiev
link subparth requir approv
would think combin seladelpar nash base
profil drug
term nash market develop import
factor focus success commerci level
effect seen seladelpar pbc patient give
els excit move forward
confid could feasibl treatment option nash
mri-pdff data phase nash studi
phase top-lin data readout nash clinic trial w/ biopsi data
short interest float
analyst daniel antalffi medic suppli devic
primari sepsi cardiac surgeri
liver failur given broad indic potenti expans
distributor fit ctso strategi vs direct salesforc
investor expect growth segment
acceler direct sale level
full swiss reimburs effect
impact start cytosorb util countri
next cytosorb reimburs
exit product path exit
manag target long-term goal
sale growth driven reimburs indic expans
gm expans quarterli basi exit
clinic data progress remov refresh ii-aki cytosorb registri
new product develop cytosorb-xl hemodefend immunotherapi
current quarterli adjust oper profit
break-even investor expect go forward
manag current expect complet
refresh ii-aki pivot trial larg us opportun vs
current impact could trial posit
neg cytosorb util ou
pleas give high-level overview cytosorb registri
inform ctso decisionmak interim analysi time
ctso excit new product
short interest float
happen bla file viaskin peanut peanut
remind us epitop year old studi design
allergi led withdraw
enrol differ pepit year old
could provid updat sinc announc plan
phase vipe studi demonstr clear divis efficaci
resubmit bla tack
younger older patient work done
work left resubmiss challeng
introduc ideal viaskin patch adult
could expect repons fda
oral immunotherapi undergo fda review assum
viaskin patch complex
make drug
see phase pepit studi
viaskin peanut also enter market envis
treatment paradigm evolv peanut allergi
phase trial design viaskin milk cow milk
allergi shown far
viaskin peanut bla file resubmiss peanut allergi
viaskin peanut phase epitop data peanut allergi
viask milk strategi updat cow milk allergi
short interest float
learn qbrexza launch told us
atop dermat quickli get crowd lebrikizumab
larg unmet need launch reflect
sfair share captur upsid
tout robust number cover commerci
live translat activ popul
differenti specif antibodi
receiv feedback patient product usag
far sens custom satisfact potenti
home-run efficaci safeti durabl speed onset
implic return custom
rate upcom phase result
primari palmar hyperhidrosi fit strategi
import less frequent dose view critic
qbrexza timelin studi
april phase data lebrikizumab ad
quarterli sale number qbrexza launch on-going basi
short interest float
paula schwartz ir
expect phyox open-label extens ole studi dcr-phxc ole result inform strategi differ primari
commerci regulatori advantag pediatr trial dcr-phxc children age
plan enrol patient idiopath ph iph addit open-label studi think iph market oppti
expect proof concept poc data dcr-hbv bar efficaci stage given evolv hepat hbv
moa hbv differenti competitor product
give us updat partner program think cadenc candid select data releas
cash balanc burn-rat
initi pivot trial dcr-phxc primari hyperoxaluria
proof-of-concept data dcr-hbv
phyox ole readout dcr-phxc
short interest float
given leadership transit compani aspect
dova review follow transit
kind price strategi could reconcil differ cost
market itp cld
revis outlook doptelet chronic liver
what long-term strategi compani interest
rigel tavaliss didnt launch well entrench idiopath
thromboycytopen purpura itp market what plan
doptelet european approv thrombocytopenia cld
doptelet us approv itp pdufa
ye data doptelet phase trial pre-surgeri thrombocytopenia pst
drug candid and/or diseas area
short interest float
biopharma co enter fund collabor dyai
evalu perform gene express platform
pipelin look attract addit pharma biotech
compani provid research fund evalu
data gener date sanofi/aventi mitsubishi
molecul interest
statu prior collabor sanofi pasteur
evalu whether could use develop season flu vaccin
quicker lower cost
what statu attempt produc primari metabolit
scienc advanc achiev past
year leverag industrially-proven technolog meet
need pharmaceut industri
up-list nasdaq
statu plan becom sec report compani
statu proof concept studi show
move otcqx
speed develop lower cost one type
short interest float
takeaway vyndaqel tafamidi trial use clinic trial design clear curv separ took
attr-act potenti show earlier benefit
tafamidi hasnt shown robust data nyha class iii/iv polyneuropathi stage ii/iii patient attr-act respect
patient progress far benefit stabil use think could still potenti candid
hope see ph ii ole data time horizon data becom meaning enough consid disclosur
work done daili extend releas formul would time new formul
head-to-head trial tafamidi undertaken purchas tafamidi us requir avail two tafamidi formul
influenc thought design execut compar arm
envis biolog rational combin treatment rnai silenc agent ttr stabil
cash balanc burn-rat price decis tafamidi assum approv us eu influenc latter
initi ph trial ttr-polyneuropathi
initi ph trial ttr cardiomyopathi
short interest float
repres christi shaw svp presid lilli bio-medicin
older anti-tnf continu domin dermatolog
anti-ngf therapi offer promis pain data emerg
could lilli newer biolog like taltz mirikizumab take share
around seriou case rapid bone cartilag loss
due data potenti chang reimburs
tanezumab solv market segment
lilli respond fda focu thrombot event
cgrp class three drug launch last year rel
around jak inhibitor like olumi especi given import
close togeth appear similar clinic profil
higher dose market pipelin aspir
compet emgal differenti space
mirikizumab pipelin antibodi get crowd
see potenti differenti product
stock catalyst biomedicin
fda review lasmitidan acut migrain
fda review emgal galcanezumab cluster headach
phase data olumi baricitinib atop dermat
phase data tanezumab long-term safeti studi osteoarthr
phase data taltz ixekizumab psoriasi head-to-head js tremfya
short interest float
rna-modul read-through technolog develop
effect non nonsens mutat ie
diseas benefit technolog
assum posit phase data envis phase
crispr gene edit technolog rapidli emerg
trial believ could acceler path forward
envis technolog fit treatment landscap
could provid overview cystinosi second indic
eloxx drug candid differ aminoglycosid
program similar and/or differ cf
term efficaci safeti profil
phase data cf de-risk program cystinosi
demonstr far clinic
pipelin asset
predict organoid model seen far
preclin seen far use compound
organoid model use
usher syndrom retin diseas
phase mad data cystic fibrosi
phase top-line data cystic fibrosi
phase top-line data cystinosi
short interest float
recent announc updat plan seek broad approv
tazemetostat first approv expect epithelioid
tazemetostat follicular lymphoma fl drove shift
sarcoma es rel small indic investor
regulatori postur gate element file
view opportun
outstand issu resolv
talk portfolio expans see
talk broad approv would shape
valu addit asset expand
opportun fl
tazemetostat franchis combo studi
diffus larg b-cell lymphoma dlbcl tazemetostat move
forward combin r-chop give us overview
program opportun beyond layer top
standard care prolong mainten treatment
submit nda file tazemetostat epithelioid sarcoma
updat tazemetostat data registr dataset fl mid
initi tazemetostat combin studi prostat cancer parpi
platinum resist tumor
submit nda tazemetostat fl
potenti approv tazemetostat es
short interest float
gvhd becom crowd valu proposit
treatment current test may chang
patient phsyician indic efficaci threshold
number patient receiv allogen hsct fundament cut
see blockbust trial graft vs host diseas
number gvhd patient need treatment
gvhd set site
go differenti asthma treatment
view readout divers
seem crowd field particularli base recent icer
indic connect view posit signal
gvhd direct posit asthma vice versa/neg signal
biocon partnership enabl equillium execut
psoriasi studi done itolizumab show margin
superior shot goal strategi concern regard
respons antibodi expect outperform
transfer ip cuba biocon us
equillium indic select strategi dose
improv previou result
earli initi ph clinic trial agvhd
begin phase trial cgvhd
select one addit indic develop
like initi poc trial treatment sever asthma
short interest float
compani strateg goal medium-term prioriti
opportun compani pursu area
compani lead product develop
commerci potenti recent licens product
includ
commerci strategi pipelin
consider outlicens product done
nda file
potenti approv
potenti approv
nda file
nda file
nda file
short interest float
ind fate initi ipsc-deriv nk cell candid
fate allogen t-cell platform knock tcr direct
clear updat us trial design
trac locu potenti advantag approach
patient enrol begin
disadvantag
allogen nk cell expect similar benefit
one attribut engin cell therapi seem add new
seen monoclon antibodi patient high-affinity/high-
function time allo function long term
differenti nk cell product engin
discuss result whether met expect
see path fda approv cell platform person
function near term decid go forward
product registr rather continu continu improv
talk invest manufactur made
real differ manufactur process across ipsc
ipsc clone select synergi
candid challeng scale product
substant dataset would need either term patient number
follow-up time make inform decis program
initi trial solid tumor
initi trial hematolog malign
updat trial
ind submiss allogen
complet enrol studi protmun
short interest float
lot focu jak revolv around safeti
idiopath pulmonari fibrosi ipf initi two phase
filgotinib specif contribut stronger safeti profil
trial base good result small phase
cv outcom mg xeljanz open label effect
understand filgotinib safeti
trial gave confid move forward fda
recommend develop add-on standard care
influenc decis posit compar
thing stand filgotinib testicular toxic
implic steroidogen tissu overal could lead
limit dose filgotinib fda
think filgotinib outsid term
depend manta trial
atx/lpa pathway critic ipf progress
set apart drug target pathway
fri use secondari endpoint phase studi
bring phase trial well
phase readout ra
public phase result
phase proof concept data sjogren syndrom
report top-line result phase toledo gener
top-line result phase select trial
short interest float
gener advair reflect guidanc current
expect price announc gener
compani expect price and/or volum eros follow
standard gener trajectori expect special
share parp inhibitor class achiev label
indic futur growth opportun term new
indic combin
would hif inhibitor gsk daprodustat replac
use gener erythropoietin dialysi treatment set
expect safer esa equival
plan balanc sheet comfort
current leverag ratio consum joint ventur
eventu spin affect gsk leverag
regulatori submiss cabotegravir rilpivirinela hiv treatment
fda approv hiv
pivot data trelegi athsma captain phase
pivot data bcma mm monotherapi
pivot data zejula ovarian cancer prima
short interest float
chang hemoglobin suffici voxelotor regulatori approv
think valu proposit voxelotor
prefer patient report outcom data
see voxelotor fit competit landscap
anticip fda conven advisori committe
particularli context gene therapi
meet voxelotor
intend commerci voxelotor
pre-nda meet voxelotor
top-lin result full trial
nda accept voxelotor
public phase trial
short interest float
analyst richard newitt medic suppli devic
plan evolv trauma portfolio becom
contempl revenue guidanc w/ respect us core spine
domin player space time
emerg tech robot placement vs trauma intenational growth
exciting/potenti needle-mov product
reason assum robot implant pull-through could add
lanch core spine
gmed underli us core spine growth msd run-rate
think normal cadenc robot
competit pressur compani experienc
placement year vs year couldv includ
mazor stealth avail launch jan
pent-up demand/unusu launch factor
give management confid stabil us spine market
reason time-frame expect new robot indic
rate gmed abili sustain above-mkt growth rate ex et
approv type addit app contempl
cfo search progress
full-scal launch trauma expect
excelsiusgp indic expans estim least one new indic
short interest float
come neoantigen identif investor think
current time biopsi vein process
rel predict capabl edgetm artifici intellig model
effect edgetm predict neoantigen induc vs
respons clonal vs subclon inhibitori vs stimulatori t-cell
marker other believ clinic relev
grtss neo-antigen vaccin platform also proprietari prime boost
system work believ rel
contribut system vs neo-antigen predict
beyond safeti signal would give confid
move forward program understand rel
impact vaccin nivolumab ipilimumab
march-april edg platform present aacr
ind submiss share neoantigen therapi
initi trial nsclc pdac
earli efficaci data portion
improv quick turnaround becom
set believ grtss neo share antigen vaccin
transform impact path registr
set potenti biomark enrich
explor combin beyond
expect ind grtss first bispecif program
bisab platform differenti competitor
share neo-antigen bispecif program
given recent sell-off among compani peer group
investor understand neoantigen space
short interest float
analyst puneet souda life scienc tool diagnost
fda approv could elabor convers
omni could elabor demand omni pickup
fda head file remind us
far biopharma product featur client
expect fda file timelin approv nation
appreci omni
coverag decis ncd
commerci org ramp-up commerci organ
lunar could elabor earli read lunar
far kind mix shift see
launch what custom biopharma/academ feedback
biopharma overal view biopharma biomark project
trial funnel go project negoti
common request get biopharma compani
present data major oncolog confer
fda approv ncd pan-canc indic
short interest float
updat commerci launch progress epidiolex
epidiolex market opportun tuber sclerosi
strategi go forward anyth think street
complex follow-on indic could potenti open
underappreci regard us launch ramp far
door addit indic road
launch prepar go europ could give
could discuss patent ip situat epidiolex
us updat time cost setup
sativex expect patent expir
registr plan sativex expect
timelin us launch
provid view long-term outlook
opportun medic use cannabinoid product
sativex fda feedback file requir
epidiolex phase data tuber sclerosi complex
epidiolex phase inititaion rett syndrom
sativex phase initi multipl sclerosi spastic
short interest float
commentari regard potenti valu avail futur bd/acquisit priorit earli vs late clinic stage asset
elabor plan expand new area
long-term growth trajectori key market product current portfolio
think rexulti competit especi vraylar given potenti label expans vraylar bipolar depress
perhap major depress disord mdd later
bar success upcom foliglurax data readout
intern drug discoveri progress spend plan
lu phase studi initi alzheim diseas
foliglurax phase proof-of-concept data parkinson diseas
rexulti pivot trial data phase alzheim diseas agit
short interest float
follow anim health spin focu chang benefit sharehold
expect na dental equip sale trend year robust view driver equip sale
character competit on-line vendor zensuppli segment expos on-line
pay revolv line credit dividend anim health spin view chang
growth dental servic organ remain concern posit servic larg organ also protect
perform guidanc
short interest float
likelihood time approv
market dynam progress rel
assumpt chemotherapi induc nausea
initi launch expect
like see fastest adopt market
segment surgeri type
opportun post-op pain control day
design address
april pdufa date post-operative pain
phase result opioid elimin trial bunionectomi
file
septemb potenti begin arbitrag period cinvanti
potenti launch
initi phase studi
short interest float
outlook compani exist product clozaril
develop strategi commerci opportun
trinomia canada
compani busi develop strategi
compani prioriti regard balanc sheet
commerci opportun vascepa canada
leverag posit execut strateg vision
file vascepa regulatori approv canada
file trinomia regulatori approv canada
potenti launch vascepa canada
potenti launch trinomia canada
short interest float
repres lucia chairman ceo robert borchert svp
long-term risk opportun
continu trajectori bp annual margin
stave threat disrupt
expans
beyond revenu earn outlook
tx judgement afford act risk
expect growth rate acceler
converg payor provid consolid
payment integr pi sustain pace growth
impact
organ ss inorgan driven
popul manag pm go-to-market bundl
talk cfo capital-expenditure outlook capit
strategi payor mix distribut
coordin benefit cob drive growth
updat pm sale cycl
new pi busi win particularli true commerci book
 build pm pi solution-set
short interest float
analyst puneet souda life scienc tool diagnost
prioriti mr lubniewski would great get view
prioriti come ceo role
project funnel give us sens overal biopharma project
funnel level engag biopharma
could provid timelin next catalyst
time could elabor time pdp project
enbed view master
updat pdp earli
updat pdp
recent report extens us
expect read-out indic expans
manag addit pleas see dr maureen
cronin role well prioriti
therapeut area would like explor
short interest float
silverstein head corpor strategi develop
advantag disadvantag target ligand
would like see would constitut home-run
rather receptor
advantag
thought competit landscap hs
rational initi anti-neutrophil
see phase studi hs hs clinic
respons hiscr measur
latest attribut
current known impact ethnicity/rac
differenti
patient hurley stage drug respons
phase shine studi differ phase
chang youv implement implement
phase shine top-line data hidraden suppurativa
short interest float
lumox facilit compani evolut fulli
emerg io space highli competit talk
investor think commerci opportun
iph program posit emerg io landscap
target nk cell attract approach
lumox addit opportun beyond current
overal view squamou cell carcinoma
head neck scchn landscap see
see posit competit cutan t-
phase durvalumab solid tumor data initi cohort
expans
updat monalizumab partner azn cetuximab
build-up us commerci infrastructur lumox start us co-
commerci
eu file lumox
short interest float
analyst daniel antalffi medic suppli devic
given controversi around real discrep estim recent
short report driver patient new oxygen therapi enter market per year patient pass away
oxygen market growth given enrol origin medicar program declin despit growth medicar advantag
think declin beneficiari oxygen therapi past year
penetr look current poc penetr base assess offer product warranti vs year
averag lifespan patient poc right way think number devic avail redeploy dme channel
long-term strategi think long-term strategi compani option avail poc becom
fulli satur busi look like year
dtc sale rep product could increas lead keep rep hire cleveland facil attrit trend sale rep
peak product per rep fast new rep ramp full product point manag expect full scale
product launch inogen one
short interest float
chief commerci offic blain davi head ir
first quarter sale arikayc surpass street
expect around discontinu
expect launch pattern see far
approach import medicar segment ntm
launch compar expect far
ex-u sale come much
could american thorac society/at infecti diseas
increas could expect ex-u prior approv
societi america/idsa guidelin updat impact arikayc
metric provid provid revenu
guidanc arikayc
mani doctor prescrib arikayc outsid
physician target therapeut specialist
adopt insight arikayc could integr
compani track submit arikayc eu japan
regulatori file respect
mycobacterial/ntm lung diseas caus mycobacterium avium complex/mac
arikayc eu file submiss ntm lung diseas caus
arikayc japan file submiss ntm lung diseas caus
phase willow data non-cyst fibrosi bronchiectasi earli
short interest float
factor contempl guidanc respect
aetna effect cross shield bcb
management see potenti sourc upsid guidanc
insp reimburs team secur addit
reimburs decis larg insur management
contempl model addit coverag decis
bcb region plan repres meaning mover
statu categori code re-submiss
adopt posit polici market access team engag
point management think econom could potenti
review process
effect pace/veloc adopt
es includ reason assum region
plan expand criteria includ broader
categori code review februari ama meet
addit bcb posit coverag devis next month
addit posit coverag major payor
japan inspir iv approv launch expect approv
commerci launch
short interest float
given flexibl platform share us view make good target indic
process indic select partner nv ex-vivo oncolog program
optim minimum effect dose platform readthrough competitor clinic endeavor
strategi partner vs retain futur drug candid
build pipelin expect balanc addit vivo ex vivo gene edit program
cash balanc burn rate
initi ind-en glp toxicolog studi attr program
submit ind applic attr program
short interest float
analyst richard newitt medic suppli devic
factor give management confid abil secur
management expect see benefit rep hire kick
expect impact cadenc base biz growth
perman j-code factor besid cat code
increment headwind could aris would put
sunset differ recent applic
pressur gm/opex guidanc
management anticip medic polici formulari impact
right time pursu dcb taken
eob data collect progress anecdot feedback
long mfter pursu type product
suggest help convert physician side-lin
appropri forum expect see
top-lin result ascend trial expect year-end
puts/tak consid get low high end
y/i revenu guidanc rang
ascend studi complet expect end
ascend top-lin result expect end
short interest float
commerci strategi lumateperon launch
bipolar depress doesnt work indic
success highli generic schizophrenia market
could pursu
could remind us lumateperon mechan action
latest thought pursuit depress indic
plan advanc early-stag pipelin product given
bipolar depress studi lumateperon
late-stag program lumateperon finish
bar readout clinic meaning
think street appreci current
could label expans support boost commerci
earlier stage clinic program lumateperon
success lumateperon
lumateperon phase data two phase monotherapi studi studi
bipolar depress
sep lumateperon pdufa data acut treatment schizophrenia
phase studi inititaion parkinson diseas
lumateperon phase data adjunct studi bipolar depress
short interest float
analyst richard newitt medic suppli devic
key consider get low high end
expect broader sp launch type clinic
data need obtain addtl reimburs reg approv
think quarterli cadenc ion placement
management hear field respect new
similar sp anticip time ou launch
robot platform jnj/mdt develop featur
mgmt view jnj/auri acquisit
management expect platform compet
impact isrg sell strategi monarch hand
describ right time step invest
ion combin diagnostic/therapeut capabl
new geographi india china long management expect
invest take payoff
what involv china tender process impact time
system placement think time respect
volum meaning ramp newer system
da vinci sp transor indic pend fda approv project
ion flexibl cathet robot launch
ion clinic trial commenc subsequ fda approv approv
industri confer societi american gastrointestin endoscop
surgeon sage apr american colleg chest physician chest
short interest float
analyst puneet souda life scienc tool diagnost
nip pleas see non-invas prenat test
gross margin see opportun
launch earlier month could discuss market opportun
improv gross margin reach exceed gross margin
test view part overal
patient pay recent launch patient pay offer
transmit last last year caus number
greater access genet tests us
compani look weather bill medicar germlin
see patient access servic anyth
test could elabor background polici
provid fit current payer
interpret submit bill medicar patient
earliest would know receiv payment
test
resolut uncertain around cmss interpret foundat
medicin ncd germlin test
announc new biopharma academ partnership
biopharma give us view trend see busi
instiut biopharma partner
short interest float
opportun olinciguat sickl cell diseas
outlook competit landscap us linzess
aspect offer support potenti use
growth trend linzess outsid us
develop partnership plan praliciguat
opportun persist gastroesophag reflux
current cash need futur financ plan
opportun delay releas non-opioid pain-
long-term vision compani develop solubl
expect separ legaci ironwood cyclerion
initi phase trial abdomin pain ib
phase result linaclotid evalu abdomin symptom claim
phase data olinciguat sickl cell diseas
phase data praliciguat diabet nephropathi dn heart failur w/
progress make studi praliciguat hfpef
diabet nephropathi hope see set
current statu olinciguat program sickl cell
diseas phase studi particular
distinguish idiopath pulmonari fibrosi program
lung retent issu riociguat vericiguat address
short interest float
datapoint give manag confid success
opportun explor ex-u develop
medium-to-long term strateg growth opportun
manag commerci plan drive market adopt
compani
sulopenem
would potenti financ need support launch
top-lin phase result sulopenem uncompl urinari tract
infect uuti complic urinari tract infect cuti complic intra-
potenti nda file sulopenem uuti cuti ciai
potenti file sulopenem
potenti fda approv launch sulopenem
short interest float
analyst daniel antalffi medic suppli devic
overal medic devic strategi think jnj devic busi within competit landscape/overal market
jnj strategi evolv devic busi time
long-term growth outlook analyst day talk medic devic busi whole return market growth rate
give confid achiev procedur volum grow price perpetu pressur
medic devic portfolio think portfolio holist whether right piec place lead competitor
ever-evolv medic devic market within exist portfolio import product launch next month
 strategi context previou question approach potenti inorgan build portfolio
think need fill gap portfolio compet effect other increasingli diversifi portfolio
hospit purchas environ chang broader volum growth price dynam within medic devic market
product launch first light-adapt contact len contain
photochrom darken expos bright light
new product launch medic devic includ attun
cementless system echelon next-gen power stapler vizigo steerabl
sheath acuvu oasi transit light intellig technolog
product launch verb surgic platform orthotaxi
short interest float
help set expect ahead potenti selinexor
see selinexor posit vs car-t multipl myeloma
launch penta-refractori multipl myeloma
dlbcl
current think around potenti european
reason confid confirmatori phase
boston combin studi relapsed/refractori multipl myeloma
data
see selinexor posit competit multipl
myeloma diffus larg b-cell lymphoma dlbcl landscap
boston data
nda submiss r/r dlbcl base sadal studi
short interest float
statu manufactur infrastructur see trade-off vs manufactur invest vs
relationship program matur
see clinic practic epidermolysi bullosa eb evolv success develop commerci
size ichthyosi opportun clinic trial execut challeng popul differ
role aesthet program krystal long-term strategi
final result phase i/ii trial
initi phase clinic trial ichthyosi
commenc pivot phase trial
initi phase clinic trial aesthet condit
break ground second gmp facil
short interest float
see squamou cell carcinoma head neck
present data retrospect studi pancreat cancer
scchn landscap evolv see tipifarnib
suggest tipifarnib could role next
posit head neck cancer treatment landscap
potenti step pancreat cancer
challeng get head neck cancer doc
differenti earli stage erk inhibitor
adopt routin genet screen clinic practic
stumbl develop
tell us reason confid
pathway potenti target tipifarnib
updat on-going phase ii run-hn studi scchn
scc cohort
updat tipifarnib phase ii studi hematolog malign
possibl european hematolog associ
initi data erk inhibitor phase studi
short interest float
analyst daniel antalffi medic suppli devic
nich strategi think nich strategi view key pro con strategi
sale nich market smaller priorit busi line alloc sale rep
stratifi high growth vs low growth market busi high-growth market
product portfolio vascular product line look portfolio holist key project drive growth given
lmat market leadership product line what right way think competit landscap
mix shift drive mix shift biolog past year ultim right way think long-term busi
mix dispos non-biolog implant biolog implant
 strategi criteria place potenti acquisit accret strateg fit perspect given acquisit
loss higher averag sale multipl paid acquisit think overpay primari reason loss
april hold earn call
beyond cash exit expect continu
acquisit
short interest float
tell us genedr technolog differenti vs competitor hemophilia defici
partnership strategi capsid
strategi indic select think opportun target tissu outsid liver
variabl sever methylmalon acidemia amongst patient larg market opportun
potenti endpoint could use approv biomark would suitabl acceler approv
short interest float
see margetuximab posit competit
target posit emerg io landscap
make attract target
havent seen full sophia data yet talk
mgnx bispecif antibodi platform compar
kind data would need commerci uptak
bispecif antibodi platform competit landscap
think addit partnership opportun
clinic updat
flotetuzumab clinic updat
short interest float
continu glucos monitor cgm chang treatment
lesson learn manag gross-to-
paradigm afrezza posit within shift
net go chang move forward manag
kind impact expect dtc campagin
discuss strategi regard target certain
walk us strateg rational shrink territori
interim updat one drop studi
publish ad-hoc analysi afrezza data
complet dose cohort phase pediatr studi
complet preclin toxicolog studi pipelin asset
file ind new pipelin asset
effect
short interest float
updat clinic path commerci strategi
expect learn refractori statu epilepticu
depress franchis post partum depress
studi success plan next phase
market potenti ganaxalon epilepsi
potenti biomark factor
capit need
could give us progress updat busi develop
effort diversifi product portfolio
could explain differ sage zulresso
fail super refractori statu epilept ganaxolon
potenti effect refractori statu epilepticu
ganaxolon phase data magnolia studi iv oral
ganaxolon phase data amarylli studi oral
ganaxolon preliminari phase data refractori statu epilepticu
ganaxolon phase inititaion epilepsi
ganaxolon phase data defici disord
short interest float
base analysi brand price increas januari appear declin slightli volum amount consist
seen latest view chang
entic option join wbad consortium competit renew process specif would point lead
success renew
chang anticip new leadership incom ceo brian tyler style differ think affect
oper result
opioid remain area concern respond fda warn letter earlier month
recent rebat propos affect distribut industri middleman protect econom
continu govern pressur drug price
short interest float
repres rouven bergmann cfo betsi frank head ir
growth opportun present mdso result pharma and/or cro consolid
shyft weigh earn deliv expect revenu see revenu ramp time
contribut earn growth
follow shyft acquisit mdso still room leverag view capit alloc futur come vs
character competit market largest competitor competit landscap chang last
year seen new entrant take share
character apac market win share apac govern agenc look expand presenc life
continu implement shyft
veeva continu expans clinic
life scienc industri expans apac
short interest float
analyst daniel antalffi medic suppli devic
rtg guidanc put take sale guidanc
rtg long-term outlook long-term sale guidanc compound-annual-growth-rate provid analyst day driver
growth acceler beyond
rtg portfolio portfolio reshap activ like order add higher growth higher margin busi also shed lower
growth lower margin busi rtg
rtg pipelin pipelin product critic rtg sale growth near medium term
catalyst rtg busi need watch next month
 product seem like overal rtg acceler new product develop last year think
product within rtg chang sinc youv taken busi could continu evolv
margin expans ebitda margin rtg think peak margin could
continu roll-out mazor stealth edit robot guidanc platform
earli fy product launch interstim micro sacral nerv micro
stimul bladder control full bodi mri compat
product launch closed-loop db deep brain stimul system
beyond launch adb adapt db closed-loop therapi
short interest float
youv guid data help
talk lesson learn roch disappoint
set investor expect ahead data
bulk data like platinum resist
ovarian cancer see benchmark
talk pro con target
effort lifastuzumab vedotin reason confid
mrsn approach could succeed
think busi develop opportun
phase data
short interest float
pw unmet meedic need
learn zfgn fail program
hyperphagia impact live pw patient
livoletid unacyl ghrelin analogu
differ acyl ghrelin
livolitid differ zfgn beloranib
discontinu due safeti issu livolitid safeti
learn intreg advanc livoletid
competit landscap look like pw
hyperphagia livoletid differenti
nevanimib congenit adren hyperplasia improv
upon current standard care
data support nevanimib potenti efficaci patient
livoletid phase studi initi prader-willi syndrome/pw
livoletid phase initi data pw
nevanimib phase initi data congenit adren hyperplasia/cah
short interest float
analyst richard newitt medic suppli devic
puts/tak contempl mgmt retier y/i
mgmt outlook china biz relat consum
revenue growth reason think growth deceler
growth capit sale sonastar sale transit royalti vs
level y/i asid tough comp
direct sale intenational mkt could help drive growth
nexu combin exist solut bonescalpel
impact suppli constraint us consum growth
sonicon sonastar initi surgeon feedback
els equal could us consum growth
nexu post-north american spine societi nass
suppli wasnt issu give management confid suppli
busi model nexu consid
constraint impact sale rearview mirror
happen recent sale forc turnov
contempl guidanc us capit sale
impact mson plan sale rep addit
launch nexu cross-sel and/or
criteria use evalu potenti accretive/tuck-in
 opportun prioriti particular part
busi wound vs neuro vs spine vs
nexu regulatori approv launch expect us china market
potenti acceler growth
short interest float
expect updat l-mind data
relapsed/refractori diffus larg cell lymphoma r/r dlbcl
longer follow-up central reader confirm respons
averag durat therapi
patient still therapi clinic trial could mean
durat increas time
discuss fda data guid
partner asset clinic valid event
collect delin contribut part safeti
efficaci lenalidomid alon combin
worth pay close attent
final data l-mind r/r dlbcl
us fda l-mind biolog licens applic bla accept
short interest float
analyst puneet souda life scienc tool diagnost
genesight could updat us current expect
genesight among pcp could elabor onyour plan
commerci reimburs timelin genesight pleas
pursu genesight primari care physician popul
discuss market penetr your see genesight
addit color provid around expect
counsyl could provid earli view benefit
complianc requir could elabor bit
recent sale forc cross-train physician custom
medicar complianc document requir
view overal offer
expect situat get resolv
risk score risk-scor market
elev could provid updat elev
time impact seen uptak volum
initi remain agenda relat
genesight reimburs unit top commerci payer
recoveri counsyl
short interest float
strategi offic corpor develop offic director ir
analyst puneet souda life scienc tool diagnost
genoptix view genoptix spent
per test elabor abil reduc cost per
time team look hood speak
test clinic test steadili declin
timelin facil consolid integr
synergi could remind us cost synergi
multi-gen could provid updat multi-gen panel
view cadenc year what
pursu
opportun sale synergi spent time
genoptix
pharma servic backlog pharma servic
stand expect see faster convers rate
broader commerci coverag genoptix test
short interest float
recent share data person neo-antigen vaccin
investor think rel predict capabl
give confid post-vaccin respons
deepen vaccin learn data
 go nivolumab run-in design rather treat
patient progress nivo nivo respond mainten
ntgn recon versu competitor platform effect recon
predict neoantigen induc vs respons clonal vs
subclon inhibitori vs stimulatori t-cell marker
other believ clinic relev
 learn anyth result help optim
go forward anticip explor therapeut modal
recon dose schedul process
tcr-t employ recon neo-antigen predict
ntgn explor sever combin strategi anti-
chemo agonisim
rel merit approach priorit focu
set believ ntgn neo share antigen vaccin
transform impact path registr
set potenti biomark enrich
differenti advantag disadvantag neo-pv-
person neo-antigen cell therapi
given recent sell-off among compani peer group
investor understand neoantigen space
data person neo-antigen vaccin
nivolumab melanoma nsclc bladder dancer
cta submiss person neo-antigen cell therapi
submit ind share neo-antigen vaccin breast cancer
data pembro chemo non-smal cell
immun data agonist
short interest float
analyst daniel antalffi medic suppli devic
capit need current burn rate quarterli perspect reduc conserv cash cash hand
exit long cash posit fund daili oper financ option nvcn
total address mitral market think market opportun tiara type patient could benefit tiara
mitral competit landscap number differ valv develop manag view competit landscap
market support competitor coapt data present tct transcathet cardiovascular therapi septemb
chang manag view role replac vs repair tiara differenti transcathet mitral valv
tiara mani patient implant date mani implant center momentum seem build enrol
last quarter current quarterli enrol rate expect see updat dataset medic meet
reduc reduc manag access address market reduc treatment avail
refractori angina patient think price reimburs eu
nvcn discuss fda final regulatori pathway
reduc explor financ option studi
nvcn plan submit ce mark approv transap deliv
tiara nvcn enrol patient includ tiara-i clinic studi
tiara-ii clinic studi compassion use novemb
short interest float
patient access growth trajectori xadago sinc launch
clincial develop pathway evenamid schizophrenia
updat pivot studi xadago levodopa dyskinesia
updat progress early-stag new pipelin
could label expans support commerci success
could explain proport apnea rett syndrom
patient current treatment regimen
could remind us clinic design on-going
xadago pivot studi initi levodopa dyskinesia
evenamid pivot trial initi schizophrenia
sarizotan phase star studi data rett syndrom apnea
short interest float
recent partner allscript veradigm discuss went process result benefit compani
given success formerli eagledream health strong popul health solut acquir look
monet invest
attrit elev sever quarter saw improv attrit trend far
improv attrit level
primari driver behind continu larg win discuss market competit custom
implement timelin differ larger enterpris deal tradit implement
custom satisfact rank kla
short interest float
pharmaceut us richard pulik north america head ir
import commerci stage clinic stage
type ii/iii spinal muscular atrophi sma greater revenu
driver futur revenu growth franchis
opportun zolgensma expect differ price
increas competit alter compani think
thought icer analysi zolgensma cost effect vs
particip establish therapeut categori
nv ad two new platform gene tx radioligand
expect addit bolt-on establish new franchis altogeth
add exist franchis
may zolgensma approv type sma
may zolgensma phase data type ii sma present american
academi neurolog
phase result entresto hfpef paragon-hf
broluzicumab fda approv launch wet
short interest float
engag insulin price
novo acquisit chang strategi
pipelin hyperforcus metabol diseas what
boost growth
exit inflamm immunolog
obes wimper despit explos diseas
gene therapi offer solut challeng
plan enter build market
solv plan wet feet
lot folk wonder plan nash non-
core protein compani believ
alcohol steatohepat given size problem
challeng solv metabol diseas
unmet posit market
address protein chemistri
innov left insulin and/or diabet
top-lin result phase explor studi concizumab hemophilia
supplement chmp opinion sustain data ozemp type
regulatori chmp european panel result esperoct hemophilia
short interest float
analyst richard newitt medic suppli devic
management feel nuva lt margin target time
give management confid underli us spine market remain
achiev factor give management confid stabl
rel flat stabl
oper west carrolton facil go forward
took step back us core spine spine
insourc attain
player saw improv happen nuva us core spine
busi transient
busi model puls begin book revenue
investor expect learn puls robot nass
go biolog meaning step vs
fair assum asp puls robot
give management confid growth trend
management estim nc end-market growth rate
robot address spine procedur bat lt
dynam play guidanc
contempl in-lin growth vs above-mkt growth prior year
strategi indic like pursu first
see biggest oppti vs robot market
need happen intenational busi return y/i level
robot arm launch puls navig platform like event
short interest float
clinic risk around nolasiban on-going
mechanist rational behind use pre-term
labor upcom data readout tell us
manag price commerci strategi
plan fund late stage trial lead product
nolasiban us ou market
well
linzagolix like differenti gonadotropin-
releas hormon gnrh antagonist development/on
interim efficaci result phase prolog studi pre-term
initi phase studi linzagolix endometriosi
primari endpoint data phase primros studi
linzagolix uterin fibroid
primari endpoint data phase studi nolasiban vitro
potenti eu file nolasiban
fda feedback regulatori pathway nolasiban
short interest float
commerci opportun nuzyra pneumonia
addit label expans opportun nuzyra
develop plan commerci opportun
earli launch activ progress nuzyra
nuzyra outsid us
key metric investor watch track
potenti ema approv nuzyra
phase data omadacyclin urinari tract infect uti
launch progress nuzyra us
short interest float
inc subsidiari intrexon corpor xon
mani investor may new tell us
uniqu safeti clinic manufactur risk
leadership team vision compani
platform approach
decemb last year receiv ind first sleep beauti
system ultracar-ttm program aml md
uniqu sleep beauti ultracar-ttm platform
term clinic commerci potenti
 approach requir lympho-deplet kind
 optim vector could other copi
ziopharm/intrexon/mdacc point care car-t differ
sleep beauti ultracar-ttm platform
adenoversetm vaccin platform differenti
competitor deliveri immun respons antigen design
dose schedul necessari possibl
target modal multifunct therapeut
 look data-wis valid
platform inform registr path look
site-specif data valid commer potenti
relationship intrexon well
scope oper freedom intrexon
initi trial ultracar-ttm aml md
advanc ultracar-ttm solid tumor
advanc adenoversetm vaccin solid tumor
advanc one infecti diseas candid
short interest float
character competit core group purchas organ gpo market segment size geographi
import pinc growth potenti in-sel opportun drive adopt variou technolog consult servic
addit technolog consult servic add valu custom sticki relationship
improv
center medicar medicaid servic human servic hh focu promot value-bas care
impact busi
recent earn call caution adj ebitda ep may come midpoint guid drive
busi look counteract
hh propos vbc
hospit activ volum
short interest float
initi phase ii result pemphigu
plan pv studi rituxan treatment failur
data show time respons depth
respons data updat new patient
fit treatment paradigm pemphigu
current rituxan steroid futur anti-fcrn
timelin phase pemphigu studi
could theori becom pipelin molecul
promis new indic beyond pemphigu
much earli stage invest new molecul versu
new indic
enrol data file
full data present phase iib pemphigu
full data present phase iib immun thrombocytopenia
initi phase ii multipl slecrosi sanofi sni
updat data fibroblast growth factor receptor fgfr
short interest float
lead program recent replac back-up
partnership janssen come ptg-
compound superior preclin effiaci
crohn diseas
come
differ much
improv could expect
phase data compar entyvio
ind submiss crohn diseas
phase pharmacodynam data ulcer coliti
phase initi data patient beta-thalassemia iron overload
disord
phase initi data tba
phase top-line result patient beta-thalassemia iron overload
disord
deal term
investor think market opportun ptg-
iron overload disord
updat search cfo
short interest float
compani proprietari combin therapi differenti
differ busi develop path pti take
vrtx tripl combin therapi
pend prioprietari combin therapi add-on therapi
compani on-track report combin therapi doublet
updat
triplet data add-on therapi symdeko background
could expect busi strategi updat
symdeko background data updat
licens agreement genentech allow
bogey aim achiev proprietari
genentech right portfolio small molecul modul
phase high dose data cystic fibrosi
phase low high dose data cystic fibrosi
initi data add-on symdeko cystic fibrosi
initi data add-on symdeko cystic fibrosi
short interest float
larg portoflio size organ think
success prosecut asset
drug success made finish line celiac diseas
better posit market opportun celiac diseas doesnt
ibd particularli challeng area recruit trial compet
abstin gluten work
rest field get patient onboard crohn diseas cd
system lupu erythematosu sle notori difficult treat
competit space set apart field oral drug
issu knock previou drug develop effort cours
cd difficult develop
appli lesson development plan
teplizumab fell short first time phase trial investor invest
drug time around success drug need real
impact type diabet
streamlin oper benefit risk
approach confid pull
use biomark translat medicin streamlin effort
investor miss compani
use databas amgen decod infrastructur
phase puls studi top-lin result ulcer coliti
phase princ studi top-lin result crohn diseas
initi phase studi type diabet
file ind type diabet
complet glp tox studi
launch phase trial celiac diseas
initi phase trial ulcer coliti
initi phase trial crohn diseas
short interest float
presid chief busi strategi jd ph
pleas discuss model puretech health differenti
akili digit therapeut pediatr adhd pleas
ventur fund differ typic
discuss approv pathway reimburs landscap
type intervent
 decid asset fall intern vs
gelesi role agent
common theme link project puretech
chose fund
continuum weight loss agent given difficult commerci
histori weight loss agent differ
fda review akili pediatr adhd proof concept result
fda review gelesi weight loss initi clinic studi
end phase feedback fda potenti initi phase studi
restorbio respiratori tract infect
phase top-line data result karuna karxt schizoprenia initi
proof-of-concept studi karxt addit indic
initi two phase trial vedanta peanut allergi
oncolog modul immun system microb colon
short interest float
analyst puneet souda life scienc tool diagnost
growth area us key area growth opportun
backlog could provid updat around backlog
establish presenc neurolog
srx
oncolog what experi expand
pharma servic us bit effort
oncolog area beyond neurolog
sr-x pleas sr-x launch far
import biomrieux licens termin could
stand total sale rep field enough
elabor opportun provid longer run
broadli reach custom
detail sr-x launch
short interest float
analyst puneet souda life scienc tool diagnost
manag mr walt familiar compani
eu market view eu market market overal
could elabor key step taken sinc join
opportun expctat soft launch
compani
europ ce mark updat impact european
regualtori fda could updat us regulatori timelin
what ahead point what left complet
capit recent restructur debt look
microarray trial expect fda submisson
overal capit structur suitabl drive growth
menu walk us current menu use blood
test lab test menu compar
demand catalyz
short interest float
zilucoplan differ eculizumab
insight provid second neurolog
remind us saw phase gener myasthenia gravi
indic preval market opportun etc
statu updat zilucoplan extend releas formul
trial design outcom compar phase
briefli comment phase paroxysm nocturn
studi soliri
exactli refractori gmg popul mean
phase plan pnh next updat
phase particip baselin characterist
investor think zilucoplan price
preliminari design phase gmg studi
zilucoplan end-of- phase regulatori meet gmg
zilucoplan phase studi initi paroxysm nocturn hemoglobinuria/pnh
zilucoplan second neurolog indic announc
short interest float
guidanc tymlo sale
addit elacestr phase ii data investor expect
assumpt market growth market share achiev
goal
hear result partner
incorpor potenti launch gener forteo
differ elacestr phase ii
amgen romosozumab tymlo guidanc
launch delay much revenu upsid could
phase trial hr advanc breast cancer
initi phase bridg studi tymlo patch
data elacestr phase cohort advanc hr breast cancer
execut partnership agreement elacestr
short interest float
see phase portion cardin studi
phase adpkd data compar tolvaptan
expect phase cardin
experi across cardin phoenix
indic pursu phase phoenix
compar aginast beacon trial
make differ egfr improv pattern
measur taken dispel hyperfiltr
seen across variou indic phoenix
hope show phase fsg studi
statu updat omaveloxolon friedrich ataxia
power assumpt phase moxi trial
phase falcon trial design power assumpt
bardoxolon phase phoenix data focal segment glomerulosclerosis/fsg
bardoxolon phase cardin data alport syndrom
omaveloxolon phase moxi data friedrich ataxia
bardoxolon phase catalyst ctd-pah
short interest float
unmet need pylori patient treat
potenti crohn diseas
talicia clinic profil differenti altern
pipelin asset investor focu
manag commerci strategi talicia
nda submiss talicia pylori erad
initi pivot phase studi pulmonari
potenti approv launch talicia
short interest float
much impact think brolucizumab launch year
eylea much eylea risk
approv age-rel macular degener
much eylea market medicar would propos part
 chang affect competit risk
led termin combin program libtayo
antibodi enthusiasm
six month ago dissip
dupix fda approv atop dermat adolesc patient
praluent fda approv cv outcom data hypercholesterolemia
eylea fda approv diabet retinopathi
dupix ema approv asthma
plan differenti libtayo market leader
competitor non-smal cell lung cancer nsclc
see bispecif potenti util nsclc
think market dynam play car-t
bispecif hematolog malign regeneron
stand competitor like roch
short interest float
analyst puneet souda life scienc tool diagnost
mab market see overal market demand
margin expans see opportun drive margin
mab give us view new therapeut excit
expans could discuss gross margin new
product mix
gene therapi term visibl vaccin gene therapi
asia give us view presenc asia area growth
newer market could provid color around market
see asia long-term outlook
dynam see penetr runway
spectrum almost year sinc announc
commerci org look commerci organ sale
spectrum acqusit pleas holllow fiber
rep give us top prioriti develop
consum deliv import spectrum
diversif overal
new product facil come line
pickup opu
short interest float
emerg io space highli competit talk
t-vec preclin data compar
oncolyt virus attract approach emerg io
space oncolyt virus compar approach like
talk pro con intratumoral-bas
deliveri approach pursu vs iv-bas approach
pursu player competit landscap
youv guid initi clinic data help set
investor expect ahead data
think potenti t-vec data readout year
beyond studi your pay attent
look data
initi phase data possibl
preclin poster present
short interest float
end phase ii meet fda occur
rational mtor inhibit neurodegen
agre propos phase design
diseas arent multipl contributor patholog
phase iib data tell us inform
phase potenti commerci opportun
explain recent hire vice-president drug discoveri medicin
counter argument investor say data
inconsist part drove efficaci
chemistri read
end phase ii meet fda
initi phase ib/iia parkinson diseas
initi phase respiratori tract infect rti
initi phase ii studi proof concept indic
short interest float
phase fort trial design power assumpt
scientif basi phase protect studi
seen compassionate-us pkan patient
investor expect igan data thought
confid effect due drug rather
competitor egfr improv ml/min week
enrol progress phase duplex top-line guidanc
determin go/no-go decis
assum posit data would fit treatment
see sparsentan phase duet trial
paradigm gene therapi emerg
proteinuria assess interim readout fsg
advantag thiola
need full approv
phase top-line data phenylketonuria/pku
neurodgeneration/pkan
thiola fda approv us launch cystinuria
glomerulosclerosis/fsg
short interest float
aspect trial design danon diseas endpoint durat trial number patient final
timelin expect recruit trial boy danon diseas girl women danon diseas
potenti util express surrog endpoint acceler approv danon diseas biomark
could serv surrog endpoint purpos
think patient receiv therapi process fanconi anemia fa clinic trial outcom
patient import eventu biolog licens applic bla file focus treatment process
could walk us improv made process process fa impact manufactur
clinic outcom could expect see chang
opportun compar fa patient undergo hsct could expect expand
number fa patient treat addit supplant hsct mani patient
initi phase trial danon diseas
addit data process patient fanconi anemia fa trial
dose first patient fa clinic trial use process
dose first patient leukocyt adhes defici trial
in-pati data process fa
short interest float
red cell compar cell therapeut
time reason confid rubi red cell
there potenti broad applic platform given
could long circul time
malleabl approach think priorit
talk potenti risk immunogen reason
indic pursu target go
long circul time red cell could key
advantag platform talk circul
confid wont issu rubi red cell
help set expect ahead initi clinic data rtx-
initi clinic data
preclin data multipl cancer program oncolog confer throughout
short interest float
fda expect studi complet
potenti swing factor cash burn come
new devic furoscix
month fda submiss
agreement west pharma chang econom
addit opportun exist technolog
product
leverag
furoscix commerci opportun
type meet request fda furoscix
potenti type meet fda furoscix
potenti nda submiss furoscix
short interest float
repres todd simpson cfo peggi pinkston vice-president ir
drive broader uptak adcetri hodgkin
expect pivot data tucatinib breast cancer
lymphoma skeptic adcetri valu proposit
data investig sponsor trial ist colorect cancer
addit evid need chang current nccn
discuss think program
guidelin avd recommend
set would consid move tucatinib
investor view opportun enfortumab vedotin
give us overview tisotumab vedotin trial
ev bladder cancer expect ev compet vs fibroblast
broadli express target role play
run trial ev keytruda bladder
cancer regulatori path set
top-line data cohort pivot trial enfortumab vedotin r/r
bladder cancer post checkpoint platinum
data pivot trial tucatinib metastat breast
cancer mbc follow prior agent
data investig sponsor mountain trial tucatinib herceptin
mcrc
potenti bla file enfortumab vedotin r/r bladder cancer post checkpoint
platinum base late
data innovatv trial tisotumab vedotin r/r cervic cancer
short interest float
factor contribut improv opu implant suppli level
earli feb right time gm chang give
give management confid vesta suppli level
management confid newly-appoint gm kirk gunhu abl
enabl sale rep agress target next tier
accl us capit sale keith sullivan gm prior mr
physician
engag strateg advisor role
give management confid agn decis suspend sale
leadership chang impact sien near lt outlook
textur implant ou minim risk/-iv read-through
miradri biz potenti sale forc disrupt
think potenti topics/outcom fda
breast implant panel sien revenue exposur
give management confid us miradri placement cont
ti us could risk shift away ti occur
accl step take attract capit rep
talent reason assum miradri still
growth busi in-lin consensu model
short interest float
commerci opportun tpoxx us
competit landscap biodef
compet market
compani growth strategi expand outsid us
compani capit alloc prioriti come
opportun label expans tpoxx
establish develop pathway us tpoxx addit label
indic post-exposur prophylaxi monkeypox
progress regulatori effort tpoxx ou countri
short interest float
presid clinic research medic affair regulatori farley vice-president
benefit srne pressure-en deliveri pedd car-t
differenti lead versu next gener car-t
cell indic like benefit
program mm decid continu registr
base small number respons car-t deliveri via
oncolog therapi would benefit sofusa lymphat
pedd move forward registr studi
deliveri could approach differenti mab
chosen pancreat cancer instead
 therapi sir-spher liver metastasi
fail show overal os benefit give
confid car-t administ via pedd differ
develop commerci plan mab
share detail koki system engin cell therapi
advantag look valid clinic
compar non-vir system like sleep beauti piggybac
see enthusiasm uptak ztlido sinc launch
talk celular place srne vision
initi pivot trial car-t pancreat cancer liver metastas
initi next gener cart multipl melanoma
initi bcma car-t multipl melanoma
initi mab sofusa deliveri platform solid tumor
initi target antibodi drug conjug multipl melanoma
short interest float
icl unit growth base case management hope
analyst richard newitt medic suppli devic
toric enabl open new account ophthalmologist
outperform reason think icl unit growth
previous sidelin
deceler new product momentum
investor think gm/oper margin
dynam play within intraocular lens iol
given invest made
busi given guidanc contempl reduct revenue
investor think averag sell price
similar declin seen
management estim staa market share china
staa expect rev/unit growth china
spend prioriti dtc market
differenti evo/evo product
impact surgeon willing treat lower diopter patient ou
give management confid earli presbyopia patient
will get icl realist way think
initi surgeon feedback visian toric icl
peak penetr staar estimate earli presbi eye oppti
us activ surgeon util trend sinc launch
evo visian icl fda approv pma supplement submit fda
evo edof european trial complet enrol complet
evo edof ce mark submiss mid-year
short interest float
analyst richard newitt medic suppli devic
continu drive revenue upsid rel lrp much
realist think mako util rate continu climb
management will drop-through bottom line vs reinvest
strong level y/i fuel share gain
reason assum could upward estimate bia
us knee custom base target
mako mgmt expect cementless knee
adopt tka cementless
adj org revenue growth highest rang head
factor continu drive revenue growth accel us hip
new year issu yr factor give
potenti needle-mov product launch
management confid strength underli busi
reason assum growth driver similar
give management confid trauma suppli issu behind
new product contribut seq growth accl
area business/exist portfolio management think could
sustain low-dd neuro/spin growth ex
benefit inorgan vs organ invest
what latest view market
mako total knee arthroplasti tka data expect time-frame
camera launch endoscopi expect end
short stem shoulder launch expect
industri confer american academi orthopaed surgeon aao
orthoped
short interest float
syneth biotic platform differenti
difficult execut sinc program util
biotech compani utilizing/target microbiom
two engin pathway vs one could
engin metabol pathway
biomark measur hepat
encephalopathi urea cycl disord accur
assess efficaci
goal pursu hepat encephalopathi
urea cycl disod assum show earli promis
engin metabol pathway
challeng translat clinic
could fit treatment regimen among
approv pku therapi program develop
immuno-oncolog differenti
sting agonist develop could expect studi
enter clinic
mani addit io program could expect futur
phase top-line data liver cirrhosi elev ammonia/hepat
encephalopathi
phase top-line data phenylketonuria/pku
ind file immuno-oncolog
phase data urea cycl disord
short interest float
provid brief overview differenti alpha alpha therapi
confid thor approach suffer therapuet window toxic challeng aldesleukin
take away result competitor trial rhhbi fusion protein combin nivolumab
adapt strateg plan base data
phase trial plan efficaci pk/pd signal need decid broader develop path
segment patient believ benefit combin hypothes select biomark
beyond combin excit
lead program thor synthorin platform statu cytokin synthorin valu see long term platform
explor addit therapuet modalitit
synthorin platform manufactur challeng risk
file investig new drug ind applic
single-ag biomark data on-going
initi combin trial checkpoint inhibitor
combo checkpoint inhibitor biomark data on-going
short interest float
analyst puneet souda life scienc tool diagnost
er would describ traction
demand could speak current funnel propos
emerg depart far
overal demand
sale process could updat us sale process
blood cultur could tell us much bacteri opportun
time take go initi propos final order
cover current menu expect
expans current menu
pipelin could provid us progress updat
carb-x allergan collabor
adopt clinic
addit addit pathogen
short interest float
manag outlook opportun gener
outlook expans buena nj manufactur
inject topic formul space
latest updat orphan gener product
financ agreement chang capit
receiv complet respons letter septemb
progress compani made obtain new approv
updat orphan gener product
continu expans manufactur capabl buena nj facil
short interest float
excit mdco drove join
advantag inclisiran antibodi
remind us orion studi on-going theyr
much competit threat vascepa inclisiran
differ one anoth
purpos repatha-switch studi
main takeaway latest guidelin
much flexibl cog compet
time orion data long-term outcom data
repatha praluent
latest dsmb review show anyth
hypercholesterolemia market evolv sinc price
reduct monoclon antibodi
inclisiran phase top-line data hypercholesterolemia
inclisiran nda/maa submiss hypercholesteroemia
inclisiran dsmb review hypercholesterolemia
short interest float
svp clinic develop dobbin head ir
earli launch metric yupelri launch chronic
patient would clinic meaning chang symptom
score disclos power assumpt
revenu potenti trelegi phase asthma studi
far cash runway recent debt financ provid
analog copd tripl therapi use similar proport
asthma copd patient diseas popul
larger absolut number patient tripl therapi today
expect baselin symptom score ohsa
phase neurogen orthostat hypotens noh
pivot data trelegi phase captain athsma
launch metric yupelri copd
phase data inhal jak inhibitor
option sourc capit point time
short interest float
toca retrovir replic vector rrv platform lead
rgbm earli signal rare replic author
bemoan difficulti statist design
updat collabor oncolog studi
give confid except
 fc newli diagnos gbm patient
 done mitig risk scale
 fc recurr high grade glioma rhgg five
design registr trial
durabl three year elig group number
durabl compar favor histor data led
btd/prime design efficaci evalu group
surviv rate closer histor
give confid impress signal real
 biolog elig patient make
like respond fc
 given inclusion/exclus criteria percent rhgg
popul would elig fc
stratifi mutat kp geographi
gbm astrocytoma statu tumor size
give us detail price launch strategi
second interim analysi registration-en rhgg
final analysi registration-en rhgg
data metastat solid tumor
updat launch plan regulatori convers ndgbm regisr
short interest float
comment progress phase i/ii cystic fibrosi
first data readout consist safeti data
expect see efficaci data specif data
comment statu fda clinic hold over-the-counter
defici fda provid inform
safeti data cf phase i/ii trial
efiicaci data cf phase i/ii trial
clinic hold anyth anim data might
caus concern
progress regard collabor sanofi
disclos specif target go
short interest float
recent updat
preliminari thought phase trial design
briefli see long-term kinet
think could benefit singl registr
phase hope-b studi
comment pre-exist antibodi titer phase
comment gene therapi manufactur
exclud patient phase base antibodi
early-stag program work
shown preclin
phase data updat hemophilia
initi phase studi huntington diseas
short interest float
acut price growth continu elev level seen
acuiti payor mix manag care organ
rate embed guidanc
macro environ becom pressur point volum la
vega nevada south texa play
acut jv perform updat pipelin uk
wage labor cost environ look like
pressur salari wage benefit swb line health system
behavior privat equiti asset compet talent across
nurs also psychiatrist
acceler payor-driven acut shift outpati
 pipelin acut behavior asset
asc factor guidanc capit
govern reimburs environ behavior
like see continu length-of-stay lo pressur
much go shift manag medicaid
capit deploy prioriti invest de novo facil
outpati substanc abus electroconvuls therapi ect servic
increas dividend pay-out acceler share repurchas
updat govern investig oper fallout time
offic inspector gener oig settlement
stabil behavior segment reset growth expect
regulatori settlement offic inspector gener oig
acut market acceler ambulatori buildout
potenti transact fuel consid best-in-class
short interest float
analyst puneet souda life scienc tool diagnost
collabor could provid us detail
address recent question around potenti competet liquid
recent collabor investor think
biopsi uniqu percepta make integr
durat collabor mileston associ
current diagnost procedur conduct pulmonologist
envisia cash break-even guidanc next year came earlier
afirma current stand penetr afirma
expect could discuss main factor
could number potenti reach longer term
contribut
sale forc could updat us sale forc cross-
percepta provid updat uptak percepta
train complet across product
convers commerci payer could also
present data beyond like start american
thorac societi may
extens partnership
short interest float
pleas describ copiktra posit
follow commerci partnership china japan
drug rel gilead zydelig
think commerci europ
sinc launch copiktra septemb describ
import move copiktra combin studi
initi feedback physician see copiktra
think potenti combin ventoclax
differenti zydelig
initi market strategi see launch
cll/sll vs fl
commerci updat copiktra earn
interim data duvelisib investig sponsor trial
addit busi develop partnership duvelisib ex-u
short interest float
 vice-president busi develop
analyst daniel antalffi medic suppli devic
total address market rais estim help us bridg
think growth outlook cartilag repair market key driver market growth
indic expans indic expans possibl indic expans possibl exist much expand
tam/acceler long-term growth profil
maci year maci ramp think penetr perspect relat patient popul
potenti physician procedur quickli physician ramp volum complet train bottleneck adopt
epicel given much volatil busi think sustain long-term growth profil long-term
growth driver epicel busi ad new epicel user driver growth skew toward exist center procedur
capit deploy come possibl type asset would make sens busi criteria
manag consid evalu opportun current balanc sheet size deal might abl
estim complet studi compar efficaci
safeti maci vs arthroscop microfractur treatment patient age
year symptomat articular chondral osteochondr defect knee
short interest float
main sell point new smartbadg pitch exist custom new badg justifi
impact govern shutdown end year book convers progress sinc govern re-
deal increas mix shift devic softwar sale softwar sale limit potenti devic revenu
guidanc rel disappoint compar consensu estim lead expect second half recoveri
market dynam like larg deal still see traction intern
dod va win
short interest float
could give us introduct aav gene therapi
durabl treatment effect vy-aadc still
platform decid focu diseas
think new collabor neurocrin
updat preclin pipelin project prioriti
current partnership sanofi
move clinic develop
could remind us clinic design endpoint
on-going pivot trial vy-aadc could open-label
phase data translat clinic benefit pivot trial
vy-aadc long-term data phase posterior-trajectori dose part
select lead candid friedreich ataxia program
vy-aadc pivot trial initi parkinson diseas
advanc al huntington diseas program toward ind file
short interest float
trend see drug price gener deflat stabil brand inflat rel last year
view landscap market follow cvs-aet ci-esrx deal merger affect competiv environ
partnership accomplish see partnership grow futur
seem like walgreen announc multipl cost save program past year differ transform
save program timelin save look like
view capit deploy move forward open larger deal type deal would find attract
updat view potenti purchas remain stake
expans exist introduct new innov partnership
save program save end third year
short interest float
outcom measur expect see readout precision-hd trial could earli data chang unifi huntington
diseas rate scale score function measur present addit htt protein level
compet oligo ionis-httrx huntington diseas hd demonstr mutant htt protein knockdown highest dose test
month treatment fair expect mutant htt knockdown
competitor roch mention possibiltiy file approv huntington diseas within next month possibl
similarli expedit approv pathway
investor argu bar dystrophin express duchenn muscular dystrophi dmd gene therapi seen
efficaci view bar oligo dmd
expect updat design trial suvodirsen exon amen dmd fda complex innov trial
design pilot program factor trial design indic
initi phase trial exon amen dmd wve-
frontotempor dementia ftd amyotroph later sclerosi al
top-line readout phase i/ii trial
interim analysi suvodirsen exon amen
select lead ophthalmolog candid
short interest float
xncr bispecif antibodi platform compar
potenti indic
bispecif antibodi platform competit landscap
think indic worth pursu
youv guid sever phase bispecif dataset
among technolog licens program alexion morphosi
help set investor expect initi phase data
two advanc program ultomiri
obexelimab size
phase data
phase data
phase data
talk econom partner
potenti near-term mileston payment
short interest float
formal remain outstand ahead fda pdufa date
key clinic data announc early-stag
gvoke hypopen
pipelin expect next month
xeri commerci strategi gvoke hypopen
follow recent capit rais manag anticip
interest pipelin opportun
addit capit need would next year
june pdufa date gvoke hypopen sever hypoglycemia
eu phase result glucagon rescu pen sever hypoglycemia
phase vial/syring result self-administ glucagon post-bariatr
phase result diazepam auto-injector acut repetit seizur
phase result continu glucagon hypoglycemia-associ
phase result self-administ glucagon exercise-induc
short interest float
director billi cho cfo jonathan wang svp head busi
talk evolv healthcar landscap china
develop plan margetuximab china breast
zlab posit evolv landscap
gastric cancer
niraparib posit china parp poli ribos
investor view commerci opportun niraparib
china
margetuximab licens posit sophia studi
result recent report breast cancer talk
niraparib china phase data recurr platinum-sensit ovarian cancer
mainten
niraparib prima readout
potenti niraparib china nda approv launch
potenti optun china approv trial waiver launch
sophia data present
also gastric partner bemarituzumab talk
margetuximab bemarituzumab fit
short interest float
analyst richard newitt medic suppli devic
rosa go posit vs robot
expect op leverag situat thing
differenti
normal busi think
rosa total knee enhanc zbh abil regain market
revenue growth dropthrough bottom-lin
share begin take order
look across busi -- -not knee
think revenue contribut
seem big focu robot -- -where see
suppli remedi new product
biggest opportun chang turnaround
initi focus help shift organ
back offens potenti hurdles/bottleneck still need
commerci strategi rosa total knee
overcom aggress target physician
spine competitor yr head start
asid rosa exciting/potenti needle-
brain mgmt view discount capit exchang
move product launch across zbh busi
area busi present greatest oppti
rosa total knee launch limit launch full launch tbd
investor event american academi orthopaed surgeon aao
person revis full launch anticip
short interest float
commerci strategi fintepla compet
could give us updat japan approv process
epidolex launch dravet lennox-gastaut
fintepla dravet syndrom
plan product portfolio diversif fintepla
plan monitor cardio safeti signal real
would consid intern and/or busi
world set mirror clinic trial reason
children epilepsi
could provid color thought price
expect phase readout fintepla
fintepla approv dravet syndrom
lg work indic
fintepla fenfluramin pdufa date dravet syndrom
fintepla fenfluramin phase date lennox-gastaut syndrom
short interest float
valuat price target appli ev/sal multipl estim
assum stabl multipl vs current estim continu believ top-tier sale
growth profil profit warrant premium repres uniqu asset increasingli volatil market
valuat pt base sotp analysi forecast cash flow
risk valuat risk rate valuat includ failur
drive increas util rate and/or continu add new account steadi rate failur
execut pipelin launch new geographi potenti reimburs declin
potenti competit pvad product secur approv gain meaning market share
potenti product recal
risk valuat nuplazid rx rebound neg news new indic
nuplazid work trofinetid rett syndrom mani new competitor may steal
valuat price target base npv methodolog assign
probabl success po luspatercept rs esa-refractory/ineligible/intoler md esa-na
md md subpopul also assign po luspatercept
transfusion-depend -independ beta-thalassemia respect assign po candid
sotatercept pah fshd deriv price target discount probability-
weight annual cash flow small/mid-cap biotech discount rate assum
termin growth rate cash flow beyond addit factor acceleron cash balanc
risk valuat risk valuat includ clinic regulatori commerci
competit risk compani import pipelin product luspatercept well
develop disappoint phase result luspatercept
posit acceleron program remain rel earli stage therefor signific
uncertainti exist development-stag compani sever year away turn profit
compani also face risk associ continu access capit market given
continu oper loss financ invest
akao valuat subsequ date investor reli invest rate valuat and/or
estim deriv price target akao month use dcf analysi discount
rate termin growth rate model gross us sale assum
partnership akao receiv mid-double-digit royalti also model
gross us sale cuti small royalti royalti rate discount rate
rang earli stage commerci compani coverag univers howev longer put forth
achn valuat pt base discount cash flow dcf analysi incorpor two
complement-medi diseas paroxysm nocturn hemolysis/pnh
current estim penetr pnh patient whose diseas well control
soliri roughli treatment-nav pnh patient peak ascrib probabl
success po indic believ repres peak sale approv assum
peak penetr coincid expir orphan drug exclus ode us order account
potenti gener competit also includ potenti revenu po reflect earli
stage develop peak sale achn complement inhibitor portfolio benefit
extens patent protect last whose extens could strengthen longev
revenu stream pre-commerci compani appli discount rate termin growth rate
consist similarli situat compani coverag bold
akao risk valuat longer put forth price target longer put forth
risk valuat
achn risk valuat risk valuat includ competit risk
product receiv approv enter commerci risk associ clinic trial
valuat pt base sotp analysi forecast cash flow
adap valuat price target adap base blend dcf analysi
revenu multipl analysi assign valu probability-weight sale tcr
probabl success nsclc scchn melanoma bladder probability-weight sale tcr
probabl success nsclc scchn bladder ovarian probability-weight royalti
ny-eso tcr probabl success synovi sarcoma probabl success mrcl
afp-tcr program repres upsid valuat use discount rate termin growth rate
risk valuat gocovri may meaning improv believ
versu amantadin payer tougher expect reimburs new improv
old molecul adama abl replic clinic success gocovri
molecul gocovri ms walk success physicians/pay may prefer gener
adap risk valuat adap pipelin program face clinic regulatori develop
risk well commerci intellectu properti risk adap also face execut risk
financi risk adap may addit financ need turn cash flow posit
valuat agil share current trade ev/ebitda under-valued compar
life scienc tool peer group averag believ
ev/ebitda valuat provid best measur agil valu price target
expect agil trade premium averag lst group ev/ebitda multipl
result appli ev/ebitda multipl ebitda estim given number tailwind
posit agil better compar lst peer group continu exposur robust biopharma
growth china demand believ premium warrant sustain
risk valuat primari risk price target biopharma declin
pose greatest risk agil margin expans plan declin biopharma fund could
highli impact agil revenu given revenu lever biopharma industri
believ gener biopharma price risk mute given elect outcom howev
impact regulatori chang could see biopharma compani becom cautiou
 spend could impact capit equip purchas includ
agil slowdown biopharma fund would result downsid risk estim
valuat biomolecul forecast ramp drug market mid-teen
believ prolifer drive use agil mass spectromet character
molecul pronounc slowdown biopharma core growth requir
margin expans would sever slowdown global budget research could
pose downsid risk forecast tighten budget govern academ
fund could result lower revenu rel estim agil much
academ government exposur competitor nevertheless
slowdown academ spend could headwind plan margin expans assum
expect core growth furthermor restrict global budget could result shift focu
strategi growth could increas oper risk declin government spend
could risk downsid forecast growth nih spend flat
soft demand emerg market could derail growth forecast geopolit risk emerg
market could disrupt oper downsid risk valuat forecast geopolit risk
could also impact agil strategi creat higher barrier entri exist futur market
agil oper numer intern market includ china middl east europ
macroeconom impact chines market could lead declin compani revenu
regul chines polici could also caus restrict oper lead lower activ
china question remain china concern detail headwind could
emerg polici continu volatil energi chemic sector could impact growth
agil consider exposur revenu chemic energi industri agil
expect recoveri next year continu volatil crude oil could result downsid risk
agil expect low-single-digit growth next year volatil oil price could impact
budget next year spend certain countri dictat commod price
would lead lower spend chemic energi
valuat use risk-adjust sum-of-the-part methodolog valu agio examin clinic
regulatori commerci risk opportun individu indic region assign
probabl success account likelihood achiev revenues/expens risk-adjust sum-
of-the-part analysi appli discount rate cash flow gener one agio asset
determin total net present valu risk-adjust asset total npv reflect remain clinic
regulatori risk program
risk valuat clinic risk agio numer clinic trial on-going
pipelin asset trial fail either safeti efficaci reason would repres
risk current valuat regulatori risk even agio clinic trial success
regulatori approv still need commerci compani drug failur obtain time
regulatori approv repres risk current valuat acquisit possibl agio
acquir larg pharma biotechnolog compani signific premium current level
repres potenti upsid risk current rate pt
valuat price target base simpl averag three
approach believ reason basi valu stock today approach simpl
price earn multipl compar large-cap biopharma compani
nvo growth adjust near-term earn multipl ratio discount cash flow dcf use
rel multipl similar growth compani ep appli ep estim
alexion give fair valu stock use expect ep compound-annual-growth-rate alexion
period current averag ratio larg molecul large-cap biotech give
ep multipl discount multipl compress alexion appli
ep estim give fair valu final dcf use termin growth rate post
give current valu averag three valuat methodolog pt
risk valuat risk view outlook valuat alexion includ
major chang price reimburs coverag label soliri compani main
product today risk includ commerci develop disappoint recent
launch product strensiq kanuma well develop disappoint addit
indic soliri successor complement inhibitor product final brand
gener competitor product soliri come market captur greater share caus greater
market price disrupt current expect futur outlook valuat would
undermin opportun better perform valu expect includ stronger
initi adopt recent launch new product forecast success develop
commerci new indic soliri beyond neuromyel optica
myasthenia gravi novel rare diseas medicin time horizon forecast
valuat pt base sotp analysi forecast cash flow
agn valuat pt base sotp base busi plu pipelin discount
valuat price target base discount cash flow
methodolog forecast sale onpattro basi probability-weight scenario
analysi risk-adjust sale pipelin agent givosiran lumasiran risk-adjust royalti partner
program fitusiran inclisiran explicitli model expens result cash flow assum
discount rate consist compani coverag univers revenu gener approv
product wholli own independ commerci least one end-market termin
growth rate addit factor net cash balanc valuat
valuat pt base dcf analysi forecast cash flow
use wacc termin growth rate
valuat price target month base discount cash flow dcf
analysi probability-weight sale use discount rate termin growth rate plu net cash
risk valuat earlier-than-expect deterior royaltiesflatten growth
trajectori vivitrol aristadalow royalti revenu due earlier-than-expect
gener entri tecfideraneg efficacy/safeti data
agn risk valuat new competit impact botox expectedmed
aesthet franchis growth strategi workneurosci pipelin fail materi
risk valuat risk view outlook valuat alnylam includ
major chang price reimburs coverag unit state europ rare
diseas drug onpattro compani key pipelin drug givosiran
lumasiran forecast onpattro also subject risk better-than-
expect market share inotersen tafamidi unmodel competit entrant use
disrupt technolog gene edit risk alnylam includ clinic regulatori
disappoint pipelin excess factor probabl adjust
addit onpattro sale profit fail match estim dilut financ beyond
forecast model may requir order support futur commerci oper
clinic develop pipelin agent
risk valuat risk valuat includ sticki market share makena
subcutan auto injector faster signific gener im makena penetr earlier
gener competit ferahem slower-than-expect uptak intrarosa meaning penetr
intrarosa non-prescript dyspareunia market regulatori risk vyleesi clinic risk
ciraparantag
risk valuat risk includ potenti disappoint clinic data regulatori
setback commerci shortfal dilut financ sinc present two late-stag
product candid possibl setback may impact stock significantli
aptx valuat price target base discount cash flow dcf analysi
current expect patent expiri dcf valuat account cash
flow current net cash use wacc termin growth rate
assign probabl approv dpn fm assum drug launch
reach risk-adjust us sale assum aptinyx engag larger
pharmaceut partner ex-u commerci exchang royalti reach mid-teen
also model signific share dilut time commerci launch expect
compani requir substanti addit equiti financ develop commerci larg
aptx risk valuat price target base discount cash flow
dcf analysi current expect patent expiri
dcf valuat account cash flow current net cash use
wacc termin growth rate assign probabl approv nyx-
dpn fm assum drug launch reach risk-
adjust us sale assum aptinyx engag larger pharmaceut
partner ex-u commerci exchang royalti reach mid-teen also
model signific share dilut time commerci launch
expect compani requir substanti addit equiti financ develop commerci
larg indic
valuat price target base dcf forecast cash
flow includ termin growth rate forecast sale colorect
cancer non-smal cell lung cancer triple-neg breast cancer begin grow global
probability-of-success adjust total assum discount rate given earli
stage compani addit factor project cash posit valuat longer
term valu stock could appreci significantli on-going plan trial increas
probabl assign develop compani lead compound
risk valuat subject typic risk associ clinic stage
biotechnolog compani earli stage asset product candid either phase
preclin stage carri signific develop risk proof-of-concept efficaci
human safeti establish sinc major asset concentr
adenosin pathway fail demonstr efficaci discov unforeseen safeti liabil
adenosin inhibit would signific downsid cash flow forecast
valuat forecast valuat also risk intens competit
compani develop molecul target adenosin pathway competitor immuno-
oncolog gener final multipl round dilut financ like requir
success advanc portfolio regulatori file approv
valuat pt base dcf analysi forecast cash flow
use wacc termin valu
risk valuat tenapanor drive valuat clinical/regulatori failur would
significantli impact valuat and/or inabl rais capit fund busi beyond
valuat rate share outperform pt shift focu away legaci
product belviq weight-loss toward proprietari pipelin innov medicin target
cardiopulmonari gastrointestin gi autoimmun indic could creat signific sharehold
valu view leverag biolog mechan valid garner attract
 valu ozanimod rcpt/celg op selexipag atln/jnj op management focu smaller
nich market also enabl compani independ pursuit commerci larger market
ulcer coliti uc could attract partner alreadi establish space pah longer term
could introduc follow-on candid well execut life cycl manag lcm strategi
expand proof concept demonstr lead cardiopulmonari gi indic pursu
diseases/afflict share biolog mechan current assign probabl etrasimod uc
extraintestin manifest eim program pyoderma gangrenosum pg primari biliari cholang
pbc ralinepag assign probabl pulmonari arteri hypertens pah
pain associ crohn diseas respect discount cash flow dcf analysi use
discount rate termin growth rate reflect manag execut optim toward
arql valuat price target arql base blend dcf analysi
revenu multipl analysi assign probability-weight us sale arq chronic lymphocyt leukemia
cll probabl success assum royalti ex-u sale futur partnership also
assign valu probability-weight royalti arq intrahepat cholangiocarcinoma icca
probabl success probability-weight sale arq proteu syndrom probabl
success arq arq repres upsid estim use discount rate
risk valuat shift focu proprietari pipelin risk
associ clinic trial execut disappoint trial data regulatori review commerci
success relev meanwhil manag on-going effort divest/off-load belviq
franchis could lead unfavor term agreement may impact valuat
arql risk valuat arql pipelin program face clinic regulatori develop
risk well commerci intellectu properti risk arql also face execut risk
financi risk arql may addit financ need turn cash flow posit
arri valuat use risk-adjust sum-of-the-part methodolog valu array biopharma examin
clinic regulatori commerci risk opportun individu indic region
assign probabl success account likelihood achiev revenues/expens use
wacc termin valu nopat indic depend length patent
protect account valu beyond add cash requir invest
asnd valuat deriv per share price target asnd month base dcf analysi
use discount rate termin growth rate price target assum probabl transcon
hgh approv pediatr growth hormon defici pghd lead peak risk-adjust net sale
estim addit model early-stag program expect gener
addit revenu begin peak risk-adjust net sale estim combin
valuat price target base dcf methodolog cash flow
termin valu forecast risk-adjust sale assum
discount rate base compani wacc addit factor cash balanc valuat
valuat next month believ share trade valuat
appli ev/sal multipl revenu estim assum basic stabl multipl
current level estim compani get back track deliv consist
out-performance street estim move higher current level believ share deserv
least maintain slight discount broader small-cap med-tech univers averag includ
nxtm believ compani continu deliv given
stabl mid-to-high teen sale growth outlook longer term mi come line potenti meaning sale
oper synergi estech ncontact acquisit close increasingli clear
pathway profit turn ebitda posit base estim
arri risk valuat commerci risk array launch two product
braftovi mektovi treatment braf melanoma repres compani first
commerci product failur meet exceed sale expect repres risk
valuat clinic risk array number on-going trial develop candid includ
encorafenib binimetinib trial produc clinic data
disappoint rel investor expect repres risk valuat competit drug
compet array could produc superl clinic data lead increas
competit market less-than-anticip uptak arri product repres risk
current valuat
asnd risk valuat risk valuat includ potenti neg clinic
competit regulatori fda surpris particular emerg landscap biosimilar
may limit premier price asnd inject signific technolog advanc
develop longer-act version inject biolog
risk valuat risk view outlook valuat assembl includ
major clinic failur competitor cpam could lower probabl
success class potenti commerci outlook could also diminish
novel hbv therapi produc superior clinic data drug profil accept
physician patient regardless competit risk uptak new approv
medicin hbv minim payer creat arduou restrict prevent access
assembl never achiev product revenu posit cash flow futur period provid
adequ return current invest addit dilut financ like requir order
support futur commerci oper clinic develop
risk valuat risk includ failur success execut surgeon
train new af indic drive slower-than-expect revenu ramp slow open
heart procedur growth and/or adopt concomit surgic ablat clinic trial delay
failur receiv clearanc next gen atriclip system ou regulatori delay
bold valuat bold leverag in-hous manufactur capabl har gene therapi
potenti deliv cur therapi treat rare ultra-orphan diseas bold program seek either
improv upon current standard care pomp diseas introduc transform treatment
approv therapi exist light recent develop fda recept toward patient
advocaci accommod polit climat rare diseas drug believ bold could benefit
expedit develop timelin wherea bold may first-to-market gene therapi product
believ compani strateg adapt lesson gene therapi frontrunn like op
qure op mp admittedli uncertainti surround payor would deem accept
price gene therapi product may significantli impact bold valuat howev drug
deliv meaning improv standard care believ bold could garner price power rare
ultra-orphan drug either singl up-front payment pay-for-perform form payment
mp pioneer method luxturna drug valid bold gene therapi approach may
also draw interest compani seek tap novelti gene therapi and/or rare diseas
space believ bold share best valu via dcf analysi use discount rate termin
growth rate yield pt
bold risk valuat risk includ disappoint clinic data regulatori setback
potenti dilut financ commerci shortfal sinc bold product candid earli
develop risk associ clinic trial well unforeseen issu may aris
durabl shortfal higher pre-exist neutral antibodi titer higher immun respons
seen small clinic trial could impact stock significantli common
compani develop therapi orphan diseas true epidemiolog could also meaning
implic market opportun lastli given linger polit pressur drug price
uncertainti surround payor coverag decis amount reimburs gene therapi
product one-and-don could pose signific risk compani busi model
auph valuat deriv per share price target auph share month base dcf
analysi use discount rate termin growth rate fulli generic revenu
ascrib probabl success po voclosporin lupu nephriti ln po focal
auph risk valuat risk auph primarili relat clinic develop
voclosporin sinc auph one product pipelin data qualiti time setback
could impact stock significantli auph small cap biotech compani may need access
capit market financ risk also possibl
valuat valuationour pt vs prior support dcf assum
achiev out-year penetr compani estim total address market close
next year next year ev/sal basi share price would
translat estim in-lin high-growth med-tech peer group
average multipl think appropri compar select group quot ultra-high
growth quot med-tech peer trade current group includ
current trade
group averag ev/sal vs group vs group
believ trade least in-lin ev/sal basi vs group given top-
line growth prospect compound-annual-growth-rate vs averag peer above-averag gm profil vs
average peer believ estim repres base case leav room upsid
risk valuat potenti slower-than-project adopt curv
adopt remain sidelin extend period hand surgeon plastic surgeon
perform trauma procedur oral maxillofaci surgeon tend slower adopt
nerv repair technolog prefer trial new product wait long-term result
dive develop degre product reorder take longer expect
convinc middl adopt clinical/econom valu proposit product could
result flatter adopt curv potenti result risk estim new product
pipeline/market expans area could take time materi recent launch product
pipelin product new market expans area still develop could take longer
materi current project model could mean downsid risk sale
ep forecast exposur regulatori risk pursu bla lose
inher exclus avanc bla discret continu sell avanc pursu
bla could hamper compani abil enjoy uniqu commerci opportun
potenti diminish believ strong competit advantag could ultim
lead competit allograft segment bake avanc revenu
project avanc market opportun furthermor guarante avanc bla
success get approv repres potenti regulatori risk result
recon phase trial expect higher requir support bla
could result higher expens forecast assum model price pressur
could put downward pressur sale gm forecast contempl certain degre
price pressur model moder gm time may experi
signific price pressur estim assum could put revenu gm
forecast risk worse-than-expect price pressur could materi need
discount greater degre assum integr deliveri network idn group
purchas organ gpo compani tri drive bulk order larger institut
valu proposit around portfolio avanc axoguard aviv perceiv
strong enough justifi current higher asp commerci execut risk compani
unabl hire rep quickli project take longer model rep come
product curv could lead slower revenu growth trajectori
forecast likewis prove harder expect requir invest
model open new account and/or drive deeper penetr exist account could
repres sourc downsid risk revenue profit forecast and/or lengthen oper
leverag prospect competit compet nerv repair busi unit part
larger diversifi med-tech compani cross sell capabl bigger resourc
current nerv repair product compris small revenue larger
competitor believ market major focu compani
howev compani increas investment/focu could result higher level
competit vs compani experienc past
valuat next month believ share trade rang
dcf valuat deriv base case upsid scenario supplement price
target arriv via ev/fcf ev/ ebitda analys estim price-to-earnings perspect
valuat impli multipl ep estim repres stabl multipl current
level pe ep also line large-cap med-tech group
risk valuat risk includ failur execut margin expans initi
new product launch delay possibl acquisit either dilut perceiv
further baxter growth goal could pressur stock
valuat pt think compar larg
diversifi med-tech peer group given exposur across medic technolog life scienc peer
group includ trade ep among group
rev/ep growth profil average correspond forward price-to-earnings multipl
meanwhil cc revenue and/or ep growth profil correspond
yr forward price-to-earnings multipl think trade premium lower bound
rang discount upper bound appli price-to-earnings ep in-
line peer group forward average price-to-earnings get pt
risk valuat risk valuat includ accret estim bcr
prove overli conserv aggress fx volatil signific exposur emerg
market revenue growth volatil slower-than-anticip uptak
compani diagnost bioscienc product
bgne valuat use risk-adjust sum-of-the-part methodolog valu beigen pt
examin clinic regulatori commerci risk opportun individu indic
region assign probabl success account likelihood achiev
revenues/expens risk-adjust sum-of-the-part analysi appli discount rate cash flow
gener beigen asset determin total net present valu risk-adjust asset
total npv reflect remain clinic regulatori risk program
bgne risk valuat clinic risk clinic trial failur beigen pipelin
asset especi later stage drug includ zanubrutinib tislelizumab pamiparib
commerci risk greater anticip competit either domest china intern
could impact perceiv valu beigen pipelin clinic risk failur obtain regulatori
approv compani product unit state europ china would like diminish
valu beigen pipelin
valuat pt base sotp analysi forecast cash flow
risk valuat rimegep may get approv may get black box
warn liver toxic signal emerg clinic trialsrimegep label may still get black box
warn liver toxic due fda appli full cgrp class even issu
emerg clinic trialsth acut market smaller forecast due lack differenti
gener triptan and/or payer restrict higher expectedbiohaven struggl
compet larger competitor allergan lilli choos go aloneinvestor
skeptic glutam pipelin sinc phase trial failur spinocerebellar ataxia
sca assum compani need rais capit execut product launch
valuat estim fair valu month share sum-of-part dcf
analysi attribut naglazym kuvan aldurazym
vimizim/galn firdaps palynziq/peg-p vosoritid probability-
weight brineura valrox probability-weight remaind potenti
earli pipelin products/bmrn platform net cash
risk valuat risk includ success market initi identifi
patient naglazym kuvan brineura vimizim depend sni
market aldurazym program earlier stage develop entail
higher clinic regulatori develop risk
valuat rate outperform given uniqu high margin busi profil consist
consum instrument outlook also lever diagnost
acquisit exosom diagnost next year hope deliv revenu
believ acquisit add beyond high growth protein
scienc deliv compound-annual-growth-rate organ growth drive simpleplex technolog deeper
protein reagent biopharma even broader academ pois succeed plan
grow inorgan highli fragment research tool diagnost sector pick uniqu
differenti attract asset high gross margin fill adjac expand posit
consum time expect compani lever beyond debt/ebitda
believ gener dri powder next year given current growth rate line
expect laid recent investor acd acquisit alreadi deliv
believ could continu deliv growth long-term believ see
exosom diagnost estim manag think proven
conserv long-term though recogn largest diagnost deal ever done
manag remain confid medicar commerci payer confid
manag team led ceo charl kummeth key success last three
year believ like continu manag execut portfolio long-rang plan laid
investor day tech current trade ev/ebitda believ stock abl
trade ev/ebitda given growth profil consumables-heavi portfolio valuat methodolog
appli ev/ebitda estim yield price target peer group consist
risk valuat could face number risk downturn
biopharma fund regul chang fda lead dramat chang
profit drug compani drive compani reduc spend anticip
poor return declin nih fund due chang polit
leadership period flat declin alloc research spend could sever
curtail abil compani grow despit high consum citat
includ type citat restrict compani abil produc diagnost reagent
extend period time forc diagnost instrument provid switch away bio-
techn reagent could lead sustain declin diagnost reagent increas
competit merck sigma-aldrich bio-rad vwr could also lead declin
sale addit increas competit abcam antibodi manufactur
market could also impact sale competit also aris intern china
key growth market local reagent provid potenti suppli reagent
lower price impact higher dollar could dampen ou demand
product manufactur restrict trade certain countri
china asian countri could also dramat reduc need product
countri dramat fx chang includ sudden declin uk pound sterl could impact
compani revenu exposur uk european headquart
also locat uk
valuat use risk-adjust sum-of-the-part methodolog valu blueprint examin
clinic regulatori commerci risk opportun individu indic region assign
probabl success account likelihood achiev revenues/expens use wacc
termin valu nopat indic depend length patent protect
account valu beyond add cash requir invest arriv price target
risk valuat clinic risk number on-going clinic
trial develop candid includ avapritinib trial
produc clinic data disappoint rel investor expect repres risk
valuat regulatori risk regulatori approv requir commerci prescript drug
issu regul result longer-than-anticip timelin failur gain approv
blueprint drug would repres risk current valuat commerci risk drug
compet blueprint pipelin candid could produc superl clinic data lead
increas competit market less-than-anticip uptak product
repres risk current valuat
valuat next month believ share trade deriv
appli price-to-earnings multipl cash ep estim assum stabl multipl current
price-to-earnings multipl ep slightli price-to-earnings large-cap med-tech group
broadli top-tier sale growth profil mid-to-high singl digit rang
healthier balanc sheet head think premium multipl justifi compani continu
deliv solid execut consist meet-or-beat quarter also ramp key new product move
past litig issu see opportun multipl expans ahead
risk valuat risk includ lack meaning recoveri med-tech
market broadli major market drug-elut stent de cardio rhythm
monitor specif failur success execut key new product
launch major litig loss potenti product recal particularli within
inabl suffici reduc cost drive oper margin expans
valuat price target deriv take blend averag price-to-earnings
ev/ebitda comp peer group appli
believ stock trade discount peer capital-intens natur
busi unpredict instal despit overal improv portfolio continu sidelin
see new product gain consist traction market result see limit upsid current
risk valuat slowdown global budget research could caus downsid
risk forecast tighten budget govern academ fund could result
lower revenu rel estim exposur academ govern
signific furthermor restrict global budget could result shift focu strategi
growth could increas oper risk declin government spend could risk
downsid forecast growth nih spend lead market posit statu
nmr could result valuat risk price target entri competitor nmr
could take market share enjoy lead market posit nmr busi
entrant industri could result downsid risk forecast new
competitor gain traction industri howev upsid risk valuat also exist
innov conjunct nmr benefit sizabl exposur
intern market especi europ geopolit risk slowdown intern market
could disrupt oper downsid risk valuat forecast cite
under-perform china product alreadi continu weak brexit
result lack fund would impact revenu could disrupt intern
continu volatil energi chemic sector could impact growth
could see materi risk revenu deriv market continu volatil
crude oil could result downsid risk headwind industri market could
impact alreadi depress sale signific exposur oil ga mine
cement market current experienc long-term cyclic sizabl
leverag capit equip could reduc requir mainten capit expenditur
busi requir invest support capit intens manufactur oper
sudden reduct capital-expenditure could disrupt abil manufactur equip
impact sale estim
valuat price target base blend dcf analysi
revenu multipl analysi assign valu probability-weight p/w us sale rcc
probabl success assum royalti ex-u sale futur partnership also
assign valu probability-weight sale across sever solid tumor indic probabl
success receiv profit share us receiv ex-u royalti rang
use discount rate termin growth rate
risk valuat pipelin program face clinic regulatori develop
risk well commerci intellectu properti risk also face execut risk
financi risk addit may addit financ need turn cash flow
valuat price target appli ev/sal multipl sale
estim reflect basic stabl multipl vs sale multipl
sale estim smid-cap coverag univers averag
nxtm reflect new product-rel execut risk
atherectomi product gain market share potenti product recal failur dcb
valuat deriv one-year pt base blend dcf analysi
revenu multipl analysi assign valu probability-weight sale avacopan po anca-
associ vascul aav glomerulopathi hidraden suppurativa hs
sale po focal segment glomerulosclerosi fsg addit indic
clinic asset earlier-stag candid repres upsid estim matur clinical-stag
compani use discount rate termin growth rate repres market capit
risk valuat clinical-stag compani risk includ clinic
regulatori asset avacopan add signific binari risk head data
readout even though evalu multipl indic guarante
program understand complement system diseas still evolv
success particular indic may translat success safeti
profil includ long-term exposur remain risk associ clinic
valuat calcul pt contempl multipl inher uncertainti
potenti impact ip durat perform sensit analysi within model determin risk-
adjust npv share base exclus durat assumpt best worst base case
scenario assum probabl exclus maintain worst case scenario
probabl exclus maintain consist camsyl salt patent
expiri translat fundament valu addit see recent tsro acquisit
return option space assum similar takeout premium potenti acquisit
probabl occur result pt
risk valuat commerci risk signific competit parp
inhibitor class compet drug includ astrazeneca/merck lynparza tesaro zejula
clinical-stag parp includ talazoparib veliparib beigen pamiparib
among other commerci execut repres risk current valuat clinic risk fail
clinic trial rubraca includ trial ovarian cancer breast cancer bladder cancer
repres risk current valuat regulatori risk regulatori reject label
expans rubraca earlier line therapi addit tumor type prostat cancer
repres risk current valuat intellectu properti risk ip clovi
invalid earlier anticip would repres risk pt
valuat share current trade non-gaap ep
histor trade op mp mp trade discount histor
year ntm price-to-earnings multipl although histor price-to-earnings multipl base ep report
non-gaap basi price target base ep
believ still trade discount compani histor price-to-earnings multipl given concern
face headwind due slowdown meaning use demand solid product attract
price point down-market believ demand meaning use relat emr slow concern
manag abil predict annual earn believ invest back
softwar occur addit believ expect increas given variou
concern continu rate share market perform
risk valuat new greenfield opportun could limit risk
market perform rate would number new opportun limit given small
hospit want undergo quot rip replac quot process offer fairli
high-qual solut smaller facil may alreadi system place number
new instal seem taper recent may suggest major sale
come compani exist base competit within healthcar space intens
primari competitor includ meditech hm compani compet directli
small mid-siz hospit market secondari competitor includ
mp quadram op siemen compani typic sell
product larger hospit sometim compet directli given arra
smaller hospit may seek busi healthcar firm typic servic larger
facil lumpi quarterli result could caus errat stock behavior sale cycl
typic month sale cycl instal process system time-
consum complex may difficult manag accur forecast
quarter revenu earn consist basi certain project may get push one
quarter next result earn volatil unpredict share price
perform govern regul could pressur oper perform may new
regul custom either limit increas much will pay
new system product develop could lag larger far focus competitor
homegrown product develop engin team alabama compani abil
keep pace industri competit may difficult new product introduc
compani competitor effect respond chang industri need may
unfavor impact financi result
valuat current trade premium peer group forward ev/ebitda
vs group premium price-to-earnings vs group
discount ev/sal vs group argu histor turnaround
situat -- -where long-term revenu ep power potenti underst revenue
growth acceler -- -a higher-than-group average multipl justifi especi ev/ebitda price-to-earnings
basi pt base ev/ebitda appli ebitda reflect
premium group ev/ebitda peer group includ med-tech compani either
compet similar end-market similar type stock characterist
snn demonstr abil consist execut
beat consensu acceler organ sale growth faster project deliv commensur
oper ep upsid process believ could room multipl eventu trade
wider premium group ev/ebitda basi primari valuat metric current model turn
premium group forward ev/ebitda assum premium multipl sustain
next month appli ebitda forecast arriv howev without
convict upsid potenti out-year ebitda ep forecast troubl argu
bigger ev/ebitda multipl premium point time
risk valuat multipl expans margin expans prospect heavili
depend abil acceler sale growth margin expans stori
heavili depend sale growth acceler thu initi take longer expect
end market begin slow unabl drive better perform exist
portfolio could caus revenue/ebitda forecast risk convers faster
expect sale growth acceler model could lead higher rev/fast profit
think cnmd turnaround could take longer forecast requir heavi lift
expect abil jump-start sale growth could involv
reassess exist busi divestitur could lead near-term disrupt
model put forecast risk execut new product launch may success
past fit start new product launch includ delay redesign
new product launch edg perform poorli could neg impact percept
customers/investor compani turn corner capit equip market cyclic
exposur mostli smaller ticket item rather multi-million dollar equip
said ebb flow capit purchas could nevertheless affect compani
hospit administr re-priorit resourc alloc away product
could neg impact sale growth dilut could neg impact margin expect
 small tuck-in absorb compani oper structur limit impact
possibl manag may pursu larger deal pursuit long-term object
could neg affect margin near term similarli groom portfolio
divest asset could also neg impact near-term sale growth profit
valuat deriv price target use discount cash flow dcf analysi assum
discount rate termin growth rate model includ three program acromegali
hyperinsulinism/hi neuroendocrin tumors/net current estim gross
us/eu peak sale
respect fulli own right program account clinic regulatori risk probabl
success po estim us/eu us/eu valuat
paramet reflect encourag clinic and/or preclin data off-set uncertain safety/efficaci profil
rel earli stage develop
risk valuat crinet develop oral non-peptid drug candid target
 protein coupl receptor gpcr novel therapi platform come safeti
efficaci risk although preclin clinic data seem convinc program
compani earli stage develop clinical/regulatori develop could
requir market recept unanticip complic could impact
valuat pt contempl price-to-earnings consensu
price-to-earnings ep expect synergi across administr effici retail steerag aet
member benefit design chang floor rebat reduct store base distribut part
polici drive upsid estim also multipl expans pt trade price-to-earnings
ep estim deep valu invest across spectrum call
new integr mco pbm ci trade
price-to-earnings respect consensu ep reflect stronger growth lower exposur sector
compani specif risk see risk stori across exposur underwrit cycl
macroeconom downturn execut integr regulatori risk threat e- commerc
giant higher stock
valuat arriv price target use probability-weight methodolog discount
cash flow depend differ commerci scenario use discount rate termin growth
ratew keep probabl success constant pbc nash across commerci
scenariosw assign likelihood see meaning profil pbc versu likelihood
meaning profil nash contribut overal valuationth un-differenti scenario add
cash valuationw assign probabl seladelpar achiev breakthrough profil
pbc lead peak revenu million
risk valuat underwrit risk aet asset trade peak margin
commerci fulli insur though medacorp commerci broker price survey give us
confid price environ remain appropri hard offer flat even
potenti modestli expand underwrit margin risk potenti futur margin compress
aet health insur even meaning given associ neg impact
debt ebitda load compani need focus debt pay
next month departur shawn guertin aet cfo slate becom
cfo make us less confid price postur health insur book
commenc new bulk compet share gain commerci
medicar advantag market macroeconom risk risk macroeconom downturn
higher defens pbm sub sector given cyclic correl
retail front store sale employ data regulatori risk convinc
pbm add valu earn low probabl threat potenti drug
manufactur rebat elimin off-set new busi model includ administr
fee and/or perform guarante expos pbm retail pharmaci
busi compar player pbm risk execut integr
risk face greater risk well given integr pbm broader
organ also transform agenda around build retail front model
amid risk leverag balanc sheet e-commerce/amzn greater exposur
eros sale on-line channel well given exposur retail front store
retail pharmaci e-commerc though larg price retail multipl expect
less like pursu agenda becom pbm given associ integr clinic
evid base treatment guidelin integr provid network domin captiv pbm
model mega deal
risk valuat product concentr seladelpar account entir portion
valuat cymabay asset develop outsid seladelpar clinic delay
poor profil pbc nash creat substanti volatil seladelpar full product profil
defin remain clinic studi unclear differenti compar oca
elafibranor late-stag asset read ahead seladelpar nash next
year substanti chang view medicin ultim potenti poor uptak
address market limit access product real risk particularli respect
requir biopsi confirm nash diagnosi competit landscap nash quickli
becom crowd robust pipelin chase opportun fxr inhibitor ppar agonist
drug develop could see greater-than-expect uptak approv limit
market opportun seladelpar financ risk cymabay capit risk like larg
investor anticip dilut financ activ prior reach profit
specif expect see anoth larg equiti rais within next three year cymabay
continu burn cash expect launch seladelpar pbc note lead
dilut
dbvt valuat deriv price target dbvt share month base dcf analysi
discount rate termin growth rate assum probabilities-of-success viaskin
peanut viaskin milk respect current model peak risk-adjust revenu
across viaskin peanut milk product
dbvt risk valuat risk includ disappoint clinic data regulatori setback
potenti dilut financ commerci shortfal sinc dbvt product candid still
clinic trial aforement setback could impact stock significantli
derm valuat arriv price target use probability-weight methodolog discount
cash flow depend differ commerci scenario use discount rate termin growth
ratew keep probabl success constant qbrexza approv lebrikizumab
atop derm highest probability-weight meaning launch qbrexza coupl meaning asset
profil lebri add price target subtract oper expensesw see likelihood
breakthrough launch qbrexza likelihood breakthrough asset profil lebri would
contribut total price targetth un-differenti scenario add probability-weight net cash
valuat
valuat price target base dcf methodolog forecast
risk-adjust sale dcr-pxhc ascrib explicit valu pipelin asset explicitli model
expens result cash flow assum discount rate consist clinical-stag
pre-revenu compani coverag univers
termin growthrat addit includ net cash balanc valuat
derm risk valuat product concentr qbrexza limit primari hyperhidrosi
market build best-in-class launch critic long-term valuat poor activ
address market limit access product real riskslebrikizumab carri
signific portion price target lebri potenti indic outsid ad clinic
delay poor profil ad creat substanti volatil lebrikizumab full product profil
defin remain registration-en studi unclear differenti compar
dupi beyond lebri improv monthli dose regimen substanti chang view
medicin ultim potenti competit landscap atop dermat quickli becom crowd
robust pipelin chase opportun tralokinumab anoth ab jak inhibitor
biolog could see greater expect uptak approv would limit
market opportun lebrikizumabfinanc risk dermira capit risk like larg
investor anticip dilut financ activ prior reach profit
specif dermira million princip convert note matur may
initi convers price per share common stock believ
compani take prevent measur avoid repay entir princip pocket
altern could lead dilut
risk valuat risk view outlook valuat dicerna includ
major chang price reimburs coverag unit state europ rare
diseas drug dcr-phxc revenu forecast dcr-phxc subject risk
better-than-expect market share lumasiran unmodel competit entrant use disrupt
technolog gene edit risk includ clinic regulatori disappoint
dcr-phxc excess factor probabl adjust program addit
dcr-phxc sale profit fail match estim dilut financ may
requir order support futur commerci oper clinic develop pipelin
dplo valuat diplomat share trade ep includ increment cost
debt np ldi deal lower group averag believ discount
deserv given dplo lack growth loss pbm divis inconsist commun highli
competit market environ next month expect dplo trade
ep given increasingli competit market driven mega-merg unfavor mix shift lower
margin product loss pbm busi lower script volum rate share dplo market perform
dova valuat price target dova share base dcf methodolog
cash flow termin valu forecast doptelet sale thrombocytopenia associ
chronic liver diseas cld prior elect procedur immun thrombocytopen purpura itp
indic cld indic assign probability-of-success us po eu
revenu stream assign po itp indic us ex-u market assum
discount rate line cost equiti beta relev singl product small cap biotech
peer aldr achn addit factor dova cash balanc valuat
dplo risk valuat competit high specialti pharmaci industri highli
competit current domin three player esrx mp op mp
given rapid specialti market growth spur new drug approv drug price inflat
expect specialti market remain attract new entrant market particip
diplomat also sever retail partnership pbm relationship custom develop
acquir specialti pharmaci may result custom loss
diplomat reimburs pressur could impact growth profit specialti drug spend
scrutin payor includ govern payor medicar medicaid legisl
bodi pressur mount limit reimburs runaway cost specialti drug could
put downward pressur price trend could advers impact diplomat growth requir
diplomat deliv addit valu ad servic payor limit distribut agreement
drug access emerg limit distribut model specialti drug manufactur
repres opportun diplomat also risk compani longer abl secur
limit distribut agreement lose access drug specif manufactur diplomat
current reli celg mp signific portion drug diplomat
revenu came specialti drug integr expans diplomat
incorpor tuck-in acquisit complement organ growth risk associ
integr custom technolog servic distribut diplomat excess
facil capac posit compani absorb volum increas success growth also
reli hire new employe given high-touch servic compon associ specialti
pharmaci well retain key employe manag member litig risk
diplomat handl sensit patient inform reli inform technolog system
could becom compromis secur breach could result lawsuit exposur
compani also provid limit compound servic could expos compani certain
litig risk sale busi dplo could sell larg manag care plan retail
dova risk valuat dova singl product entiti back-up option
risk view outlook valuat dova includ regulatori reject label expans
doptelet compani sole drug recent approv cld also risk
physician prescrib doptelet volum match sale forecast commerci
risk includ risk market entri gener promacta post patent expiri though
label compet directli doptelet cld direct competit
mulpleta shionogi thrombocytopenia patient cld undergo elect surgeri risk
inher small compani includ dilut risk whereupon dova may need rais addit
capit fund commerci oper expand develop commerci shortfal risk
compani lack infrastructur experi bring drug market lead revenu
realiz lower forecast
valuat month price target base dcf methodolog forecast
risk-adjust sale explicitli model expens result cash flow assum
discount rate consist clinical-stag pre-revenu compani coverag univers
termin growth rate addit includ net cash balanc valuat
risk valuat risk view outlook valuat eido includ
major chang price reimburs coverag unit state europ rare
diseas drug forecast also subject risk better-than-expect
market share perform tafamidi unmodel competit entrant use disrupt
technolog gene edit greater-than-expect success
penetr wtttr and/or ttr-cm segment risk eido includ unexpect off-
target safeti risk regulatori requir approv requir greater-than-
expect pivot studi durat sampl size unfavor statist analysi method
case eido may requir dilut financ forecast
valuat use risk-adjust sum-of-the-part methodolog valu pt
examin clinic regulatori commerci risk opportun individu indic
region assign probabl success account likelihood achiev
revenues/expens risk-adjust sum-of-the-part analysi appli discount rate cash flow
gener asset determin total net present valu risk-adjust asset
total npv reflect remain clinic regulatori risk program
risk valuat regulatori risk despit recent resolv partial clinic hold
regul concern regard risk secondari malign may pose issu obtain
eventu approv tazemetostat clinic risk addit report secondari lymphoma
signific safeti issu may emerg clinic program meaning increas
regulatori risk and/or damag commerci potenti tazemetostat commerci risk
competit compani focus target hematolog malign could
lead greater anticip competit limit valu tazemetostat
eq valuat arriv price target use probability-weight methodolog dcf valu
depend differ commerci scenario keep probabl success constant agvhd
cgvhd across commerci scenario lion share price target come probabl
achiev meaning commerci profil gvhd bottom two commerci scenario un-
differenti increment contribut combin valuat assign probabl
achiev breakthrough profil gvhd lead blockbust peak revenu billion
ad probability-adjust valuat
eq risk valuat product concentr account entir portion
valuat equillium go announc anoth indic explor
soon clinic delay poor profil gvhd sever asthma creat substanti
volatil full product profil defin remain clinic studi unclear
differenti compar competit form treatment come market next
year substanti chang view medicin ultim potenti poor uptak
address market limit access product real risk competit landscap
gvhd crowd robust pipelin chase opportun base high unmet medic
need patient undergo transplant treatment prevent therapi includ
entyvio jak inhibitor less develop asset could see greater-than-expect uptak
approv limit market opportun seladelpar financ risk equillium
least anoth year could potenti start see revenu product sale
burn cash reason expect see anoth equiti rais within
next three year note lead dilut
glpg valuat pt determin use part valuat appli wacc
calcul discount rate termin growth rate revenu cash flow project
valuat pt assum trade ev/ebitda premium peer
hyh cybx snn
current forward ev/ebitda average current trade
ev/ebitda repres discount group assum group multipl hold
see multipl return least turn premium appli ebitda
forecast get us premium warrant view boast margin profil
almost higher peer group averag believ top-lin growth double-digit rang
sustain time-frame vs peer group average
product risk one clinic trial filgotinib may fail meet
primari endpoint necessit deeper decis continu develop particular
indic addit safeti issu occur within one trial filgotinib may read neg
across entir filgotinib franchis
collabor risk multipl product within glpg pipelin includ filgotinib
develop market away glpg control give glpg limit abil
address situat issu surround success drug
regulatori risk fda previous indic belief drug combin like futur
ipf treatment mind glpg pursu pivot trial investig
combin standard care believ creat safer path approv
nonetheless open door potenti competitor pursu path approv monotherapi
significantli disrupt expect market competit
financ risk glpg current revenu produc product market though well
capit near term neg outcom asset franchis may significantli
impact abil rais fund futur
risk valuat risks/uncertainti includ spine market
pricing/volum pressur produc bigger than-expect slowdowneith due increas
insur pushback weak economyand/or broader industri price pressur spread
minim invas surgeri mi spine product offer could put pressur sale
growth opportun compani robot trauma product pipelin could take longer
expect gain traction gener revenu new rep hire recruit initi take
longer expect drive higher rep product and/or improv compani core us
spine busi could put growth acceler trajectori risk caus improv
y/i organ growth take longer project materi integr
continu gener momentum struggling/slowli improv busi could
put ou sale growth acceler estim risk higher level reinvest
alreadi contempl model requir sustain top line could caus
ebitda margin fall level could limit ev/ebitda
gh valuat believ trade pt base dcf analysi
though compani compar guardant high growth med-tech compani believ higher
expect lunar outer year beyond omni drive dcf wacc beta
long-term growth rate yield pt recal like see upsid
panel growth cancer recurr monitor market long-term beyond commerci omni
higher reimburs test fda approv ncd follow given estim revenu
compound-annual-growth-rate still conserv growth profil believ gh share like move much higher beat
rais quarter compani deliv commerci promis omni believ
stock move higher catalyst becom realiti reimburs omni lunar
opportun realiz
gwph valuat pt base sotp analysi forecast cash flow
gh risk valuat non-profit bcb plan insur price irrat
medic cost trend come higher anticip potenti econom downturn
intens servic deliveri cobra acceler uptak member util care
advanc layoff
employ exit rapidli sponsorship health benefit combat medic cost
inflat catalyz
econom downturn
risk declin invest yield invest impair
state-bas actuari rate review limit sound price underwrit caus substanti
longer term state-bas insur exchang advers select reduc sustain
employ dump employe health insur
exchang signific margin compress potenti downsid membership top
polit shock lead singl payer
compani specif risk signific declin equiti market could result increas fund
compani
pension oblig polit legal oper regulatori econom risk foreign
gwph risk valuat investor expect solid epidiolex us launchther multipl
new epilepsi product also launch within next yearsth regulatori path still unclear
sativexour sale forecast assum off-label usag epidiolex payer could tougher
lun dc valuat dkk pt base sotp analysi valu base busi plu
pipelin discount rate
lun dc risk valuat faster-than-expect gener erosionslow revenu growth
key growth product trintellix rexulti abilifi maintena fail indic expans rexultifail
late-stag trial key pipelin candid foliglurax failur advanc early-stag pipelin
valuat current trade ep premium drug
distribut pharmaci group next month expect
share trade ep would put stock price target
valuat would slightli stock year histor averag ntm ep therefor
reason view especi given consist abil grow market share deliv upsid
expect acquisit believ current multipl reflect improv sentiment
risk/reward profil improv substanti
risk valuat competit relianc manufactur healthcar
distribut industri north america intern highli competit distributor
compet basi price product offer custom servic valu ad product
servic competitor obtain exclus right manufactur distribut certain product
manufactur bypass distributor altogeth could advers impact earn
larg competitor especi abroad use size increas price pressur group
purchas organ gpo larg provid may also demand lower price
addit manufactur disrupt shortag result unabl meet
custom demand certain product seen flu vaccin shortag
issu supplier relationship advers impact firm earn acquisit
restructur one largest player alternate-car market
made numer acquisit domest intern market acquisit joint
ventur involv numer risk may integr well manag intend
success integr acquisit past immedi short-term
impact bottom line drag earn year come acquisit may result
loss custom product line acquir busi may unintend effect
area oper cost increas relat restructur integr new
busi advers impact firm earn margin season
quarterli fluctuat tradit sale higher third fourth quarter
result end year custom purchas pattern well flu season ill
quarterli earn impact number factor includ sever flu season
product avail time price chang product releas vendor
advers impact revenu firm govern regul healthcar reform henri
schein custom healthcar industri highli regul local state feder
law firm may need adapt procedur price result polici chang
govern agenc pressur reduc budget deficit balloon
healthcar cost frequent target enact healthcar reform reduct
reimburs rate public and/or privat insur program could advers impact revenu
profit margin foreign domest tax law also subject chang current
interpret subject scrutini challeng could advers impact firm
earn ftc litig su ftc alleg price collus
believ like outcom complaint settlement possibl complaint
could expand grow crimin charg expand area busi
valuat deriv pt use dcf project cash flow htx-
patent expir use wacc termin valu
risk valuat sustol growth trajectori impact reimburs hurdl
slower-than-expect uptak longer-than-anticip arbitrag period sustol
valuat pt contempl ev ebitda blend adj
ebitda believ trade line high growth hcit compani given rapid
balanc sheet flexibl afford upsid
risk valuat difficulti implement new contract win may caus variabl
quarterli result hm technic issu onboard new pi contract win led
delay revenu gener compani complet reengin implement process
recent start bear fruit price pressur payment accuraci market
highli competit check medacorp industri specialist indic retroact review
hm gener vast major pi revenu larg commodit payor exert
signific price pressur believ hm differenti platform best-in-class data asset
invest ai machin learn show demonstr better error find rate yield
mitig risk price secondari roi payor vendor select one payment
accuraci profession put import thing abl offer custom solut
improv error find rate look price also yield determin type
roi expect delay integr acquisit hm expand adjac
market diversifi revenu base cross-selling/upsel exist client new product
offer core hm growth strategi combin sale organ retrain legaci hm
employe sell new product suit may prove difficult anticip hm
acquir eliza build pm vertic eliza under-perform manag initi
expect gener revenu vs expect mainli due sale
forc reorgan manag indic kink work eliza
perform line expect past two quarter slower-than-expect cross-sel
divis hm core growth strategi sell pi pm product cob client
manag expect growth come exist client exist client increas
uptak hm offer growth slow dramat payor consolid may disrupt hm
exist contract hm well-diversifi custom base compani ten largest
custom repres total revenu payor consolid could caus renegoti
price loss busi payor develop in-hous solut healthcar payor
in-hous solut compet directli hm core product suit hm must continu
demonstr error find rate exceed exist technolog within client base
htgm valuat take averag comp analysi dcf price target
believ compani compar htgm small cap diagnost dcf analysi use beta
long-term growth rate wacc arriv valuat expect continu
growth beyond reach equilibrium growth rate averag dcf comp method yield
price target note htgm trade multipl ev sale versu
ghdx
htgm risk valuat primari risk htgm price target success
htgm pdp project depend heavili partnership becausehtgm repli
world-wide enterpris level franchis deep relationship withbiopharma compani get
pdp project contract believ hold leveragesov htgm term project
mileston profit share contract negoti qgen need develop panel
htgm contribut ifqgen decid creat menu collabor
partner biopharmacollabor see htgm pdp busi futur cdx
pipelin could success htgm pdp project also depend greatli
success biopharmadrug trial hard predict drug trial readout
end htgm stage pdp program good could happen time
depend drugind pdp collabor project termin
depend thecontract like collabor gener futur
progress assay develop pdp project may acceler asforecast
expect htgm receiv fda approv alkplu andlaunch new assay
next coupl year ruo busi maintain growth howev assay could
receiv fda approv develop newassay delay uptak new
assay good expect rate ofruo project pdp project high
expect risk estim theprofit htgm could delay
competitor could threaten chemistri multiplex low sampl input requir
extraction-fre sampl prep competitor launch panel bettersensit
similar sampl volum requir could affect htgm competitiveposit hamper
adopt platform custom lack enthusiasm adopt htg edgeseq
platform could still last despit thenew assay launch htgm small sale forc
adopt htgm instrumentsha slow past two year order acceler ruo
product adopt themarket educ effort must increas reach differ research
lab around theworld poor execut market sale strategi could affect adopt
imdz valuat price target imdz base blend dcf analysi
revenu multipl analysi assign valu probability-weight sale follicular lymphoma
potenti address indic repres upsid estim use discount rate
imdz risk valuat imdz pipelin program face clinic regulatori develop
risk well manufactur commerci intellectu properti risk imdz also face
execut risk financi risk also imdz may addit financ need turn
ifrx valuat ifrx leverag proprietari mab first-in-class therapi patient
moderate-sever hidraden suppurativa hs rare autoimmun diseas skin caus excess
activ project probabl success po us eu hs due differenti
preclin data togeth success complet safeti trial demonstr
respons rate refractori moderate-sever hs patient balanc uncertainti due limit patient
exposur date current model assign credit program anca-associ
vascul aav believ inflarx share best valu via dcf analysi use discount rate
termin growth rate convert impli market cap eur usd use fx
averag yield pt
ifrx risk valuat pre-commerci stage compani risk valuat includ
clinic trial outcom delay clinic develop regulatori risk prior approv
reimburs risk post-approv also sinc first-in-class therapi unforeseen
complic risk may emerg financi perspect clinic develop requir
signific invest could necessit dilut financ road
iph fp valuat price target iph base blend dcf analysi
revenu multipl analysi assign valu probability-weight opportun lumox hairi cell
leukemia hcl probabl success us eu also assign valu wholly-own
cutan t-cell lymphoma ctcl us eu probabl success valuat also contain
expect mileston payment royalti astra-zeneca azn monalizumab sale squamou cell
carcinoma head neck scchn probabl success metastat colorect cancer mcrc
probabl success earlier stage develop program repres potenti sourc long-term upsid
valuat use discount rate termin growth rate
iph fp risk valuat iph pipelin program face clinic regulatori develop
risk well commerci intellectu properti risk iph also face execut risk
financi risk iph may addit financ need turn cash flow posit
valuat price target vs prior appli ev/sal multipl
sale estim assum stabl multipl current estim
ev/sal multipl small-cap med-tech univers
broadli believ repres uniqu asset within small-cap med-tech
top-tier growth profil profit togeth warrant premium
risk valuat risk share includ account issu possibl
greater reimburs cut current model loss increment competit bid
contract exclud compani access new patient potenti competitor
replic implement compani dtc strategi inabl build awar drive
increas penetr poc oxygen therapi market
valuat estim risk-adjust per share price target month valu
base discount cash flow analysi use discount rate termin growth rate
risk valuat risk includ potenti disappoint clinic data regulatori
setback failur obtain intellectu properti protect abroad commerci shortfal sinc
present unprofit one commerci product possibl
aforement setback may impact stock significantli
valuat pt vs prior base dcf assum achiev base
case out-year penetr us cpap market opportun vs
risk valuat addit reimburs coverag take longer materi
could limit upsid potenti adopt trajectori reimburs coverag key factor
consid evalu potenti adopt trajectori annual revenue growth
coverag decis take longer materi current project model
beyond could present downsid risk sales/ep forecast could meaning impact
rate abl penetr estim cpap market
opportun competit osa neurostimul devic first fda approv
neurostimul devic moder sever osa patient awar two competitor
neurostimul solut develop imthera/livanova nyxoah competit
show posit potenti better clinic result could provid patient physician
better perhap less expens altern inspir system could put adopt
trajectori risk part think earliest potenti impact competit imthera like
least year away possibl impact inspir system adopt trajectori if/when
approv may limit mere market expansionari unless competit system show
better data vs robust data given year experi
navig challeng reimburs landscap commerci execut risk compani
unabl hire rep quickli project take longer model rep come
product curv could lead slower revenue growth trajectori
forecast likewis prove harder expect requir invest
model open new account and/or drive deeper penetr activ center could
repres sourc downsid risk sales/ep forecast and/or lengthen op leverag
prospect timelin profit long-term clinic data year result
futur long-term data yr show compromis patient health qualiti life
daili hypogloss nerv stimul could potenti derail adopt trajectori repres
downsid risk sales/ep forecast check medacorp specialist suggest
physician hesit adopt inspir therapi long-term impact beyond yr
daili hypogloss nerv stimul unknown part believ highli unlik
signific drop-off reduct osa event inspir given trial
consist shown reduct year check continu highlight trial
high success rate inspir procedur econom incent physician particularli
compel procedur could limit pace adopt compani move
beyond earli adopt phase even though physician make money procedur may
less like adopt procedur least may acceler util rapidli
project physician end econom sensit expect respect
current medicar payment commerci payment relat
procedur payment amount inspir cover increas and/or procedur
time eventu reduc possibl could eventu repres limit factor
procedur uptak compani move beyond academic-ori earli adopt phase -- -to
extent factor outweigh/influ physician behavior beyond procedur
valuat price target base dcf methodolog forecast
risk-adjust sale royalti program ttr amyloidosi liver failur defici hbv
well mileston payment key announc partnership explicitli model expens result cash
flow assum discount rate consist pre-clin compani coverag
univers termin growthrat addit includ net cash balanc valuat
valuat arriv price target use probability-weight methodolog discount
cash flow depend differ commerci scenario use discount rate termin growth
ratew assign likelihood see price nash target small group
desper group patient would avoid complet cannib pbc revenuesw sequenti assign
likelihood price oca nash around would creat slightli lower valu creation
pbc much less nashw assign combin likelihood bottom two scenario would
reflect price rang would lead meaning revenu nash also destroy
pbc market
risk valuat risk view outlook valuat intellia
therapeut inc includ major chang price reimburs coverag one-
time/intent-to-cur genet therapi agent unexpect safeti efficaci signal clinic
develop intellia drug candid crispr gene edit technolog
broadli advers chang regulatori environ extend develop timelin
increas develop expens intellia asset beyond forecast forecast
subject greater expect market penetration/shar captur competitor entrant
ttr liver failur includ disrupt low-cost product high-efficaci
oral small molecul convers sale royalti forecast includ estim impact
competit agent ttr market agent fail enter market
poorer expect clinic profil otherwis fail garner share expect could
repres materi upsid estim intellia revenu cash flow advers ip
decis could undermin intellia freedom oper target indic subject
compani royalti oblig monetari damag materi impact compani
prospect futur cash flow
risk valuat product pipelin current ascrib entir valuat
oca pbc nash howev meaning data gener well-defin strategi
pbc clinic progress combin therapi util betafibr could creat upsid
potenti icpt competit landscap sever compani meaning phase
read-out nash next year expect competit
nash space clinic failur would creat larger market opportun oca
expect oca meet primari endpoint revers studi fibrot meaning
efficaci signal trial would significantli chang asset profil oca would expect
stock see signific upsid commerci uptak believ payer requir biopsi
reimburs patient nash treatment howev util non-invas diagnost
measur diagnos patient without biopsi would meaning expand potenti
market opportun could lead oca outpac revenu expect
valuat pt vs prior base updat dcf
assum discount rate long-term free cash flow growth rate start
gener posit free cash flow nopat a-capex-work capit rapidli increas
margin thereaft dcf horizon go-forward tax rate risk-adjust
sinuva forecast sale compound-annual-growth-rate model sale
compound-annual-growth-rate risk adj price target reflect ev/sal ev/sal vs
current trade ev/sal reflect discount comp group high
trade average ev/sal think trade closer small-cap
med-tech group average given mid-teen growth prospect acceler potenti beyond
sinuva launch kick full gear compani acceler revenue growth beyond valuat gap
vs high-multipl small-cap carve-out grower could narrow even reach pariti even
risk valuat estim could risk exist product propel
propel contour sale take longer expect materi adopt compani
product progress level model reimburs reduct
went effect jan begin greater impact util privat insur follow
lead reduc payment level sinu procedur compani ultim
receiv broader reimburs addit favor coverag decis hinder greater
adopt secur reimburs sinuva product competitor
abl pursue/ develop solut compet product
valuat pt base sotp analysi forecast cash flow
risk valuat regulatori delay unfavor feedback fda
lumateperon schizophrenialumateperon fail gener posit clinic data
indicationsweak execut commerci lumateperoneth compani fail advanc
valuat valuat base dcf analysi yield pt discount rate
calcul use capm model current trade price-to-earnings ex-cash basi
incl cash ex-cash incl cash vs broader market cap med-tech average incl
ew pt impli appli adj ep
less int incom cash believ premium group sustain given above-
averag top- bottom-lin growth potenti vs peer amid multipl new product cycl help drive
increas penetr still-larg under-penetrated long-term robot surgeri opportun
valuat current trade ev/consensu sale still averag
diagnost group multipl consist ttoo
believ trade line peer group given somewhat commod busi continu
grab market share higher growth profil believ continu develop commercial-stag
diagnost compani focus build busi around genet test sizabl grow multi-billion
dollar market appli peer-group multipl sale arriv price target
risk valuat risk valuat includ high volatil wide-trad
rang stock compani relianc singl product robot potenti chang
wors hospit capit spend environ continu debat around cost/benefit
come adopt robot procedur current project valuat could
risk gyn/uro trend slow greater degre model newer gener surgeri
robot procedur slower expect adopt forecast anticipated-to-
launch nexgen sp platform delay fail gain traction launch compani
achiev revenu contribut model flexibl cathet robot program
key risk includ ou growth slower anticip -- -either due delay
develop new japan procedur opportun and/or new china system tender/quota newer
robot entrant mdt/jnj beyond come onto scene result
competit trial potenti caus hospit purchas cycl elong given robot
solut evalu sg invest combat competit develop new
market lead greater opex spend -- -potenti limit near-term earn power -- -v
model
risk valuat reimburs hereditari cancer propos
increas per test rule final reimburs declin
ramp would sever impact given still earli commercial-stag compani
look addit contract order secur futur gave expect
posit gross margin posit cash flow still plenti uncertainti
busi busi develop forecast expect face challeng
earli commercial-stag compani face competit disadvantag establish
fda regul could impact product number product offer
compani addit increas regul fda requir addit sg expens
satisfi complianc increas cost could also affect abil ramp
compani need anoth round financ exist debt could lead addit interest
expens increas net debt balanc sheet could also lead increas capit cost
itrm valuat deriv pt use dcf project cash flow termin
valu use discount rate line clinic stage anti-infect compani
itrm risk valuat sulopenem may success phase trial iterum
may face difficulti commerci dilut risk compani may need
addit capit beyond current assum
valuat next month believ share trade price target price
target appli price-to-earnings multipl ep estim share current trade
ep estim large-cap med-tech group rang
price target assum see multipl expans line broader comp
group compani manag top-lin headwind continu manag cost
benefit actelion -- posit sustain ep out-performance view total
return capabl attract increasingli volatil stock market environ like attract fund
risk valuat risk includ failur success integr actelion amo
synth potenti futur acquisit failur resolv outstand consum consent
decre success re-launch product product recal failur advanc
late-stag pipelin success launch new product protract recoveri procedur
volum trend lack real macroeconom recoveri
valuat price target base blend dcf analysi revenu
multipl analysi assign valu probability-weight us sale selinexor multipl myeloma
probabl success tripl class refractori earlier line patient diffus larg cell lymphoma
dlbcl probabl success assum royalti ex-u sale potenti partnership
also assign valu commerci opportun dedifferenti liposarcoma probabl success
dcf analysi use discount rate termin growth rate
risk valuat earli stage biotech compani face signific clinic
regulatori develop risk well commerci risk also face execut risk
financi risk vast major valuat base selinexor compani lead
clinic stage product candid potenti setback due possibl safeti and/or efficacy-rel
issu selinexor could signific impact valuat
valuat price target base blend dcf analysi
revenu multipl analysi assign valu probability-weight us sale tipifarnib hra mutant
squamou cell carcinoma head neck hnscc probabl success hra mutant squamou
non-smal cell lung cancer nsclc probabl success hra mutant solid tumor
probabl success peripher cell lymphoma probabl success chronic myelomonocyt
leukemia cmml probabl success pancreat cancer probabl success assum
royalti ex-u tipifarnib sale futur partnership earlier stage program
menin-ml inhibitor repres upsid valuat use discount rate termin growth
valuat price target base blend dcf analysi
revenu multipl analysi assign valu probability-weight sale margetuximab breast cancer
gastroesophag cancer probability-weight sale enoblituzumab scchn nsclc
probability-weight sale flotetuzumab aml probability-weight mileston partner
program earli stage bispecif pipelin repres upsid estim use discount rate
termin growth rate
valuat arriv price target use probability-weight dcf analysi differ
commerci scenario keep pipelin valuat net cash debt constant across commerci
scenario lion share price target come probabl afrezza achiev base case
sale growth project bottom scenario arriv project compani valu per share assign
probabl afrezza achiev breakthrough profil commerci sale lead blockbust
peak revenu
valuat pt base sotp analysi forecast cash flow
risk valuat pipelin program face clinic regulatori
develop risk well commerci intellectu properti risk also face execut
risk financi risk may addit financ need turn cash flow posit
risk valuat pipelin program face clinic regulatori
develop risk well commerci intellectu properti risk also face execut
risk financi risk may addit financ need turn cash flow posit
risk valuat singl product succeed fail back afrezza
afrezza suffer checker past earlier gener inhal insulin initi
failur launch overcom obstacl key commerci
success competit landscap afrezza target competit market within diabet care
meal-tim insulin market larg domin two major pharmaceut compani
histori resourc depth patient experi significantli deter market
particip financ risk despit commerci stage product continu oper
neg cash flow consist requir addit capit fund remain oper
indic futur need believ requir addit fund near
intermedi term time afrezza becom self sustain mnkd carri signific
debt rel current balanc sheet market capit manag debt
continu meet debt coven crucial futur oper
risk valutaion although statist signific small number
patient phase orphan epilepsi trial possibl ganaxolon wont success
larg pivot trial
allopregnanolon biomarker-driven strategi may success
marinu abl partner program instead rais money ramp
spend significantli execut go alon strategi larger better financially-
back compani launch first two product market
slower-than-expect neg clinic develop progress marinuss clinic program
faster-than-expect loss patent protect assum
valuat share current trade ep
cardin mp ep op ep next
month believ trade ep pt
believ lower multipl rel histori deserv given challeng gener price environ
linger risk tie washington induc reform manag highlight price competit
brand inflat mid-single-digit rang odd gener inflat return low see
on-going headwind custom loss given challeng rate share
mdso valuat medidata histori competitor decid util ev/ebitda
ev/sal multipl valu compani medidata current trade ev/ebitda slightli
two-year averag minim fluctuat peak trough
two-year span ev/sal basi mdso current trade ev/sal two-year
averag peak bottom around ntm ev/sal base analysi
compani enterpris cloud industri medidata trade discount measur median
ev/ebitda group mean mdso trade discount median
ev/ebitda multipl ev/sal median mean mdso trade
discount median past month mdso trade rang given volatil
market fairli high revenu earn expect expect mdso trade next
month base blend ev/ebitda ev/sal
stock trade reason ev/ebitda ev/sal multipl compar enterpris cloud
compani fairli high rel tradit hcit distribut stock believ multipl
expand next month given state equiti market risk forward estim given
risk valuat gener econom condit may reduc demand
compani product servic economi weaken consum may less inclin
purchas drug addit believ healthcar reform posit impact
chang reimburs law fund client may impact price custom
will pay compani product servic final custom demand lumpi
servic creat volatil around earn share price
mdso risk valuat subscript slow downmedidata reli heavili grow
applic base current custom attract new custom new exist product
medidata recogn backlog financi statement indic futur revenu
among custom contract remain medidata compani experi
slowdown backlog growth point time indic potenti lack alreadi book futur
revenu stock price may face declin addit medidata abl attract new
custom fail meet revenu guidanc consensu estim may face
signific neg reaction increas competit eas chang providersa life
scienc industri continu grow term compani drug trial clinic trial
medidata competitor medidata abl develop new applic pace
competitor risk lose custom switch one cloud provid
anoth life scienc compani rel inexpens base lack infrastructur
requir medidata provid face competit legaci vendor
legaci compani built reput leader cloud comput
resourc capit increas effort life scienc field
intern expans rel eas medidata premium pricingmedidata charg premium
applic believ custom will pay product competit
increas medidata may face price pressur custom begin weigh option
heavili could advers effect revenu either lose custom
decreas price keep custom pressur recogn merger synergiesmedidata recent
purchas shyft analyt provid avenu commerci side
life scienc someth focus time acquisit shyft
analyt employ peopl small number custom share
medidata revenu run rate medidata predict acquisit expand
total address market expect fall short combin compani
fail realiz expect synergi may neg reaction market medidata
enter new side industri open addit revenu stream high
expect may difficult achiev requir mani resourc sale cyclemedidata sale
cycl span one five year certain product contract size variabl
depend number user custom use applic although backlog
repres activ contract futur renew contract guarante custom may
use product trial trial basi startup may complet trial
immedi start new one result period time servic need
expand commerci may prove benefici reason compani leverag
shyft applic maintain on-going relationship certain custom addit
downturn busi new exist custom one quarter may immedi
recogn revenu recogn term subscript anywher
year mention recognit model result revenu recognit new
custom take place time current quarter chang complianc procedur
valuat share trade ep assum stabl multipl
current multipl ep estim moder area
broader large-cap med-tech univers though believ could eventu return
path consist mid-single-digit top-lin growth time less certain see limit multipl
expans mid-single-digit growth trajectori larg predic recent
upcom new product launch sustain trend without risk price
target appli basic stabl multipl ep estim
valuat price target base blend revenu multipl
analysi dcf analysi assign valu probability-weight sale royalti
probabl success ovarian probabl success lung cancer use discount rate
valuat project price target month base discount cash flow
dcf analysi assum discount rate termin growth rate model project revenu two
pipelin program livoletid prader-willi syndrome/pw nevanimib congenit adren
hyperplasia/cah current estim gross peak sale livoletid
pw nevanimib respect account clinic regulatori risk probabl
success estim livoletid nevanimib respect valuat paramet reflect
assess quantum clinic data gener date regulatori path go
forward residu uncertainti associ biotech compani medium late stage
mor gy valuat price target mor base dcf methodolog cash
flow termin growth driver forecast royalti tremfya risk-adjust sale
risk-adjust royalti assum discount rate base compani
wacc also includ valuat gantenerumab royalti stake base compar anti-
amyloid transact addit factor mor cash balanc valuat
risk valuat risk valuat includ continu signific spine market
spine sale declin market fail regain momentum greater-than-expect drug elut
stent de market share loss greater infus sale declin failur deliv product
pipelin failur success execut cost save initi
risk valuat pipelin program face clinic regulatori
develop risk well commerci intellectu properti risk also face execut
risk financi risk may addit financ need turn cash flow posit
risk valuat novel therapi develop millendo platform
come safeti efficaci risk although clinic data far suggest potenti
attract therapeut commerci profil program still clinic develop
manufactur regulatori requir market recept unanticip complic
could impact stock neg
mor gy risk valuat risk view outlook valuat morphosi
includ failur obtain approv either us ex-u jurisdict
base l-mind forecast product also subject risk better-than-expect
market share gain competit brand product roch polatuzumab lack
willing physician patient chang new treatment long-
stand treatment option payer us europ could also refus reimburs
expens combin plu revlimid could potenti cost
year treatment addit morphosi current sole sourc incom royalti
tremfya could lower-than-expect due chang highli competit immunolog
treatment market risk morphosi includ develop regulatori disappoint
partner outlicens antibodi two product fail compani valuat
would reduc approxim
valuat trade price-to-earnings believ blend dcf analysi price-to-earnings
appropri given growth potenti test legaci hereditari cancer busi use
blend averag price-to-earnings among peer dcf analysi valu reach
price target dcf includ long-term growth equiti risk premium beta
risk valuat could get broader adopt among commerci payer
result aggress negoti contract could lead signific upsid revenu
gener success negoti hc test contract given well-entrench
posit commun oncologist could potenti replic market
well inclus test nccn uspstf other could benefit test futur
drive signific payer adopt improv coverag test repres upsid risk
estim recommend medic societi includ american colleg
neuropsychiatri potenti drive chang guidelin could lead improv
coverag revenu upsid genesight qualiti control problem among test competitor
could drive volum problem recent highlight despit
impact limit believ qualiti control issu competitor could drive
provid use establish hc test clinvar databas qualiti
improv time would embolden variant databas even believ fda
could regul ldt lab develop test increas pressur smaller lab current
conduct hc test thu potenti benefit given experi resourc
believ like fare better vs competit chang regul consolid
within industri also mean could target given patient databas wealth
proprietari inform collect year could view databas
person medicin inform patient recruit clinic trial companion
diagnost could growth driver sector longer term still lever
believ could present upsid portfolio test evolv biomark requir therapi
select therapi manag
valuat given grow oncolog specialti test nich oper breadth
offer market penetr thu far believ trade premium current
ev/sal multipl view current valuat slightli under-valued compar lab test servic
test product provid group lh ghdx htgm
trade ev/sal valu ev/sal multipl premium
peer group averag result multipl price target believ
warrant premium peer group given growth potenti expand market uniqu posit
risk valuat companion diagnost could growth driver sector longer
term cdx opportun predict subject factor beyond
control failur materi certain project cdx opportun could neg effect
investor outlook compet larg lab oper labcorp
other lab offer similar portfolio servic could
problemat term brand recognit market adopt differenti
servic speed reliabl failur continu effect manag relationship could hamper
abil realiz market expect consolid continu theme
within lab test space howev market could shift larger compani may becom less
acquisit may less interest acquir compani grow brand one scenario
consolid potenti acquisit market turn chanc may
taken one larger lab test compani may expect high volum growth
clinic genet oper pharma servic test busi failur achiev optim
market share could lead drop test volum grow test volum high
enough could materi impact revenu valuat may
oncolog test market dynam industri new test methodolog biomark
discoveri chang rapid pace compani like foundat medicin grail
guardant work liquid biopsi exist potenti threat market posit
technolog may chang physician test prefer may chang guidelin recommend
regulatori bodi may updat guarante abl withstand
materi part valuat depend abil retain
competit grow market share one way possibl acquisit
certainti come time structur gener natur acquisit sinc
imposs predict acquisit occur exact dynam said acquisit caution
investor weight invest hope acquisit addit acquisit may bring
risk associ integr
nvcn valuat next month believ nvcn share trade arriv price
target use discount cash flow dcf analysi take averag valuat base rang royalti
rate dcf use discount rate probability-weight price
target reflect averag believ possibl royalti rate rang royalti pay-out
conserv scenario view acknowledg small-cap med-tech compani
valu base compar compani ev/sal multipl believ dcf best captur total
address market opportun neovasc tiara tmvr market estim potenti
nvcn risk valuat risk neovasc rate valuat includ
possibl tiara and/or reduc approv us and/or europ commerci ramp
tiara and/or reduc fail meet expect challeng fda approv pathway
tiara and/or reduc fairli robust competit landscap mr replac pipelin
on-going trademark potenti patent litig potenti reimburs risk failur
obtain suffici reimburs tiara and/or reduc secur approv
valuat formerli qualiti system inc share current trade
adjust ep hcit group averag
ep compani histor ep averag ntm ep estim next
month share trade ep appear piec
turnaround plan take hold attrit sale forc address achiev
book growth goal entrada eagledream deal posit higher
convict abil improv client satisfact howev believ compani new product
take time gain traction expect higher remain earn headwind furthermor
 quot core market quot slow convinc stock benefit takeout
specul convict pipelin start stabil appear manag take
right step restructur compani increas oper leverag drive cross-sel effort
encourag turnaround effort manag put forth believ work remain
fulli transform busi cloud-bas enterpris result maintain mp rate
risk valuat sever vendor begun undercut
premium vendor price effort buy market share believ
resist price pressur point could forc either conced price share
face intens competit addit revenu earn may fluctuat significantli
quarter quarter given delay purchas relat arra lack clariti around certain
definit within legisl pressur sharehold previou board member hussein
repres distract uncertainti remain around futur board composit
believ share could neg impact hussein attempt rejoin board
begin dump share final lumpi earn revenu may caus stock price volatil
either direct
valuat pt vs prior assum ev/sal appli
sale forecast ev/ebitda ev/sal ev/ebitda basi
forward valuat sit ev/sal ev/ebitda discount respect peer group
price-to-earnings basi trade discount peer group forward multipl vs peer
pt assum steep ev/sal ev/ebitda discount still warrant level given choppi
execut past month on-going downward estim revis sales/ebitda/ep
valuat impli discount ev/sal discount ev/ebitda discount price-to-earnings vs
group averag trade ev/sal ev/ebitda price-to-earnings respect think
discount warrant given slower sale profit growth prospect
obsv valuat pt base dcf analysi forecast cash flow use
discount rate termin valu wacc rang phase compani
bigger sale momentum project lead bigger share gain spine
faster-than-model sale growth re-acceler trajectori key op margin expans
initi vertic integr drive larger-than-expect gm benefit magnitud
quickli model us spine market begin acceler either due eas price
pressur and/or less insur scrutiny/reimburs pushback procedur believ
contribut soften us spine market recent quarter risk
slowdowneith due increas pushback insur weaken economi sale
new product launch materi slower expect due limit clinic data reliabl issu
lack perceiv clinic econom benefit provid rep difficulti penetr new
sale territori drive higher sale per procedur recent introduc about-to-be-
introduc compet spine technolog cannib near-term market share gain
above-ment risk factor would like inhibit compani abil increas sale forc
product believ would put oper leverag ep growth potenti
risk dis-synergi johnson johnson/synth integr sourc share
gain other spine industri struggl spine franchis
previou year howev spine growth begun improv recent qtr
may come expens likewis synth integr gradual hit stride
could repres diminish sourc share gain opportun smaller player
could repres risk sale forc turnov would increas averag
level compani abl fill posit
obsv risk valuat risk valuat includ unsuccess regulatori action
linzagolix nolasiban and/or data readout linzagolix may less competit
elagolix relugolix elagolix head start may preclud uptak linzagolix current
expect food effect add-back therapi flexibl advantag may reson
physician potenti restrict payer environ gnrh antagonist class long-term
safeti class may turn wors current expect nolasiban live birth rate lbr data
may posit
valuat deriv price target share base dcf analysi use
discount rate termin growth rate see consist rang use model
late stage compani posit phase data believ nuzyra clinic potenti uti sinus
could repres upsid long term current model probability-of-success former
risk valuat risk valuat includ potenti disappoint
clinic data uti regulatori risk uti commerci shortfal given nuzyra compris
vast major valuat efficaci safeti regulatori commerci setback
program may impact stock significantli investor also face potenti dilut risk current
fund provid oper runway
valuat consist histori posit earn believ appropri valuat
methodolog valu share price-to-earnings basi current trade ep
compar healthcar peer allscript athenahealth nextgen trade
mean price-to-earnings next month expect share trade
ep expect post low-single-digit revenu growth recent acquisit
boost sale demand perform servic remain steadi provid gain healthcar polici clariti
ntm price-to-earnings basi year averag today stock trade below-averag price-to-earnings though
help higher ep lower corpor tax rate still believ share remain attract current
level offer solid double-digit upsid patient investor believ reward/risk attract
current level rate share outperform
risk valuat competitionpremi oper fragment highli competit
market greatest competitor larg gpo own
healthcar provid specialti pharmaci busi compet larg nation
mani small local specialti pharmaci perform servic compani encount wide
rang competitor includ special provid consult outsourc firm
compet basi price segment could see price pressur
competitor well chang industri provid consolid compani expect
competit continu increas result consolid healthcar healthcar
servic industri chang healthcar industri regulationspinc busi depend upon
condit healthcar industri gener dynam impact hospit healthcar
system particular industri highli regul feder state author new
administr washington risk chang regul cover
purchas sale medic product restrict permiss discount financi
arrang could caus compani modifi product servic result
delay order reduc demand hospit custom consolidationin recent year mani
healthcar provid consolid creat larger integr deliveri system
increas market power trend expect continu could result custom and/or
revenu loss member gain enough scale could choos contract
directli supplier rather gpo addit provid consolid
may choos move busi anoth gpo could use scale negoti fee
reduct servic segment custom concentr top five member
make approxim total annual revenu largest member gnyha purchas
allianc llc compris revenu signific member gpo
contract relationship includ member sudden
loss member could materi advers effect financi result could
also result greater competit suppli chain servic segment gpo particip
agreement termin time either parti one year written notic
caus pinc control companypinc member owner class share
total vote power combin class class common stock
give signific control compani includ elect director
employe member owner mean member owner determin
outcom essenti matter requir action stockhold control
compani quot corpor govern standard exempt
major independ direct independ compens committe could make
compani class stock less attract investor
valuat price target base dcf cash flow
assign termin valu forecast sale pemphigu begin
grow probabl success adjust total revenu itp begin
grow global probabl success adjust total assum
discount rate base wacc use averag beta similar small-cap platform compani
addit factor cash balanc valuat
valuat pt base discount cash flow dcf analysi assum
discount rate termin growth rate estim probabl launch
assum peak penetr biolog refractori uc patient peak penetr first-lin
treatment uc patient lead ww risk-adjust peak revenu also current model probability-
weight peak revenu royalti partnership janssen
pti valuat deriv price target correspond market capit month
model assum probabl success po approv
commerci cystic fibrosi cf patient mutat us row compani
drt diseas relev translat platform seek identifi novel drug candid optim
screen process assign valu earli preclin asset overal valuat
price target base dcf analysi use discount rate termin growth
prvb valuat revenu cash flow project dcf sum part
analysi wacc calcul discount rate termin growth rate appliedth sum part
dcf analys separ arriv target price per sharer cost consid part
oper asset valuat adjust probabl receiv regulatori approv base histor
risk valuat principia subject typic risk associ clinic stage
biotechnolog compani signific downsid cash flow forecast valuat would occur
futur clinic trial fail disclos unforeseen safeti liabil principia
also subject competit dynam autoimmun diseas could substanti reduc
expect revenu potenti exampl includ emerg clinic profil anti-
fcrn monoclon antibodi commerci adopt off-label rituxan biosimilar
principia reliant upon multipl collabor advanc partner asset decis
cancel partnership compani would impair valu asset increas
perceiv risk principia drug develop platform addit whether on-going clinic
trial success dilut financ like requir order support futur clinic
risk valuat includ potenti disappoint clinic data
regulatori setback commerci shortfal amend partnership janssen/jnj
asset
pti risk valuat risk includ disappoint clinic data regulatori setback
potenti dilut financ commerci shortfal sinc pti product candid
earli stage clinic develop aforement setback could impact stock
significantli novel technolog ameliorate/enhance/repair ctfr cf patient exampl
prvb risk valuat strateg risk prvb greatest risk lie compani size
rel portfolio size decis maintain streamlin oper strategi help
extend cash runway also make execut clinic trial difficult may result
failur achiev target mileston timelin financ risk abil rais addit fund
crucial continu development cours across compani pipelin inabl rais
suffici fund need may result program triag offload asset abil rais
suffici capit may difficult due higher need fund pipelin prvb
size stage develop typic requir licens risk
call back provis relat prvb licens agreement janssen respect
factor impact activ call back provis would
valuat prvb full impact truli account within valuat methodolog
without project potenti date and/or probabl provis activ
valuat take averag comp analysi dcf price target
believ direct busi compar advanc cell diagnost acd
acquir acd forward sale see parallel acd
given similar growth profil y/i next year combin differenti sensit
capabl highli valu biopharma custom acd valu sensit
immunohistochemistri among lab valu sensit elisa
immunoassay acd gener major revenu biopharma market
research remain clinic anatom pathology/ihc diagnost lab similar given
biopharma account revenu tech bought acd ev/forward sale multipl
consid expens time acd deliv promis still expect grow y/i
trade sale estim given manag histori
conserv calip believ like beat estim near term like
prove growth compound-annual-growth-rate estim conserv longer run thu believ forward
sale estim feasibl deriv valuat look compar fmi
ttoo valu line fmi
op dx believ op closest compar even acd within dcf
analysi use beta long-term growth rate wacc arriv valuat
expect continu deceler growth beyond reach equilibrium growth rate
histor beta beta conserv account early-stag phase
compani averag dcf comp method yield price target
risk valuat primari risk price target includ competit
peer threaten unmatch sensit competitor launch anoth platform
better sensit could threaten competit posit competitor
develop sensit platform adopt could hamper significantli custom could
lack awar simoa platform small sale forc order acceler
adopt market educ effort must broaden differ lab around world
current team sale rep may enough poor execut
market educ could hamper adopt biomrieux agreement may caus lose
exclus use simoa agreement two parti give biomrieux pathway
market distribut platform clinic applic base simoa technolog
biomrieux abl develop platform clinic applic like lose
market share immunoassay market adopt may acceler forecast
expect instal base instrument total uptak instrument
high expect demand low-abund protein detect high despit
posit feedback far expect risk estim multiplex cost may prove
burden custom would demand shift less costli consum
lower cost per sampl attract razor-razorblad model
consum expens busi model might get util much
valuat month price target base dcf methodolog cash flow
termin valu forecast sale subcutan tymlo risk-adjust sale
tymlo patch elacestr assum discount rate base compani wacc addit
factor cash balanc valuat
risk valuat risk view outlook valuat radiu includ
major chang price reimburs coverag unit state sc tymlo
compani main product today forecast product also subject risk better-than-
expect market share gain gener forteo unexpect competit respons forteo
manufactur launch new superior drug class osteoporosi risk
radiu includ develop regulatori disappoint tymlo patch oncolog
asset elacestr two product fail compani valuat would reduc
approxim addit whether tymlo sale match estim on-going
clinic trial success dilut financ like requir product launch
order support futur commerci oper clinic develop
valuat rate share outperform pt leverag proprietari
target therapi bard omav develop novel therapeut patient rare life-threaten
diseas caus dysregul metabol mitochondri function program seek either
improv upon current standard care ctd-pah becom first-to-market therapi diseas
approv therapi exist alport syndrom fa mitochondri myopathi conserv project
probabl success po bard ctd-pah due advanc follow rel
small phase residu uncertainti surround mechan action appropri
patient popul howev believ catalyst trial highli power alport syndrom
ascrib po bard base highli encourag cardin data extens clinic histori
increas estim glomerular filtrat rate egfr singl endpoint approv ascrib po
omav fa due earlier stage develop rel intract diseas base posit
phoenix data includ model assign po well po
adkpkd po lgan bardoxolon model assign credit program
potenti revenu gener collabor pipelin multipl innov product
routin seen clinic stage biotechnolog compani result develop regulatori market
reimburs uncertainti believ share best valu via dcf analysi use discount
rate termin growth rate yield pt
risk valuat pre-commerci stage compani risk valuat includ
clinic trial outcom delay clinic develop regulatori risk prior approv
reimburs risk post-approv also sinc bardoxolon omaveloxon first-in-class
therapi unforeseen complic risk may emerg financi perspect clinic
develop requir signific invest could necessit dilut financ
valuat price target regeneron base simpl averag three approach
believ reason basi valu stock today approach simpl price earn
multipl compar high growth larg molecul biopharmaceut compani price sale multipl
larg cap high growth compani discount cash flow dcf use averag larg cap larg
molecul therapeut compani nvo nv earn multipl ep
appli current ep estim give valu use high
growth revenu multipl similar compani nvo consensu
sale appli revenu estim give valu lastli dcf
valuat given wacc termin cash flow growth rate give present valu
averag three method current price target upon complet analysi quarterli
result revisit price target present remain unchang
risk valuat risk view outlook valuat regeneron
includ major chang price reimburs coverag label competit posit
eylea compani main product today risk includ commerci develop
disappoint compani next partner program launch dupix
kevzara well continu weak demand price pressur compani cholesterol
treatment praluent lastli compani convert rel littl revenu cash flow today
histori return cash investor ultim may undermin valu
stock investor willing continu
valuat price target base blend dcf analysi
revenu multipl analysi assign valu probability-weight sale royalti probabl
success melanoma probabl success cutan squamou cell carcinoma cscc
probabl success nonmelanoma skin cancer nmsc bladder cancer microsatellit instability-
high msi-h tumor probability-weight sale royalti probabl success tripl
neg breast cancer tnbc use discount rate termin growth rate
risk valuat earli stage develop uncertainti efficaci
safety- though possibl less uncertainti oncolyt viru compani
platform design manag experience- masterkey trial t-vec plu pembrolizumab
read neg could neg read-through across oncolyt viru landscape- need
prove clinic differenti t-vec- t-vec get approv combin may need
differenti well- expand competit clinic stage oncolyt viru
companies- mani differ type virus develop multipl recent larg pharma
acquisitions/partnerships- competit drug market melanoma relat skin cancer
indications- high bar approv first line melanoma setting- may need show superior efficaci
combin indications- competit oncolyt viru
approach util intraven administr vs intratumor administr competit
immunotherapeut approach gener
valuat price target base dcf methodolog cash flow
assign termin valu forecast sale rti prevent begin
grow global probabl success adjust total assum
discount rate given earli stage novel mechan program addit factor
cash balanc valuat
risk valuat restorbio subject typic risk associ clinic stage
biotechnolog compani singl asset futur clinic trial fail unforeseen safeti
liabil emerg would signific downsid cash flow forecast valuat
uniqu risk due limit oper histori found potenti
competit mtor inhibit develop addit whether on-going clinic
trial success dilut financ like requir order support futur clinic
valuat believ price target reflect strength base busi inclus
thiola chenod cholbam potenti valu pipelin asset appear under-valued
current market valuat estim gross market opportun sparsentan
fosmetpantoten formerli probabl launch sparsentan
fosmetpantoten respect addit believ igan program repres peak
market opportun obtain po could add current pt liquid udca
ursodeoxychol acid phenylketonuria/pku yet reflect model
valuat pend visibl market opportun develop pathway respect
dcf analysi assum discount rate termin growth rate indic price target
valuat price target base dcf methodolog forecast
risk-adjust sale compani gene therapi candid fa lad-i ascrib explicit valu
pipelin asset explicitli model expens result cash flow assum
discount rate consist clinic stage pre-revenu compani coverag univers
termin growth rate addit includ
net cash balanc valuat
valuat price target base blend dcf analysi
revenu multipl analysi assign valu probability-weight sale rare diseas
probabl success phenylketonuria preclin rare diseas program probabl
success homocystinuria refractori gout hyperoxaluria aip also assign valu probability-weight
sale oncolog formerli probabl success solid tumor non-respons
therapi probabl success patient acut myeloid leukemia aml follow
hematopoiet cell transplant hct procedur also assign valu probability-weight sale royalti
preclin program autoimmun diseas probabl success type diabet
probabl success pemphigu vulgari use discount rate termin growth rate
risk valuat risk valuat includ potenti commerci clinic
regulatori disappoint across compani exist product includ thiola cholbam
chenod develop pipelin includ sparsentan fosmetpantoten formerli re-
contribut materi way valuat
risk valuat risk view outlook valuat rocket
pharmaceut includ major chang price reimburs coverag unit
state europ rare diseas drug cur gene cell therapi forecast
compani drug candid treatment lad-i fa also subject risk poorer-than-
expect efficaci safeti profil clinic develop threat unmodel competit
entrant use disrupt technolog gene edit lower-than-expect profit due
manufactur challeng regulatori regim us end-market includ
revenu forecast becom less accommod probabl success
compani product could materi reduc time expens clinic trial requir
approv could substanti increas potenti caus compani requir
dilut financ forecast
risk valuat pipelin program face scientif clinic regulatori
develop risk well commerci intellectu properti risk also face execut
risk financi risk may addit financ need turn cash flow posit
scph valuat pt scph base dcf analysi forecast cash flow
use discount rate termin valu
scph risk valuat risk valuat includ fda requir devic
modif and/or clinic studi may take less/mor time execut delay approv
payer coverag may take longer anticip pipelin failure/delay
valuat use risk-adjust sum-of-the-part methodolog valu pt
examin clinic regulatori commerci risk opportun individu indic
region assign probabl success account likelihood achiev
revenues/expens risk-adjust sum-of-the-part analysi appli discount rate cash flow
gener seattl genet asset determin total net present valu risk-adjust
asset total npv reflect remain clinic regulatori risk program
risk valuat commerci risk competit compani develop
treatment hodgkin lymphoma breast cancer urotheli cancer clinic risk fail clinic trial
compound develop includ adcetri trial tucatinib
enfortumab vedotin compani earli stage pipelin regulatori risk fda reject
pipelin asset adcetri tucatinib enfortumab vedotin
valuat pt base ev/sal multipl analysi support dcf
assum wacc long-term growth rate would translat
ev/sal vs current still current trade ev/sal discount vs
trade ev/sal
howev given above-avg top-lin growth prospect higher gm think stock see
multipl expand current depress level move toward group average compani
demonstr recaptur market share us breast implant market beyond launch
opu implant see sale growth materi grow miradri instal base associ
consum revenu -- would like help valid miradri opportun fact larg
includ us think could
risk valuat share re-gain us breast product market could
challeng expect follow approv opu implant abl convert
prior user see rise util exist user extent model could put
breast product estim risk compani could face bigger appreci hurdl
respect brand percept and/or physician willing go back start use given
year window compani manufactur product -- -follow
manufactur issu facil fire occur compet two larg
manufactur johnson johnson allergan two entrench compani abl
provid plastic surgeon broader offer technolog beyond breast implant lower
price bundl type program doctor decid fulfil major need
singl supplier provid multipl product addit breast implant filler botox
etc could troubl make inroad new account win back prior custom
entrench competitor competit us breast implant segment
road could make market crowd barriers-to-entri us breast implant segment
signific suspect earliest new competitor would come market us
year if/when competitor secur fda clearanc pre-market approv pma
process -- -or somehow secur expedit clearanc -- -thi would increas number
player segment beyond current could becom harder drive
higher util breast implant also possibl new entrant choos pursu
investig devic exempt breast implant space could creat headlin risk
even achiev actual approv potenti competit sweat manag
on-label devic energi substitut miradri current awar howev
rule possibl competitor energi modal laser rf eventu
get use market off-label separ advanc tradit sweat manag
therapi topic treatment could offer pt better option vs current avail
today -- -possibl make miradri purport benefit consid mind consum
less advantag otherwis might view dermira if/when
approv one product could potenti offer pt provid better altern
current topic solut address hyperhidrosi depend extent increas
pt willing deal drawback typic associ topic might decreas
pool pt potenti will activ seek altern type therapi miradri
part think impact like minim medacorp feedback suggest
even dermira product success approved/commerci like replac
type topic treatment pt still like consid altern miradri given
topic solut still requir repetit use dermira market expansionari and/or
success convert pt topic therapi limit impact miradri potenti
patient popul balanc sheet risk compani like need rais capit near-to-
intermedi term order grow busi satisfi certain mileston payment come
due sale threshold met certain recent acquir product portfolio
valuat current share trade cash ep discount large-
cap med-tech averag ew given
averag sale growth prospect think premium warrant confid
average sale growth sustain profit earn growth prospect capabl
track least line larg cap med-tech peer group averag faster given potenti
revenu upsid year potenti invest erp transatlant cost initi yield
meaning oper leverag futur potenti room accret stepped-up
buy-back activ drive upsid estim given stabil compani top line new product
way think trade premium vs peer group average appli turn premium vs
group average forward multipl ep yield pt
risk valuat risk valuat includ prolong pullback possibl
deterior hospit purchas trend either due economi uncertainti around
limit upsid potenti medsurg estim unabl gain hundr basi
point market share result total knee launch mako system -- -or adapt mako
system new ortho indic deploy cash possibl dilut
acquisit new product launch robot success forecast
gener increas sale momentum beyond unabl
deliv oper leverag and/or dd ep growth despit sustain above-averag top-lin
valuat estim per share valu share month base dcf analysi
assum discount rate termin growth rate account risk clinic regulatori
drug develop probabl success estim rang pku
ucd valuat paramet reflect promis preclin data
view off-set uncertain safety/efficaci profil candid still earli stage
develop given lack visibl progress collabor develop synthet biotic
ibd explicitli model royalti revenu program
risk valuat develop proprietari platform transloc
metabol function variou organ gut novel approach innov
platform come high safeti efficaci risk although preclin data seem convinc
platform earli stage develop clinical/regulatori develop could disappoint
market recept unanticip complic could impact stock neg
ttoo valuat price target base averag dcf ev/ sale
project remov overhang regard pend approv assign ttoo
ev/sal multipl high-growth peer group trov fmi qtnt
multipl given ttoo superior novel technolog dcf model wacc long-term
growth rate rate consid conserv ttoo growth could easili continu see moder
double-digit rate futur period
ttoo risk valuat primari risk ttoo price target reimburs
could revers cours reimburs drg code current pay
chang rate like reduc adopt test system
could present risk competit could arriv market improv
bacteri cultur technolog mean acceler turn-around time ttoo
differenti technolog deliv faster turn-around time rang hour vs blood
cultur base techniqu take hour day blood cultur technolog improv
could see chang adopt ttoo instrument percept benefit
could chang greatli would delay ramp time scale despit benefit
diagnos sepsi quickli administr may maintain percept
test necessari demonstr ad valu adopt could suffer
due slow uptak instrument
mdco valuat estim fair valu month mdco share sum-of-the-part
dcf analysi includ net cash overal use wacc discount rate sinc risk involv
drug develop regulatori approv alreadi handicap probability-weight
revenu estim pipelin asset appli termin growth rate continu assum peak
vabomer revenu mdco receiv royalti net sale melinta
probability-weight peak inclisiran revenu
mdco risk valuat risk associ clinic develop commerci
activ impact mdco valuat earn power signific invest necessari
develop inclisiran trial delay dilut financ and/or failur deliv non-dilut financ
plan continu weak broader market pose risk
valuat estim price target month use dcf analysi
discount rate termin growth rate discount rate consist model
biotech de-risk ph asset multipl program develop higher risk
aldr valuat inclus net cash
risk valuat investor face multipl risk includ limit
commerci risk gsk trelegi close tripl combin well clinic risk label
expans indic signific clinic risk earli stage program given stage
develop partnership risk maxim opportun inflammatori
bowel diseas develop risk sinc exploratori phase ii data
enter pivot trial dilut risk compani need equiti rais
opt-in believ could impact stock significantli
valuat month price target base dcf methodolog cash flow
assign termin valu forecast sale cystic fibrosi begin
grow probabl success adjust total assum
discount rate given earli stage compani longer term valu stock could
significantli appreci result on-going anticip trial increas probabl success
assign develop lead compound
qure valuat estim fair valu qure share one year base discount cash
flow dcf analysi use wacc discount rate similar earli stage pre-commerci small-
cap biotech stock coverag auph ifrx pti termin growth valu due
inabl repeat dose gene therapi
risk valuat earli stage compani disclos littl
inform mrna construct lnp deliveri system henc investor subject
typic risk associ clinic stage biotechnolog compani also risk
associ lack valid overal technolog mrna compar
therapeut approach mrna medicin develop therapeut approach
mani year medicin come market yet lead program face
technolog risk usual develop risk earli stage target biopharmaceut
program also face risk associ competit develop categori
mrna platform cf treatment approach industry-wid risk includ advers
regulatori reimburs polit develop final like earli stage biopharmaceut
compani capit risk like larg investor anticip signific
dilut financ activ prior reach profit forecast
qure risk valuat invest qure fundament high-risk high-reward
invest opinion despit receiv first regulatori approv gene therapi
categori glybera eu qure still need address clinic regulatori risk subsequ
candid develop hemophilia front competit longer act factor
rnai gene therapi compani could deem qure program riski broader
perspect system impact gene therapi failur new case leukemia
could pose signific risk final despit strateg initi financ risk remain
expect compani cash-flow posit sever year
valuat primari valuat methodolog base rel ev/ebitda rel
ev/ebitda track function compani histori hospit group averag assess
potenti ev/ebitda expans next month base forward forecast contempl
underli fundament implic healthcar reform dcf valuat leverag forward
forecast wacc termin growth rate point potenti multipl expans along
sector compani specif catalyst expect greater potenti multipl expans dcf
valuat point significantli upsid peer current trade level base rate
outperform price target base ev/ebitda ebitda
risk valuat downsid risk valuat includ possibl delay
medicaid expans current non-expans state acut care segment highli
concentr la vega texa cut govern commerci payer
reimburs declin receiv collect rate pay mix pressur behavior
valuat share current trade ev/sal slightli diagnost peer
qtnt ghdx ttoo multipl averag given higher rate
reimburs newli launch test gain traction back strong clinic data biopharma
revenu ramp believ share could trade turn group multipl ev/sal
estim result pt
risk valuat primari risk price target includ
limit reimburs rate decis move forward visibl test includ
percepta envisia fda regul financ commit given neg cash flow
near declin reimburs could sever impact revenu major risk
reimburs rate could decreas dramat current reimburs rate
among highest industri much revenu base
reimburs rate impact amount test administ adopt rate exist
new test ramp would sever impact refil reject even wors
reimburs rate continu fall given still early-stag visibl still
somewhat limit despit encourag sign still early-stag compani neg net
incom provid progress report afirma encourag result test gain
traction howev still plenti uncertainti busi given model still show
neg earn least busi develop forecast expect
face challeng new compani face competit disadvantag limit
fda regul remain risk regulatori concern fda
decis impact product still earli stage ramp envisia
could impact fda given nascent natur test fda regul could
impact product number product offer compani increas regul
fda would requir addit sg expens satisfi complianc increas
cost could also affect abil ramp addit financ could still happen
posit cash flow come later expect possibl may need addit financ
given expect neg net incom near term expect posit cash flow come later
expect compani need anoth round financ exist debt could lead
addit interest expens increas net debt balanc sheet could also lead increas
valuat next month believ share trade dcf arriv
valuat compar compani analysi arriv valuat
rang valuat appli ev/sal multipl sale estim
assum current multipl estim hold top-tier growth profil
monopoli larg under-penetrated market path profit believ share deserv trade
least line ev/sal multipl higher-growth smid-cap med-tech coverag univers
op rate
risk valuat risk valuat includ inabl execut physician
train drive ramp maci adopt potenti product recalls/regulatori issu either
maci epicel competit entrant current unawar need rais
addit capit reach profit could dilut exist sharehold inabl
optim variabl cog control oper expens order drive posit leverag
valuat vocera histor trade hcit group athn
ntm ev sale averag next month expect trade ev
sale reflect price target reflect chang account standard lacklust
backlog defer revenu growth rate increasingli difficult comp good sale
momentum guid indic signific slowdown busi risk
estim view also book grew revenu increas compani guid
organ growth longer term revenu increas like grow product portfolio high
custom sticki effort increas channel partner sale invest stronger integr
vendor also gain momentum larg enterpris govern deal despit
posit report backlog defer revenu growth rate expect
remain concern increasingli satur market
risk valuat relianc nuancevocera current use nuanc core
voic recognit softwar chang compani relationship nuanc lead
termin exist contract could result vocera incur signific cost redesign new
voic recognit solut transit new vendor current evergreen provis
contract allow vocera stockpil licens exist contract termin
would give vocera abil buy time develop plan transit could also result
larg up-front cost guarante new solut would amount custom
satisfact manufactur disruptionsvocera manufactur facil reli
contract manufactur produc hardwar compon accessori disrupt
manufactur facil contract disput could result difficulti obtain compon devic
initi product badg began transit mexico
could greater risk disrupt manufactur mexico acquisit
integr riskvocera alreadi made sever small acquisit futur may acquir
addit asset vocera need fulli integr acquir solut overal product
portfolio achiev strateg financi benefit integr also expens time
consum without guarante success evolv competitionw believ vocera
hand free wireless commun devic avail hospit believ vocera badg
wide valu nurs hospit staff hand free natur voic optim abil
direct hand free competitor in-build wireless phone built compani
cisco ascom polycom well avail enterpris commun softwar
voalt smartphon offer altern badg believ badg fill nich
smartphon cell phone possibl futur trend new competit could
shift user differ platform devic could advers impact vocera
sale patent intellectu propertyintellectu properti right remain import
competit advantag vocera vocera current patent patent
applic pend approv vocera technolog system fail work
expect patent protect softwar becom compromis busi could
harm intellectu properti lawsuit brought compani could also harm
oper result vocera incur cost protect intellectu properti relianc voic
commun solut healthcar marketvocera deriv revenu
sale voic commun solut hospit healthcar facil
compani revenu non-healthcar custom high
concentr one industri vertic primarili one product compani long-term success
may reliant develop new softwar featur exist solut may
challeng vocera expand new market industri countri cost may
incur add speech recognit capabl addit non-english languag lengthi sale
cycleit typic take month larg health system potenti custom
make decis whether buy vocera technolog servic contribut
lumpi compani report revenu earn quarter quarter addit
valuat next month expect share trade ep
would put stock price multipl reflect on-going reimburs pressur
minim accret continu headwind intern busi believ
posit win share becom extens network vast array clinic capabl
believ new manag team take step reduc overal cost increas sale higher
margin front-stor product posit retail rate remain signific pressur brand
gener price also headwind becom aggress overal respons
market also overhang unlik abat time soon given challeng concern
rate share market perform
valuat deriv price target share use discount cash flow analysi
forecast cash flow assign termin growth rate discount rate
account wave share global profit share collabor takeda huntington diseas al
ftd program use probabl success hd po al ftd neither
program enter market prior also includ revenu wave wholli own duchenn
muscular dystrophi dmd program probabl success dcf valuat use fulli
dilut share count includ outstand seri prefer share stock option
valuat price target base blend revenu multipl
analysi dcf analysi assign valu probability-weight sale royalti
probabl success diseas probability-weight sale royalti
probabl success acut myeloid leukemia probability-weight sale royalti
probabl success lymphoma probability-weight royalti probabl success
multipl myeloma probability-weight royalti probabl success complement-
mediat diseas probability-weight royalti probabl success lymphoma
use discount rate termin growth rate
risk valuat competit high retail pharmaci industri highli
competit contract pbm manufactur also competit walgreen
compet chain independ drug store well mail order prescript provid
groceri store on-line pharmaci pharmaceut vendor chang competit
landscap impact rx volum neg impact compani sale
earn macroeconom regulatori climat uncertainti continu econom slowdown
 would bode poorli sinc above-averag unemploy rate drive lower level
consum spend would decreas prescript drug util regulatori environ
also fair amount uncertainti time impact variou healthcar reform
provis could materi impact oper nation emphasi reduc healthcar
cost could also spawn reimburs pressur new way contain healthcar cost
devis implement intern exposur execut risk walgreen merger
allianc boot increas exposur intern market increas currenc
exposur regulatori risk partnership uniqu approach
contract distribut compani fail execut vision accret could
expect season time cost adjust swing result front-end sale
prescript sale compon season sale also lumpi
depend holiday line calendar sever cold cough flu
season magnitud compani lifo provis also fluctuat given quarter
depend inventori level sale inflat also swing result contribut
earn miss beat amazon entri amazon may seek disrupt pharmaci market
enter retail market buy build contract pbm news topic
pose headlin risk share amazon could formid competitor mail cash pay
risk valuat risk view outlook valuat includ
major chang price reimburs coverag unit state europ rare
diseas drug revenu forecast subject risk better-than-expect
market share compet product huntington diseas includ limit model
oligo competitor dmd includ limit approv product announc pipelin
product other unmodel competit entrant use disrupt technolog
gene edit gene therapi risk includ clinic regulatori disappoint
drug candid excess factor probabl adjust addit
drug candid sale profit fail match estim dilut financ may
requir order support futur commerci oper clinic develop pipelin
risk valuat pipelin program face clinic regulatori
develop risk well commerci intellectu properti risk also face execut
risk financi risk may addit financ need turn cash flow posit
valuat pt base dcf forecast cash flow use
wacc termin valu wacc rang late stage pre-commerci compani
coverag univers
risk valuat risk valuat includ potenti competit
larger player xeri glucagon rescu execut commerci risk launch
market adopt expans may take longer anticip potenti need
addit cash rais although could mitig non-dilut financ regulatori risk
xeri pen may see delay fda approv
zlab valuat price target zlab base blend dcf analysi
revenu multipl analysi assign valu probability-weight opportun niraparib ovarian cancer
probabl success ovarian cancer probabl success ovarian cancer
probabl success tripl neg breast cancer probabl success brca breast cancer
probabl success assign valu probability-weight opportun omadacyclin absssi
acute-bacteri skin skin-structur infect probabl success cabp commun acquir
bacteri pneumonia probabl success assign valu probability-weight opportun
brivanib hepatocellular carcinoma probabl success assign valu probability-weight
opportun optun glioblastoma probabl success assign valu probability-weight
opportun gastric cancer probabl success assign valu probability-weight
opportun margetuximab breast cancer probabl success gastric cancer probabl
success assign valu probability-weight opportun baumannii probabl
success assign valu probability-weight opportun tumor-tr field glioblastoma
probabl success earlier stage develop program repres potenti sourc long-term upsid
valuat use discount rate termin growth rate
zlab risk valuat zlab pipelin program face clinic regulatori develop
risk well commerci intellectu properti risk zlab also face execut risk
financi risk zlab may addit financ need turn cash flow posit
valuat trade fairli steep discount large-cap med-tech group forward price-to-earnings average
believ level discount vs large-cap peer warrant given average top-lin growth
execut risk relat zbh-biomet integr suppli issu think current discount vs peer
wide believ ultim busi time capabl gener hsd ep
growth gradual top-lin acceler low-to-mid singl digit growth territori pt vs
prior assum trade ep narrow valuat gap vs
large-cap med-tech average forward multipl would current price-to-earnings current
forward multipl would still repres discount large-cap exclud ew
forward group average price-to-earnings compani large-cap group includ
risk valuat risk valuat includ abl execut
post-biomet ldrh deal synergi guidanc take longer address suppli
issu build safeti stock inventori -- -which could limit co abil meet demand and/or
regain market share futur qtr crucial sale growth acceler stori
underli ortho recon growth rate slow vs current expect level price eros
industri ortho recon price occur dramat pace expect wors steadi
y/i declin rang unabl off-set asp price declin posit mix
benefit relat new product offer could hinder long-term share price
appreci robot total knee categori begin acceler faster-than-expect and/or
abl commerci rosa total knee applic time fashion pend fda
valuat pt base sotp analysi forecast cash flow
post-exclus fintepla discount rate
fintepla lg data need success broaden label allow
physician use refract patient
fintepla cv safeti signal could issu real world
